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CELL-TAUGHT GENE THERAPY FOR THE PRESERVATION AND 
REGENERATION OF CARDIAC TISSUE FOLLOWING CHRONIC 
HEART FAILURE  
 
 
SRIVIDYA SUNDARARAMAN 
 
 
ABSTRACT 
 
Heart failure is the primary cause of mortality and morbidity in the Western world. 
Although cell therapy has demonstrated improvement in cardiac function, these benefits 
are being attributed to the activation of paracrine factors, rather than the differentiation 
and integration of the transplanted cells into the host tissue. Based on this knowledge the 
focus of this thesis work was to deliver paracrine factors, and evaluate its effect on 
cardiac function. 
 
Gene therapy has evolved as a promising option to deliver pro-angiogenic proteins to 
infarct zones, thus providing cardiac benefit. This study has identified a gene design 
without the use of viral vectors, to deliver transient, yet therapeutic levels of an 
angiogenic chemokine, Stromal-Derived-Cell-Factor-1 (SDF-1) in rodents with chronic 
heart failure, and has reported significant improvement in cardiac function. The use of 
Kozak sequences and translational enhancers helped boost gene expressions which could 
be accurately measured using bio-fluorescence imaging techniques. This improvement in 
vii 
 
gene expression was directly proportional to the improvement in cardiac function in 
rodents with chronic heart failure.  
 
However effective plasmid delivery, via the systemic route, requires the 
encapsulation and targeting of the plasmid to infarct zones. An infarct-specific peptide 
was identified with the help of phage panning techniques and nanoparticles, formulated 
with poly lactide-co-glycolide (PLGA), were employed to encapsulate a fluorescent dye, 
6-Coumarin (6C). Targeted and efficient delivery was achieved by tagging the surface of 
the nanoparticles with the targeting peptide. Another aspect of this study was to identify 
novel paracrine factors responsible for reverse ventricular remodeling, following the 
treatment of chronic heart failure with mesenchymal stem cell (MSC) therapy, using 
microarray analysis. 
 
Overall, this study has identified the design and delivery technique for a therapeutic, 
cardiac-benefitting gene to the infarct zone, in rodents with heart failure. These results 
can be translated to a clinical setting, providing relief to patients with chronic heart 
failure. This study has also paved the way for future research in developing novel cardiac 
drugs, by identifying cardiac specific genes, responsible for reverse ventricular 
remodeling. 
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CHAPTER I  
 
INTRODUCTION 
 
1 INTRODUCTION 
 
1.1 Research Interest in Heart Failure 
 
Heart failure is a major cause of morbidity and mortality in the modern world. The 
conventional therapies involve a replacement of the tissue, either by designing total 
artificial hearts made with the use of biocompatible metals, or using a xenogenic 
transplant. However, the number of patients who die every year, or who are at risk has 
increased dramatically, leading researchers to focus on preventing the occurrence of an 
acute myocardial infarction, or to repair the tissue and thus provide relief to the chronic 
conditions associated with it and improving the quality of life.  
 
Ischemic heart disease, caused by reduced blood supply in the heart and thus the 
damage associated with it, is a leading cause for heart failure. Current therapies involve 
preventive measures in order to stop cardiac myocyte loss in an acute stage, or to 
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optimize the reversal of ventricular remodeling in a chronic condition. The heart is a 
highly aerobic organ requiring a constant supply of oxygen in order to continue its 
function. The cells of the heart, specially the muscle cells or myocytes, are terminally 
differentiated and thus do not repair themselves following damage. A reduction in 
oxygen, due to reduced blood supply, can lead to the death of the cells in that tissue, 
almost immediately. 
 
This damage elicits an inflammatory process where the dead muscle cells are 
replaced by a scar region, which is not an ideal replacement to the loss in function. This 
action, then leads to a cascade of lower cardiac output and the compensation mechanisms 
caused henceforth. The combination of ventricular fibrosis, muscle cell hypertrophy, 
dilation of the ventricle, thickening of the ventricular wall, and thinning of the scar tissue 
is termed ventricular remodeling. These pathological conditions are symptomatic of a 
more progressive condition known as chronic heart failure.  
 
Current research is now focused on reversing this ventricular remodeling, by 
inducing angiogenesis in the infarct region, thus providing oxygen to injured myocardium 
in the infarct border zones, or in triggering a cascade of pathways that can provide the 
right signals to regenerate the myocardium either with the concomitant use of stem cells 
or without.  
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1.2 Chemokine Mediated Repair 
 
Cell therapy has evolved as a promising option for cardiac repair for more than a 
decade. Pre-clinical and clinical studies have demonstrated the potential of skeletal 
myoblasts, multiple autologous or syngeneic stem cell populations, including 
Hematopoietic (HSC), Mesenchymal (MSC) Stem Cells, and Multipotent Adult 
Progenitor Cells (MAPC) to improve cardiac function when delivered in the peri-infarct 
period in animal models as well as human trials. For cell therapy to provide substantial 
clinical impact, the cells transplanted should be able to survive in a hypoxic environment 
and must protect themselves from being degraded by the host’s immune system. The 
other option for successful cell therapy is to use multipotent stem cells, capable of 
differentiating to the cells of the cardiac lineage and then engrafting into the host tissue to 
replace the damaged or dying cells.  
 
Although cell therapy has shown to provide cardiac functional benefit by improving 
the cardiac output, there is limited evidence that point to the improvement as arising from 
the differentiation of these cells to cardiac myocytes. This has led to the belief that the 
improvement in cardiac function is not due to regeneration of the myocardium but rather 
due to the paracrine effects which then help improve angiogenesis, matrix remodeling, 
cell signaling to help stem cells from the bone marrow to home to the ischemic 
myocardium, and cell survival to name a few. 
 
4 
 
Consistent with this hypothesis are recent studies by us and others, demonstrating 
that the benefit of stem cell therapy is increased by the over-expression of specific factors, 
namely Stromal Derived Cell factor -1 (SDF-1), Monocyte Chemoattractant Protein-3 
(MCP-3), and others.  The over-expression of SDF-1, in ischemic tissue, leads to 
increased stem cell homing, neovascularization, and preservation of cardiac myocytes 
due to the binding of SDF-1 to its receptor CXCR4, which is present on the cell surface 
of hematopoietic cell populations. Although SDF-1 is shown to be elevated in injured 
tissue; the naturally occurring transient increase of this chemokine, is not sufficient to 
provide a significant improvement in cardiac function.  
 
Other studies in our laboratory have demonstrated that MSC home to myocardial 
tissue in response to MCP-3 when transfected a month after inducing myocardial 
infarction in rodents, and that re-establishment of MCP-3 weeks after AMI re-establishes 
MSC homing to the heart leading to ventricular remodeling and improved function. 
However the pathways that mediate the benefits associated with cardiac remodeling are 
poorly defined. Similar results are obtained from varied stem cell sources with limited 
evidence that these different cell types actually differentiate into cardiac myocytes. The 
conclusion that the majority of the improvement observed is not due to the regeneration 
of cardiac myocytes, but rather due to the paracrine factors released by the engrafted stem 
cells, has led to growing number of research in identifying these paracrine factors.   
 
Sophisticated software is currently available to analyze and identify the changes in 
gene expression following cell therapy. The use of whole genome analysis is made 
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possible with the help of Affymetrix’s and Ilumina’s software systems, that can identify 
changes in gene behavior, whether it is differential or not. Other software, such as 
DAVID and Ingenuity Pathway Analysis, provide effective techniques in order to 
decipher the information present in the large datasets.  
 
Gene therapy has provided an efficient method of expressing these chemokines in 
vivo and assessing their effects in animal models. In cardiac applications, this method has 
evolved as a potential target for encoding angiogenic proteins which lead to repair of the 
myocardium, following a promotion of blood vessel growth in the injured area, which 
helps revive the hibernating myocardium. Although, this is a promising field and the 
expectation is that it can provide functional benefit, there are no clinically approved gene 
therapy treatment options available today. One reason is that most gene therapy trials use 
viral techniques, which pose a serious threat to the life of the patient due to 
immunological reactions, and tumor developing potentials.  
 
The alternative method is to use naked plasmid or DNA which then has a drawback 
of having low transcription efficiencies, and the potential to degrade in the host 
environment. In order to bridge this gap between low transcription and immunological 
reactions, it is necessary to understand mechanisms which will provide a platform for 
high transcriptions and not pose a risk towards pathological damage. Another concern to 
be addressed with gene therapy is to avoid the degradation of these genes in the host 
tissue when delivered systemically. The use of polymeric devices has gained popularity 
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in order to optimize the delivery of plasmids to specific organs with the focus being on 
safety and efficacy.  
 
1.3 Research Focus  
 
Our overall goal with this thesis is to determine a gene therapy based approach to 
provide benefit to myocardium with chronic heart failure, stemming from ischemic injury. 
We would like to develop and optimize a gene drug, which effectively translates to a 
cardiac benefiting protein and can provide significant improvements in cardiac function. 
Towards this main goal of designing and delivering a cardiac benefiting gene drug, we 
would like to optimize the delivery of this drug by understanding the principles required 
to systemically deliver this to the injured cardiac tissue. Having done that, we would have 
developed a drug, capable to providing cardiac relief that can be delivered systemically to 
patients, thus minimizing the trauma associated with multiple surgeries.  
 
However, the need for more efficient drugs to support the prevention and 
regeneration of cardiac tissue, and reverse the remodeling caused by ischemic injury, 
leads us to focus on other cardiac pathways, responsible for this remodeling, following 
treatment with mesenchymal stem cells. This will provide us with leads to follow, in 
future, for other candidates that may be able to provide a better benefit to the 
myocardium and improve quality of life in patients.  
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1.4 Specific Aims 
 
Hypothesis 1 
 
 Adult stem cell therapy for preventing and treating cardiac dysfunction is due to 
paracrine factors; therefore, the results of cell therapy can be achieved by gene transfer.  
To effectively design a gene it is necessary to manipulate the gene expression in vivo.  A 
bioluminescent reporter can be used as a method to determine real time information on 
gene expression for plasmid profiling. This reporter will utilize optical imaging in order 
to determine changes in expression of a plasmid with the reporter gene and other 
enhancer elements.  
 
Specific Aim 1 
 
The goal of this study was to determine if re-establishing myocardial plasmid SDF-1 
expression without the concomitant delivery of cells would provide a significant benefit 
in cardiac function by increasing myocardial vascular density in an ischemic 
cardiomyopathy condition. This study aimed to design and monitor the expression of the 
naked plasmid for effective gene therapy capable of expressing and sustaining expression 
in rodent hearts. We also wanted to evaluate if optical imaging could provide detailed 
information about changes in gene expression, with modifications to the plasmid design.   
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Therefore, the primary focus of this study was to investigate the role of naked SDF-1 
gene when delivered in chronic ischemic hearts in vivo. Transient expressions of the 
naked SDF-1 plasmids were monitored for corresponding functional responses mediated 
in rodent ischemic hearts. To manipulate gene expressions, our secondary focus was to 
identify a gene design for efficient delivery of the SDF-1 gene into the ischemic 
myocardium. We investigated the role of transcription enhancers, Kozak sequences, and 
cardiac specific promoters for this purpose. 
 
Hypothesis 2 
 
 A safe, effective and targeted delivery of naked plasmid to the heart, without having 
to reopen the chest, is important for targeted, systemic delivery of drugs to the 
myocardium. Infusion of phage display libraries within M13 bacteriophage may be useful 
in identifying specific targeting ligands in the infarct region of the heart.  
 
Poly lactide co glycolide (PLGA) derived polymeric devices may be able to 
encapsulate drugs and deliver them safely to tissues via the systemic circulation. The 
targeting peptide when tagged to the polymeric complex, may be viable and in its active 
form, and will be able to direct the polymeric complex to the injured myocardium. The 
PLGA polymer will then be able to release the encapsulated material into the area of 
injury.  
 
 
9 
 
Specific Aim 2 
 
The main focus with this aim was to engineer a targeted delivery carrier for gene 
drugs into the ischemic myocardium. The delivery of genes involves two complicated 
aspects: the targeting of the gene into the region of interest, and carriers for the 
maintenance and delivery of the gene in vivo without degrading it. Our primary focus was 
divided into two secondary focuses, a) To identify a peptide sequence, via phage panning 
to target the genes to the ischemic myocardium when injected intra-venously, b) to utilize 
nanoparticles for the encapsulation of the naked genes to prevent degradation of the DNA 
and tagging targeting peptides to the surface of these devices to mediate effective 
delivery of the DNA.  
 
We wanted to identify one or a few ligands that have a high affinity for infarct tissue 
and are specific to the heart. This can then be used to tag polymeric devices to infuse 
therapeutic genes to the ischemic myocardium. Our goal then, was to design a 
nanoparticlulate carrier capable of encapsulating a fluorescent dye, and delivering it to 
the myocardium, with the help of a tagging peptide. The uptake and in vivo trafficking 
will be monitored to determine the dose, time, and other aspects associated with this 
delivery system.  
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Hypothesis 3 
 
Recruitment of stem cells mediated improvement, in ventricular function is due to 
reverse ventricular remodeling. In previous studies, we have shown that Monocyte 
Chemoattractant Protein -3 (MCP-3) based recruitment of mesenchymal stem cell therapy 
leads to the expression of paracrine factors capable of improved ventricular function 
without the differentiation of cardiac myocytes, or blood vessel growth in the 
microenvironment. This reverse ventricular remodeling is attributed to paracrine factors 
secreted in the microenvironment.  
 
Whole genome analysis provides sophisticated, yet specific information on all genes 
in the genome that are affected as a result of the application of therapy. Therefore whole 
genome analysis would be a viable option to identify pathways associated in the changes 
that lead to functional improvement thereby leading us to paracrine factors associated 
with this improvement. 
   
Specific Aim 3 
 
The primary focus of this aim is to identify cardiac pathways associated with 
reversing ventricular remodeling, following therapy with mesenchymal stem cells and 
then identifying proteins associated with ischemic disease and repair.   
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The goal is to identify candidate proteins responsible for the improvement in cardiac 
function when mesenchymal stem cells are recruited to the injured heart tissue due to 
MCP-3 over-expression. To understand and identify these proteins and pathways we shall 
employ whole genome analysis and back that with pathway analysis studies. Important 
aspects of genome wide experiments will be the large number of genes assessed and the 
high sensitivity of this approach.  
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CHAPTER II 
 
BACKGROUND 
 
2 BACKGROUND 
 
2.1 Cardiovascular Disease 
 
Cardiovascular disease ranks among the leading causes of morbidity and mortality in 
the world today with more than 80 million people who suffer from one or more forms of 
it, just in the United States. Cardiovascular disease is a pathological condition affecting 
the normal functioning of the heart due to an injured or overworked heart muscle, or an 
electrical imbalance determining the rhythm. These fall under a general umbrella of four 
types; dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy 
and arrhythmogenic cardiomyopathy. The causes for any of these forms can be due to 
bacterial or viral infections, genetic mutations and predispositions, the growth and build 
up of fatty components in the arteries and heart walls, abuse of cardio toxic substances, 
like caffeine and alcohol, or a secondary symptom of other chronic conditions, such as 
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hypertension and diabetes. Any or all of these forms have the potential to develop into a 
more progressive heart failure. While each of these conditions can cause a clinically 
significant cardiomyopathy, the focus of this work is primarily on ischemic 
cardiomyopathy. 
 
2.1.1 Myocardial Infarction: 
 
One of the more common types of cardiovascular diseases is Myocardial Infarction 
(or Acute Heart Attack) which occurs when there is a lack of blood supply to the heart. 
This condition affects more than 8 million people in the United States with 1.1 more 
being added each year.1   The most common cause is due to a coronary artery disease 
(CAD); when a plaque ruptures and causes intra coronary thrombosis and disrupt blood 
flow, distal to thrombosis. The extent of damage to the heart depends on the duration of 
ischemia, and can lead to permanent damage if not treated immediately.  
 
The cells of the heart tissue are terminally differentiated and thus do not repair 
themselves following damage. Following lack of blood supply, the myocytes, endothelial 
cells, nerves and fibroblasts die by a process called necrosis. This is then followed by an 
influx of inflammatory components, including macrophages, neutrophils and 
granulocytes that replace the viable muscle with a dead scar region, which is not an ideal 
replacement to the loss in function. The ventricular wall with a scar tissue lining which is 
unable to contract during the pumping action of the heart is not able to provide the same 
cardiac output as a healthy, viable wall. To compensate for this loss in output the 
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ventricle enlarges by either hypertrophy of the cardiac cells or by increase in ventricular 
volume, corresponding to thinning of the scar tissue. These conditions lead to a 
progressive heart failure condition.2, 3 
 
Damaged heart, incapable of pumping the right amount of blood, can also lead to a 
life threatening condition, cardiac arrhythmia. Cardiac arrhythmias are conditions when 
the heart is unable to synchronize its pumping action thus causing abnormal beats or 
rhythms. Often times this leads to insufficient supply of blood pumped from the heart and 
may lead to cardiac arrest.4 
 
2.1.2 Heart Failure 
 
The combination of ventricular fibrosis, muscle cell hypertrophy, dilation of the 
ventricle, thickening of the ventricular wall, and thinning of the scar tissue is termed 
ventricular remodeling. These pathological conditions are symptomatic of a more 
progressive condition known as chronic heart failure.3, 5 
 
Heart failure is among the leading causes of morbidity in the Western world, with a 
prevalence of 5.4 million Americans and an incidence of 690,000 cases being added each 
year. Coronary Artery Disease leading to Acute MI is the most common cause for heart 
failure. Other causes may be due to some or various forms of cardiomyopathy, attributed 
by genetic dispositions, personal lifestyles, cardio toxic abuse, pregnancy, radiation, and 
other chronic conditions such as diabetes, hypertension etc.  
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As heart failure is a progressive condition, the diseased state is classified into various 
classes based on the quality of life, class 1 for patients who are least affected physically 
by the condition and class 4 for those who are severely limited in their day to day activity 
and class 2 and 3 in between these two. Pathologically, the disease is classified based on 
the condition of the heart muscle, Stage 1 is a classification for patients at risk for heart 
disease, due to lifestyle choices, or secondary conditions but with no cardiac tissue 
compromise. Stage 4 is assigned to patients with structural heart disease and previous 
symptoms of heart failure.3, 6  
 
The same pathways that are triggered as a response to acute cardiac injury, when 
sustained for longer periods of time, lead to a progression of events causing chronic heart 
failure.  Some of these are mediators present in the circulatory system, such as 
angiotensin II,7, 8 which is released as a result of low cardiac output can lead to increase 
in cardiac hypertrophy, others such as norepinephrine, cause cardiotoxicity and 
arrhythmias,9 and TNF-α which decrease contractility.10 A family of peptides, also used 
as a diagnostic tool, is β-natriuretic peptides that are released as a response to increased 
ventricular pressure, can cause vasodilation.11 These cytokines released in response to 
myocardial injury, can worsen cardiac and endothelial dysfunction with the progression 
to heart failure.  
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2.2 Current Treatment Options for Heart Failure 
 
Heart failure is not an isolated event that can be controlled or reversed after its 
occurrence. The current treatment options involve alleviating the symptoms associated 
with it and preventing a worsening of the condition. There are currently no available 
options to entirely cure a person of this condition. For patients without any structural 
damage or physical limitations, the simplest solution is to prevent the occurrence for one. 
This involves a few drugs that can help prevent the damages caused by secondary 
components. However, these are not sufficient for patients dealing with advanced stages 
of heart failure thus a number of other treatment options have been developed in the last 
few decades that support the heart from assistance to total replacement.  
 
2.2.1 Cardiac Devices 
 
Implantable cardiac defibrillators (ICDs) are devices that are connected to the heart 
tissues via electrodes. When the leads detect an abnormality in the beating action, e.g. 
tachycardia or fibrillation, they send a signal to the pulse generator, stored in the upper 
chest under the skin, which then sends a pulse or a shock to the heart thus setting the 
rhythm back for the pumping to continue. Cardiac Resynchronization is a technique by 
which electrical leads are placed on the atria and ventricles and these are then connected 
to a small battery operated device placed under the skin. The device sends electrical 
pulses routinely to the atria and ventricles which then contract in tandem. Such a 
procedure allows for effective ventricle ejection, reduction in ventricular size, and 
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improvement in cardiac function. A Left Ventricular Assist Device (LVAD) or a Total 
Artificial Heart (TAH) is used in patients with hearts that have completely lost the 
capability to function. Revascularization of the ventricle is a viable option when the left 
ventricle may be capable of functioning again.  The myocardium may either be ischemic, 
infracted, stunned, or hibernating. Ischemic myocardium is one where the supply of 
blood to it, has been disrupted. The flow of blood back to it will repair the damage done 
relatively quickly. Stunned myocardium is one, where there is muscular dysfunction due 
to prolonged ischemia.12 Revascularization will benefit the patient over a period of time. 
Hibernating myocardium is one where revascularization may or may not respond to 
revascularization, although revascularization coupled with other forms of functional 
assistance may provide benefit. Infarcted tissue is one where scar tissue has progressed 
with the lack of myocytes in the region. Revascularization may not provide any benefit in 
such situations.3, 12 
 
2.2.2 Cell Therapy for Heart Failure 
 
Cell Therapy has evolved as a promising mechanism for cardiac repair for more than 
a decade. The potential of several different populations of cells, including fetal 
cardiomyocytes, skeletal myoblasts, bone marrow derived progenitor cells, and 
embryonic stem cells has been studied in animal models and clinical populations in an 
attempt to repair the damage in ischemic cardiac tissue.13-15 Ideally, the right type of cell 
should be able to survive in a hypoxic environment, with reduced angiogenesis, and 
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should be able to interact with the host cardiac tissue and integrate with it in order to 
facilitate contraction of the tissue, synchronous with existing heartbeats.  
 
The first studies used fetal cardiomyocytes, which retain the potential to grow as 
they possess the required growth factors and signals necessary to do so. Leor et al studied 
the ability of human and rat fetal cardiomyocytes to engraft in ischemic rat myocardium 
following coronary ligation.16  These cells engrafted and survived for up to 2 months post 
transplantation. Similar results were observed with cells encapsulated within 
bioengineered grafts with improved vasculogenesis in the graft tissue and improved LV 
function.17,18 The improvement in LV function is due to improved morphological 
engraftment, coupled with the improvement of electrical conduction and rhythmic 
contractions of the ventricle.19,20 Fetal cardiomyocytes have been shown to couple and 
integrate with host cardiomyocytes through gap junction proteins, such as N cadherins 
and connexin-43.19  
 
Although fetal cardiomyocytes successfully engrafted with the host tissue, a scar 
region differentiated the newly formed myocardium and the host myocardium. Similar 
results with xenogenic neonatal and fetal cardiomyocytes have showed significant 
engraftment to host tissue and improvement in cardiac function in larger animals.13 In 
spite of increasing evidence, proving successful transplantation of fetal cardiomyocytes, 
the use of these cells in treating patients leads to ethical concerns. The use of xenogenic 
cells is accompanied by immunological concerns and its clinical significance has not 
been tested.21 
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Skeletal myoblasts are rapidly mobilized following injury and have the potential to 
proliferate in ischemic conditions. Also, they are not stem cells therefore can retain their 
lineage, thus reduce the risk for uncontrolled proliferation into various cell types and are 
autologous, thus eliminating the need for xenogenic transplantation. The first studies 
were performed in rabbits with cryoinjured myocardiums.22,23 Transplantation of 
autologous skeletal myoblasts, have since shown a trend towards engraftment to host 
tissue and improved cardiac function capable of being taken to larger animals and 
towards a clinical perspective.24-26  This engraftment is not coupled to the host tissue via 
the gap junction proteins, nor does it trans-differentiate to cardiac cells, but occupies the 
scar zone as multinucleated striated cells and improvement in function is only detectable 
in these pockets of striated myotubes directly proportional to the number of cells 
injected.22, 27 This has led researchers to believe that the cardiotropic benefit attained by 
skeletal myoblast transplantation is due to paracrine factors released by these cells  and 
the cardiac tissue, but these factors have been ill defined.28, 29 Also, the engraftment is 
independent of the host cardiac cells and thus may lead to ventricular arrhythmias.  
 
Bone marrow derived cells include whole bone marrow preparations,30,31 
hematopoietic bone marrow stem cells (HSC),32, 33 mesenchymal stem cells (MSC),34, 35 
multipotent adult progenitor cells (MAPC),36 and endogenous cardiac stem cells 
populations,37 all of which have been shown to improve cardiac function in animal 
models and clinical perspectives. These cells can be modified to change their phenotype 
in vitro in order to differentiate into cells of the cardiac lineage before they are 
transplanted into the ischemic myocardium, or are transplanted into the myocardium and 
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are transdifferentiated in vivo or elicit paracrine factors that assist in the improvement in 
cardiac function due to the activation of other survival and angiogenic pathways. 
Embryonic stem cells and induced pluripotent stem cells have recently become more 
attractive options due to their totipotency, thus the ability to differentiate into 
cardiomyocytes.14, 38, 39  
 
However, from a clinical perspective, there a many challenges involved, apart from 
the regulatory and ethical concerns. Embryonic stem cells are limited in the purification 
of specific lineages, concerns regarding the formation of teratomas, in vitro 
differentiation and in vivo engraftment into host tissues. Induced pluripotent stem cells 
can overcome the graft rejection and ethical concerns but the risk of teratoma formation 
still exists.   
 
2.2.3 Cell Taught Gene Therapy 
 
While there is clearly emerging evidence that future cell based therapies will 
ultimately yield clinical benefit, it is also becoming clear that, in the absence of 
embryonic or induced pluripotent stem cells, the benefits achieved may be in the absence 
of myocardial regeneration.  Rather, the benefits of adult stem cell based therapies appear 
to be due to paracrine effects delivered following cellular homing and engraftment in the 
injured myocardium. If paracrine effects dominate the benefits of adult cell based 
therapies, then one could postulate that adult stem cell based therapies will evolve into a 
new wave of gene therapies.40  This new wave of gene therapy will not be based on gene 
21 
 
product that we believe the normal myocardium should have; but rather will be based on 
gene targets that cell therapy would have taught us that benefit the myocardium in an 
injured state.   
 
The primary genes of interest were the vascular endothelial growth factor (VEGF) 
gene family, as well as fibroblasts growth factor (FGF).  These gene products were 
demonstrated in studies in vitro to induce endothelial and smooth muscle cell 
proliferation. In preclinical studies, in the absence of atherosclerosis, the administration 
of VEGF or FGF protein or gene transfer led to significant capillary and arteriolar blood 
vessel growth.37,41, 42  While no clinical product has evolved from these studies to date, 
significant advances in know-how and knowledge in the field of myocardial gene therapy 
were achieved by providing a better understanding of vectors, doses, and backbones that 
help design it.   
 
2.3  Stem Cell Therapy for Cardiac Failure 
 
Using cell therapy as means for providing cardiac benefit was developed because 
having a viable tissue was better than a collagenous scar tissue in the myocardium. Initial 
studies were performed with skeletal myoblasts and when that led to engraftment led 
arrhythmias, researchers moved to more versatile forms of bone marrow derived 
pluripotent cells.43 Stem cell therapy began with the hope of differentiating these cells, 
either in vivo or in vitro to replace the lost or damaged cardiac cells.  
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Early studies with hematopoietic cells showed great improvements in cardiac benefit by 
myogenesis following transplantation of ckit+ cells.44  This study further led to clinical 
trials, but the earlier studies representing myocardial differentiation of hematopoietic 
cells have not been corroborated by subsequent studies.15 Instead the improvement in 
function was attributed to increase in angiogenesis and arteriogenesis.45,46 Moreover, 
unknown parameters such as timing of delivery, methods of purification and storage of a 
single cell population, selection of patient population and techniques for cell delivery 
have limited the clinical trials giving rise to heterogeneity within the trials themselves.47  
 
Other cell populations, including mesenchymal stem cells, and multipotent adult 
progenitor cell, have been shown to improve cardiac function in animal models but most 
theories regarding the differentiation of these cells to cardiomyocytes have been limited 
and not unanimous. In fact, MSCs have been exploited as the more attractive option for 
cell delivery as they can be easily proliferated in vitro, they secrete a variety of growth 
hormones, such as IGF, HGF, VEGF etc,48-50 elicit paracrine factors, in vivo, such as 
sfrp2, SDF-1, MCP-3 etc,51-54  and thereby are able to provide repair in more than one 
aspect of tissue damage. Currently, the focus of research has shifted from myogenic 
differentiation to peripheral parameters that improve the environment around the infarct 
zone to provide for cardiac benefit.  
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2.3.1 Homing Factors  
 
The first few steps required for efficient cardiac tissue repair with stem cell therapy 
is the need for targeting the cells to the area of injury and to engraft it there. Traditionally, 
homing occurs as a stress response, when certain factors are released by cells, following 
injury, as a signal to recruit either stem cells from the bone marrow and inflammatory 
cells in order to begin the repair process.  
 
One such chemokine is SDF-1 which is shown to be elevated in an injured 
myocardium and recruits stem cells to the area providing cardiac benefit.55 We, in our lab 
have also shown that MSCs infused intravenously home to the heart one day post MI but 
not when infused 14 days after MI. This is attributed to the fact that SDF-1 peaks one day 
post MI and drops by 7 days. Moreover, plasma elevation of SDF-1 induces 
hematopoietic stem cell and platelet migration to the area of injury.56 Apart from adult 
tissue, stem cell homing has been shown to be critical in mice fetuses, where the 
elimination of either the homing factor (SDF-1) or its receptor, CXCR4, is fatal for 
development due to the lack of homing of the essential cells to the interstitial space to 
form blood vessels.57, 58 
 
The homing of mesenchymal stem cells is a slightly more complicated process, as 
the molecular mechanisms that define these are not completely understood. Mesenchymal 
Stem Cells possess the CXCR4 receptors on its surface and therefore migrate towards the 
SDF-1 chemotactic gradient. However, the amount of CXCR4 receptors are limited and 
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this limits the amount of MSC migration leading to limited tissue benefit. Endothelial 
progenitor cells, precursors to blood vessels, respond to IL-8, released in injured tissues, 
and prevent apoptosis.59,60 However, these cells are not capable of angiogenesis, probably 
due to reduced function in a hypoxic environment. In our lab, we have demonstrated the 
homing of MSCs as a response to Monocyte Chemoattractant Protein -3 (MCP-3).52 LAD 
ligated rodents were infused with MSCs and Cardiac Fibroblasts to show that only MSCs 
migrated to the myocardium and cardiac fibroblasts did not. Using a DNA assay, 
monocyte chemoattractant protein was identified to be a myocardial homing factor for 
stem cells.  
 
Transplanting cardiac fibroblasts over expressing MCP-3 in the myocardium we 
have been able to show an elevation in MSC homing to the heart immediately after MI, 
and late after MI. Reestablishing the homing factors can lead to reestablishing homing of 
stem cells. We also observed that the over expression of SDF-1 immediately after AMI, 
leads to the recruitment of cardiac stem cell like cells to the area of injury. Interestingly, 
although these cells are positive for cardiac myosin, they are not differentiated cardiac 
myocytes. These cells also possess CXCR4 on their cell surfaces thus determining their 
lineage to be cardiac stem cells.  Also, optical mapping studies demonstrated that these 
cells are capable of de-polarizing in vivo, therefore may possess the ability to contract. 
The recruitment of cardiac stem cell like population into the infarct zone can alter 
electrical activity and may have a significant impact on the electrical functions of the 
myocardium.61    
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Figure 2-1: Role of SDF-1 in AMI as a homing factor for stem cells 
 
 
2.3.2 Role of SDF-1 in Acute Myocardial Infarction 
 
It has been established that CD34+ cells home to the infarct zone, following Acute 
Myocardial Infarction (AMI). To understand the triggers signaling the targeting of these 
cells from the bone marrow to the heart, initial studies were performed to determine the 
levels of mobilizing cytokines in the serum plasma. The increase in the amount of CD34+ 
cells correlated to the increase in levels of G-CSF (Granulocyte colony stimulating factor) 
and an increase in SDF-1 (Stromal derived cell factor-1).62  
 
To understand the role of G-CSF and SDF-1 in promoting homing in AMI, rodents 
were injected with G-CSF in the presence and absence of cells over expressing SDF-1, 
transplanted in the cardiac tissue. G-CSF was not sufficient to mobilize the bone marrow 
derived cells, establishing the role of SDF-1 as the homing agent.55 Further studies 
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identifying the role of SDF-1 in mobilization of CD34+ cells was demonstrated with 
emphasis on the SDF-1 CXCR4 axis playing a pivotal role, in the homing of stem cells.63 
Stem cells, positive for the CD34 marker, in the bone marrow possess the receptor 
CXCR4. An increase in SDF-1, a ligand for CXCR4, in the plasma leads to the targeting 
of the CD34+ cells.  
 
This homing is prevalent in the first 12 hours following injury and then drops 
significantly over a week. Furthermore, the levels of the stress cytokines are proportional 
to this homing effect, where levels of VEGF and SDF-1 increase following AMI after the 
first day, and continue to increase for 3 days following injury.64 The levels then start 
dropping to normal levels by the end of a 7 day follow up.55 The initial theory regarding 
the trans-differentiation of these early cardiac marker cells, following the homing to 
ischemic tissue was refuted in a study from our lab, to identify trophic factors to be the 
cause of the repair mechanism.  Rodents with AMI were treated with infusions of 
mesenchymal stem cells over expressing SDF-1, and showed great improvements in 
cardiac function. This improvement was attributed to a decrease in apoptotic nuclei, a 
decrease in scar tissue formation and a significant improvement in vessel density in the 
infarct zone.35 
 
Subsequent studies have followed regarding the use of SDF-1 without the 
concomitant use of cells, to over-express SDF-1 in infarcted regions to understand the 
improvement in cardiac functions thereafter. SDF-1 protein injections was the most 
straightforward of these and injecting SDF-1 directly into the center of an infarct 
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demonstrated improved cardiac benefit by increased neovascularization in infarct zones 
and reduction in scar sizes, but the effect was short lived and failed to provide clinically 
relevant results.33, 65, 66  To prolong the effect of SDF-1, controlled release of the protein 
was then studied. SDF-1 protein encapsulated within nanofibers, when injected 
immediately after coronary ligation, has shown to provide improvement in cardiac 
function coupled with increase in vascular density.67 A controlled release of SDF-1 
provided by a PEGylated fibrin patch when placed in situ after coronary ligation in mice, 
showed a marked improvement in cardiac function following recruitment of CD34+ cells. 
The improvement was more prominent after 2 weeks and was sustained at 4 weeks.68 
SDF-1 promotes cell survival immediately after MI and also helps reverse ventricular 
remodeling and prevents heart failure. 
 
2.3.3 Role of SDF-1 in CHF 
 
As established earlier, our lab has also shown that MSCs infused intravenously home 
to the heart one day post MI but not when infused 14 days after MI.69  This is attributed 
to the fact that SDF-1 peaks one day post MI and drops by 7 days.  To determine if the 
homing reaction produced by SDF-1 could elicit a meaningful response late after injury, 
rodents were infarcted via LAD ligation, and were allowed to develop a chronic heart 
failure model for 2 months. In this time, the ventricular cavity had dilated, the scar tissue 
had developed and viable myocardium in the ischemic region had died due to apoptosis. 
8 weeks after ligation, control fibroblasts, or those over-expressing SDF-1 were 
transplanted into the ischemic myocardium. Animals that received the SDF-1 expressing 
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cardiac fibroblasts, had a greater number of proliferating cells, including, CD117+ 
(hematopoietic stem cells), CD45+ (leukocytes), CD34+ (hematopoietic stem cells, 
endothelial progenitor cells) and vWF + (endothelial cells) cells in their heart tissues. 
Apart from acting as a homing factor for these cells, the presence of the angioblasts and 
paracrine factors released by the recruited cells, led to a significant improvement in 
cardiac function, as determined by their fractional shortening.69  
 
2.3.4 Molecular Mechanisms Involved in SDF-1 CXCR4 axis 
 
CXCR4 is present in CD34+ cells, such as hematopoietic stem cells, endothelial 
progenitor cells, and cardiac stem cells.64,70-72 Following myocardial infarction, the 
mRNA expressions of SDF-1 has been shown to be elevated in the left ventricular 
anterior and posterior walls in animal studies.55, 69 Cells with the CXCR4 receptor, stem 
cells, now migrate towards a SDF-1 chemotactic gradient and thus home towards the 
ischemic myocardium. SDF-1 present in systemic circulation is sufficient to mediate this 
recruitment.61,70 When SDF-1 binds to its receptor CXCR4 it leads to the activation of 
other paracrine factors such  as P selectin ligand, E selectin ligand,73 Very late antigen 
VLA4, VLA5 etc, on the surface of hematopoietic stem cells.74 These ligands bind to the 
receptors P selectin, E selectin, Intracellular Adhesion Molecule (ICAM) on endothelial 
cells and allow them to roll over the endothelial cell layer allowing for transmigration 
along the cell layer thus recruiting cells to the area of injury.74-76  
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The interaction of SDF-1 ligand with the G-protein coupled receptor, CXCR4 
triggers intracellular pathways involving Akt phosphorylation, Ca2+ influx, mitogen-
activated protein kinases (MAPKs) phosphorylation, activation of PI3 Kinases, and JAK 
STAT pathway activation.77  Following SDF-1 up regulation in the infarct zone, 
phosphorylation of Akt and up regulation of VEGF are observed which leads to cell 
preservation.53, 78 Cell survival can also be attributed to downstream signaling of Akt 
involving BAD, NF-kB, and NO from e NOS.79 Also, SDF1 CXCR4 coupling activate 
both PI-PLC and PI3K, which activates PKC.80 PKC activation induces Pyk2 and ERK 
activation, leading to adhesion and chemotaxis as well as gene transcription via MAPK 
activation. MAPKs are a family of protein kinases that consist of ERKs, p38, MAPK and 
JNK which mediate apoptosis. PKC also mediates the activation of NF-kB which in turn 
mediates MMP-9 production allowing for matrix remodeling and reducing the scar tissue 
which in turn allows for reverse ventricular remodeling.81, 82 
 
2.4 Overview on Gene Therapy 
 
Gene therapy involves the manipulation of nucleotide sequences involving the 
recognition, selection and integration of the desired genes in a chromosome. Since early 
1990’s up to now, more than 900 clinical trials involving gene therapy in various disease 
conditions, such as cancer, monogeneic diseases, vascular diseases, immunogenic 
diseases, etc have been carried out.83, 84 The most evident application of gene therapy is to 
replace a defective/abnormal gene by its normal counterpart in order to benefit the 
organism, by supporting normal functioning. This replacement is preferred to be a stable, 
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safe and permanent one, in order to constitutively provide normalcy in the organ. Another 
application of gene therapy involves suppressing an unwanted reaction by the organ, such 
as in cancerous tissue, in order to prevent the growth of tumors. Genes can also be used 
as a drug or a prodrug, which encodes for an enzyme or a protein that can act as a 
cytotoxic drug to eliminate the tumor and its environment. This application of genes as 
prodrugs can also be used to promote the growth of certain growth factors or enzymes 
that may help provide relief to repair injured tissues or organs.  
 
2.4.1  Gene Therapy in Heart Failure  
 
Significant pioneering work was done in the 1990’s in the field of cardiovascular 
gene therapy.  Gene therapy was involved not only in therapeutic purposes, but played a 
significant role in diagnosis of key participants in the heart failure process. Multiple 
studies regarding the apoptosis of cardiac myocytes following ischemia have been 
reported, and the role of TNF-α in cardiac dilation, procaspase-8 in dilated 
cardiomyopathy, and gp180 molecules in cardiac apoptosis following pressure overload 
have been elucidated.10, 85, 86 
 
As therapeutic options in cardiac applications, gene therapy studies are responsible 
for preventing apoptosis and promoting survival signaling. The members of the PI-3 
kinase pathway also include Akt phosphorylation that leads to survival and growth of 
myocytes, as seen in the prenatal heart.87, 88 Insulin Like Growth Factor-1 is another pro 
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survival protein that prevents naturally occurring apoptosis.89 SDF-1 has been shown to 
prevent apoptosis, and induce the growth of vessels in ischemic zones. 66 
 
However, in a heart failure condition the focus is on inducing angiogenesis in an 
attempt to treat “no option” patients who are presented with diffuse coronary artery 
disease and chronic ischemia. The genes of interest could be characterized as those that 
investigators believed would benefit the myocardium, not necessarily those that were 
inherently needed by the heart.  These genes would provide peripheral support to the 
ischemic tissue, by enriching the environment thus promoting cardiac benefit. The 
primary genes of interest are those of the vascular endothelial growth factor (VEGF) gene 
family, as well as fibroblasts growth factor (FGF).90, 91  In a protein form, these factors 
were not sufficient to elicit any clinically meaningful results.92,93 Growth factors have 
short half lives, and thus it was hypothesized that a gene therapy approach would allow 
for prolonged sustenance and effect. These gene products were demonstrated in studies in 
vitro to induce endothelial and smooth muscle cell proliferation.94-96 In preclinical studies, 
in the absence of atherosclerosis, the administration of VEGF or FGF gene transfer led to 
significant capillary and arteriolar blood vessel growth.97, 98 However, none of these gene 
therapy products have been approved for clinical use in cardiovascular patients yet.  
 
2.4.2 Advantages and Disadvantages of Gene Therapy  
 
Initial studies regarding transplantation of skeletal myoblasts in ischemic regions in 
the heart have not been able to provide enough functional benefit in the heart. Moreover, 
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this effect was lost in a 4 month follow up.27 More concerning, is the fact that this cell-
therapy treatment may lead ventricular arrhythmias.25 Gene therapy is a more straight 
forward approach where the ultimate goal is either to over-express a gene such as to 
achieve therapeutic levels of cardioprotective protein, or the knocking-down of genes that 
may lead to cardiotoxicity. However, the first clinical study with gene therapy led to the 
death of a patient, due to immune toxicity. Gene therapy has to battle a few factors that 
lead to its inefficacy in clinical trials.84, 99 
 
Transient Expression: It is undesirable to let genes integrate into the host genome 
such as to provide this constitutive effect for future generations. However, it is necessary 
to have a transient supply of the therapeutic DNA for a clinically relevant period of time. 
The cells that inherit the DNA must also be able to proliferate, survive and stably express 
this DNA for the same period of time. This will prevent the need for patients to undergo 
multiple rounds of the therapy in order to sustain the therapeutic level of benefit. 
Furthermore, the level of proteins translated directly relate to the amount of DNA 
injected into the patient. However, the corollary may also pose a risk, where unregulated 
gene expression leading to unchecked protein levels may have detrimental effects.  
 
Immunotoxicity: For an effective, stable DNA expression, these plasmids are 
packaged into viral vectors and then introduced into the patient. The main advantage of 
viral vectors is that it yields very high transfection efficiencies.  However, viral vectors 
pose numerous safety and efficacy issues, ranging from toxicity and immune and 
inflammatory responses, to gene control and targeting issues. The presence of such 
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foreign bodies can lead to an enhanced immune reaction by the body, hoping to destroy 
this foreign object, thus reducing the effectiveness of the enhanced gene. This can further 
lead to the immune system attacking healthy tissues and can pose a high risk to the organ.  
Furthermore, the immune system's enhanced response to invaders it has encountered 
before makes it difficult for gene therapy to be repeated in patients. 
 
Cardiovascular Applications: Unlike single gene mutation disorders, where the 
defective gene can be replaced by the normal gene sequence, cardiovascular diseases 
come with multiple symptoms, from loss of contractility, loss of blood vessels, loss of 
growth factors, increased inflammatory reactions, deposition of collagenous scar etc. 
Treating such conditions with gene therapy will only be possible with treating it early and 
before the tissues are beyond repair. In chronic heart failure, although there may be 
methods of providing cardiac benefit and an improved life style for the patient, it is 
difficult to bring the heart back to a normal healthy tissue.  
 
2.4.3 Non Viral verses Viral Constructs 
 
Delivering the genetic material into a host cell involves the use of vectors, which 
could either be viral or non viral. Direct injection of naked DNA is widely employed in 
gene transfer studies as it is relatively safe, is cost effective and can be produced in large 
quantities in bacteria and can also be manipulated by standard recombinant techniques.100 
Moreover, it possesses low immunological toxicity, is water soluble and heat stable.  In 
earlier cardiovascular diseases, this method was widely used for the same reasons. On the 
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other hand, naked DNA has low transfection efficiencies, can be degraded rapidly and 
generally needs targeting or condensing agents to penetrate the cell wall. 101  
 
It has been seen in the past that transfection decreases with increase in animal size.102 
Expression levels are slightly lower in rats than mice and significantly decrease with 
rabbits and pigs which make it unsuitable for large animal studies.102,103 Greater 
expression of the gene can be achieved by complexing the DNA with compounds such as 
cationic polymers,104 lipopolymers,105 PEI,106 and liposomes.107 Such compounds not 
only protect the DNA from degradation but also condense them into smaller sizes so that 
it can mediate uptake by the cell. Despite alternative approaches, non viral delivery 
methods yield transient and non site specific expressions, which make it non feasible for 
conditions that require long lasting expressions such as cardiomyopathies.  
 
The major advantage of viral vectors is that its yields very high transfection 
efficiencies. The difference between viral transduction efficiencies and non viral ones are 
due to the difference in uptake mechanisms between the two. In contrast to non viral 
vectors, which may get degraded in the presence of lysosomes, viral vectors are readily 
bound to cell surface receptors, which prevent native degradation of the virus.108  
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 Advantages Disadvantages 
Naked 
plasmid 
Safe 
Cost effective 
Bulk processing available 
Low toxicity 
Water soluble 
Heat stable 
Low transfection efficiency 
Transient expression 
Adenovirus High transfection efficiency 
Can be taken up by all cell 
types 
Easy to produce 
Tropism for multiple cell types 
Adverse immunological 
responses 
Transient expression patterns 
High toxicity 
Adeno 
associated 
virus 
Non pathogenic vectors 
Long term expression patterns 
High transduction efficiency 
Can be taken up by all cell 
types 
Low immune responses 
Limited transgene capacities 
Difficult to produce in large 
quantities 
Lentivirus Long term expression patterns 
Can integrate into all cell types 
Can be driven by various 
promoters 
Safety issues 
Difficult to produce in large 
quantities 
Low transduction efficiency 
 
Table 2-1: Comparison between viral and plasmid vectors for gene delivery 
 
 
2.4.4 Naked Plasmids 
 
Most commonly, non viral delivery techniques involve the use of naked plasmid 
alone, or naked DNA either encapsulated within polymeric delivery systems or liposomes 
in order to protect DNA from degradation and to allow for a consistent expression over 
time.109, 110 The use of non viral vectors can circumvent most issues associated with viral 
vectors, mainly safety associated with immunotoxicity. On the other hand, 
unencapsulated DNA can be modified, with the help of transcriptional and translational 
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enhancers, in order to achieve similar benefits. Other aspects that affect the transfections 
involved with naked plasmid delivery are based on technical details such as the number 
of injections, the time of delivery, the amount of DNA used, site of injection and so forth 
as described in the table below.96, 102, 107 
 
Dose Needle Area Number of 
injections 
Time of 
injection 
Treatment 
20 μg / 
100 μl of 
saline  
Curved 
30 gauge 
Infarct 
border 
zone  
4 to 5  1 week after 
infarct 
Naked with bFGF 
and PGDF 
15 μg / 
200 μl of 
sucrose  
30 gauge Infarcted 
area 
1 2 weeks 
after infarct 
HVJ liposome 
method 
500 μg / 
150 μl of 
saline 
24 gauge Left 
anterior 
border 
zone 
1 24-50 days 
after infarct 
phVEGF 
60 μg / 
100 μl of 
saline  
30 gauge border 
zone 
1 1 week after 
infarct 
phVEGF and 
adVEGF 
50 μg / 
100 μl of 
saline  
30 gauge Left 
anterior 
free wall 
1 At the time 
of infarct 
HIF1 and VP16; 
phVEGF 
 
 
Table 2-2:  Various parameters involved in gene delivery 
 
2.4.5 Translational Enhancers  
 
Enhancers are a short sequence of nucleotides either present upstream or downstream 
to the transcription activator site, or the start codon and can boost the transcription or 
translation of the RNA to protein. A Kozak sequence is a short sequence present 
upstream of the transcription activation site and generally contains the full consensus 
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sequence, GCC GCC A/T CC ATG G, three bases before the start codon. The Kozak 
sequence slows the rate of ribosomal scanning and thereby improves the chance of 
translation by ensuring that the start codon is recognized.111 Similarly, the 5’ untranslated 
region (UTR) can affect the translation of mRNA, by either inhibiting or enhancing 
translation. If the untranslated region has more number of AU rich regions and is poorly 
structured, it allows for easy ribosomal scanning and thus helps the ribosomes to 
recognize the translation initiation codon.112 The UTR of the human t cell leukemia virus 
(HTLV) conforms to this poor structure and thus enhances translation when present 
upstream to the activation site.113  
 
2.4.6 Transfection Agents 
 
Transfection agents prevent the degradation of naked plasmid by encapsulating them 
and then releasing them into the cell. These encapsulating agents can either be polymeric 
or liposomes. These are either made of polymers, proteins or lipids and coat the DNA 
such that they allow for timed release and also protect the DNA from being damaged. 
Moreover, they condense the DNA to smaller sizes to mediate better uptake by the cell.  
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2.5 Encapsulation and Systemic Gene Delivery 
 
2.5.1 Poly Lactide co Glycolide nanoparticles  
 
Research involving the delivery of DNA or plasmids as therapeutic agents has grown 
rapidly. The need to safely and efficiently deliver these genes to the tissue of interest has 
resulted in a rapid growth of research in the use of polymeric nanoparticles as delivery 
vehicles for these transiently expressing, easily degradable therapeutic agents. Although, 
recent advances have led to almost 100 clinical trials with nanoparticles as carriers for 
drugs, there is no drug loaded within  nanoparticles which has been approved for human 
use yet. This is partly due to the fact that the targeting of nanoparticles to cells has been a 
challenge.114 
 
DNA plasmids have a polynucleotide structure and thus are negatively charged 
which poses a challenge for traversing the tissue layers, and they are easily degraded in 
the system. In order to overcome this, genes need to be properly condensed to a size that 
can be taken up by cells. Once they are taken up by cells, the plasmid may be lost due to 
endosomal sequestration of the nanoparticle, loss of nanoparticle by exocytosis, or 
lysosomal degradation of the nanoparticle in the cytoplasm. Therefore, an efficient 
delivery of plasmid DNA to the cell nucleus requires the condensation of the plasmid to 
allow encapsulation within the nanoparticle, stability during formulation and in vivo, 
ability to target the tissue or cells of choice by either a surface ligand or by possessing a 
specific promoter element in the plasmid, or both, capability of release from the 
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nanoparticle following endocytosis into the cell, and ability to be taken up by the nucleus 
in its active form.  
 
Polymeric nanoparticles are being widely used as delivery agents for plasmids 
because of their stability,115 ability to bind targeting ligands to the surface,116 regulated 
control over the release kinetics of the encapsulated plasmid in the cytoplasm, ability to 
be degraded in vivo,117-119 following the release of the plasmid, and are approved for use 
in human trials by the FDA.120   
 
Generally, nanoparticles encapsulating plasmids are formulated using a variety of 
techniques such as; double emulsion solvent evaporation technique,121 salting out,122 nano 
precipitation,123 cross flow filtration,124 or emulsion diffusion technique.125 The most 
common of these techniques is the double emulsion method where the hydrophilic 
plasmid is dissolved in an aqueous solution with sucrose or albumin as stabilizing agents 
and the polymer is dissolved in an organic phase. A primary, water in oil, emulsion is 
formulated between the aqueous phase and the organic solvent. This is then added drop 
wise to another aqueous phase with a polymeric surface activator, poly vinyl alcohol 
(PVA), to formulate a secondary, oil in water, emulsion.126 This is then allowed to 
evaporate slowly to remove all the organic solvents, and form hydrophobic nanoparticles 
encapsulating the hydrophilic plasmid, with surface activators that alter the 
hydrophobicity of this complex.127  
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The surface activation is a key step in this process, since the surface comes in contact 
with cell membranes, and thus is the determining factor for the internalization of the 
nanoparticle in the cell. PLGA nanoparticles enter into the cell by endocytosis partially 
by pinocytosis and partially by receptor mediated endocytosis and this process is 
concentration and time dependent.127 Other factors, such as size of the nanoparticle, 
affect cell internalization, with smaller size of the nanoparticle facilitating easier uptake 
than larger ones.119 Nanoparticles escape the endo lysosomes and enter into the 
cytoplasm immediately after, within the first 10 minutes. However, some studies have 
demonstrated that a significant amount of these nanoparticles escape the cells via 
exocytosis and only about 15% of the nanoparticles remain in the cytoplasm.127  
 
Some factors that affect the release of nanoparticles in the cytoplasm are dependent 
on the surface characteristics, such as the zeta potential, hydrophilicity and surface charge, 
all governed by the surface activator, poly vinyl alcohol (PVA). An excess of PVA on the 
surface, if not removed completely during formulation alters a process called surface 
charge reversal. In an acidic lysosome, the nanoparticles change their surface charge from 
anionic to cationic, destabilize the vesicle membrane, and get released from them into the 
cytoplasm. An excess PVA prevents this occurrence and the nanoparticles do not release 
from the lysosomes and exit the cells via exocytosis.120  
 
This portion of released nanoparticles degrades slowly and releases the encapsulated 
plasmid over a controlled period of time. The release of plasmid in the cytoplasm can be 
altered by varying formulation parameters, such as polymer to plasmid ratio or molecular 
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weight and composition of the polymer used. Higher molecular weight polymers allow 
for more plasmid loading within the nanoparticles and thus release more plasmid per 
nanoparticle, facilitating greater gene transfections. Other factors, such as higher 
viscosity, better emulsifying properties also allow for greater loading and smaller 
nanoparticle sizes, thus greater uptake and release of more DNA into the cells. The 
hydrophobicity of polymers affects loading and release, with less hydrophobic particles 
providing better release. Surface activators also help in altering the hydrophobicity.121, 128  
 
Formulations of the polymer complex with the plasmid, involving the type of 
polymer, the method of formulation, surface activators, size of the resulting nanoparticles 
and zeta potentials (surface charge of the particles) all have an effect on encapsulation 
and delivery of the plasmid and can be modulated to provide the required results.  
 
2.5.2 Targeting Factors 
 
Targeting ligands aid nanocarriers to effectively direct them to a specific cell or 
tissue type to maximize efficacy of the encapsulated plasmid or drug in the specific 
tissue.129 Initial targeting studies were used for tumors, in order to prevent angiogenesis, 
and thus prevent the growth of tumor cells, but leave the healthy tissue around it intact.130 
These ligands exclusively bind to specific receptors on the cell surface with high affinity. 
Some of the common ligands that have been studied are peptides, antibodies, sugars, 
vitamins and certain chemical compounds. Once these ligands bind to the cell surface, the 
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uptake occurs by a receptor mediated endocytosis, via clathrin dependent or independent 
pathway.127, 131  
 
To formulate a ligand tethered polymer/DNA complex, the ligand molecule is either 
linked directly or via a linker polymer to covalently bind to the surface of the polymer 
complex.  
 
Figure 2-2 : Schematic of the encapsulation of DNA within PLGA nanoparticles 
 
 
There is a lot of research involving the receptors on cell surface that target these 
homing ligands. A great body of research is dedicated to looking at integrin based 
members of cell adhesion receptors. Proteins of the extra cellular matrix such as 
fibronectin bind to a three amino acid sequence peptide commonly known as RGD, for 
Arg-Gly-Asp132,133 on specific integrins over expressed in angiogenic endothelial cells of 
tumor tissues.134,135 This led researchers to tap this targeting moiety to deliver siRNAs 
and other inhibitor drugs to these tissues to hamper its growth and block blood flow to 
this region, resulting in targeted tumor tissue damage.136  
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Other peptide sequences such as the Luteinizing Hormone - Releasing Hormone 
(LHRH) is also a tumor targeting ligand as its receptor is commonly found in various 
tumor (breast, ovarian) tissues.137 Certain iron binding ligands, such as transferrin and 
lactoferrin, are common receptor binding proteins specially used for lung targeting and 
traversing the blood brain barrier in the brain,138,139 although in gene transfections studies, 
lactoferrin mediated delivery demonstrated a greater transfections efficiency as compared 
to transferrin mediated delivery.140 A similar ligand protein is epidermal growth factor 
(EGF) that binds to the EGF receptor (EGF-R).141,142 Another similar ligand protein is the 
Receptor associated protein (RAP) that binds to low density lipopolysaccharides (LDL) 
on the cell surface.143 Several sugars, such as galactose, mannose, and folates bind to 
specific moieties on the cell surfaces such as asialoglycoprotein receptors on 
hepatocytes,144 mannose receptors on macrophages, and dendritic cells,145 and folate 
receptors on tumor cells.146  
 
Other  technologies involve combinatorial libraries, such as RNA display, yeast 
display or bacterial display to identify certain small peptide molecules that target specific 
cell types.147 A novel yet powerful strategy that is being used nowadays is called in vivo 
phage panning using a phage display library.148 Phages are screened by allowing them to 
bind to specific cell receptors in the tissue of interest. After several rounds of screening 
followed by purification and amplification of the primary candidates, a robust and highly 
specific ligand-receptor binding target is identified.  
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2.6 Phage Panning 
 
Bacteriophages or phages are viruses to bacteria that can replicate their DNA in a 
bacterial cell. Generally phages have a single stranded DNA in them, and can infect E 
coli. A phage clone has a foreign gene introduced into a phagemid vector, such that it 
possesses the phage and a replication plasmid to enhance transformations. A phage 
display library has multiple copies of various clones, with sequences for a number of 
known and unknown peptides attached to the fusion coat protein plasmid in the M13 
genome of phagemid vectors.149 The peptides are comprised of 7 amino acids, formed 
from all possible permutations from the genome sequence of the organism. When these 
phage particles enter into a bacterial cell, the genome is now released from inside the 
phage vector and is displayed on the surface, while the coat protein remains attached to 
the phage vector. On identifying a receptor to these peptides, the ligand binds to the 
receptor tagging the phage with it. Phage panning studies with specific epitopes (receptor) 
or the tissue with the epitope employs this specificity to identify the phage that binds to it, 
which is then isolated, amplified, and sequenced to reveal the peptide sequence that binds 
to the epitope of interest.  
 
The principle behind phage panning is to identify the clone that binds to an epitope 
with the affinity and selectivity that other clones do not bind to or do so with poor affinity. 
To achieve this, multiple rounds (or pans) of binding the phage to the epitope, identifying 
the bound phage, eluting the unbound phage, amplifying it and sequencing the bound 
phage are carried out. For in vivo identification of ligands specific to receptors, animals 
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are infused with multiple copies of phages expressing a library. This is allowed to 
circulate for 2 hours, to ascertain the removal of unbound phage from the tissues (organs 
and tumors). Residual phages still bound to the target organs are harvested. This residual 
phage is purified, amplified and infused into the animal for a second round. After 
multiple rounds, it will now be possible that very few phages express specificity to the 
tissue.150  
 
Several studies with this principle has led to specific ligands for traversing the 
intestinal mucosa and targeting the goblet cells,151 traversing layers of the skin to deliver 
drugs intradermally,152  targeting pancreatic cells,153 tumor cells,154 lymph channels,155 
and vascular endothelium.156  
 
In vitro affinity binding to identify targets for these antigens have been tapped for 
tumor targeting ligand selections. Certain antigens, specific for tumor cells such as 
urokinase plasminogen activator (uPA), epidermal growth factor receptor (EGF-R), 
Thomsen Friedenreich tumor associated antigen etc, are plated on a dish and phages are 
allowed to bind to them. Unbound phage is eluted and the bound phage is amplified and 
sequenced, after multiple rounds, to identify targets to these receptors.157                   
 
Although phage display seems to be able to provide crucial information regarding 
targeting ligands which can then be synthesized chemically, and tagged with photo or 
radio labels to help imaging, or be tagged to liposomes and polymeric gene carriers to 
deliver encapsulated drugs to organs, it has some serious drawbacks. First of all, in vivo 
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screening can be done only in animal models which limit translating this information to 
humans, if the targets that bind these 7-mers are not identified. In such scenarios, it may 
or may not be useful to use these ligands to target or image tissues in humans. This 
extrapolation might also lead to secondary organ damage.158 In recent times, human 
panning for identifying targeting ligands are being performed but this is limited in the 
number of subjects that can be used for this study, as organs need to be excised following 
phage injections.159 However ex vivo screenings on intact organs can be used to 
determine targeting peptides in human organs.160 
 
Other smaller drawbacks are based on the size of the phage particles, thus the 
vascular space and mostly the endothelial layer are targeted for receptors. Secondly, the 
affinity to certain receptors may be due to the large copies of libraries infused into the 
organ rather than a specific affinity of the peptide in itself, which is revealed by low 
affinities seen with mono copies. Thus there is a great deal of work to be done in 
optimizing this system towards ideal screening platforms.161  
 
2.7 Gene Profiles in Tissue Regeneration 
 
Following the human genome project, that has identified the sequences to all genes 
in the human body, researchers began to study how these genes affect each other. Gene 
expression profiling is a tool used to study the expression of multiple, or in some cases, 
all genes at the same time. Following treatment, a gene expression profile would help 
understand how all genes respond to the therapy.162,163 The ones that are closely 
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associated with the damaged organ, will have significant changes in expression as a 
response to therapy, and genes that are not affected will have no change in expression as 
a response to the therapy. Monitoring the changes in gene expression for multiple genes 
at one time will provide a comprehensive knowledge of many genes that may be 
associated with the disease state. During the early part of this century, following the 
human genome project, studying the effect of all the genes in response to therapy would 
require hours of labor but today, the same study, identifying the same data can be done in 
a few hours due to advances in chip technology and fluorescence detection. Several 
studies have identified novel pathways and peptides associated with cardiac tissue 
damage using genome wide studies. The role of chronic Akt mediated hypertrophy and 
heart failure was established.164 Novel paracrine factors associated with tissue repair, 
following Akt- modified stem cell transplantation has been attributed to a secreted 
frizzled related protein 2 (sfrp 2) that mediates myocardial survival and tissue repair.54  
 
2.7.1 Whole Genome Analysis  
 
A gene chip is a matrix of sequence specific oligonucleotides, arranged in a specific 
order, and bound to a solid surface (quartz) at the bottom. This system is known as a 
microarray chip. One company that has revolutionized the microarray chip with 
providing comprehensive data and easy experimentation is Affymetrix.165 The affymetrix 
chip has about 16 to 20 probe pairs for each gene. Each probe pair consists of a perfect 
match to the gene of interest, and a mismatch to the same gene. The difference in 
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intensity between this perfect match and mismatch is what will be provided at the end of 
the analysis.  
 
The degree of discrimination, R, which determines the ratio of the difference 
between the perfect and mismatch to the sum of the two will be calculated. R= PM-MM 
/PM+MM. An increase in gene expression would be determined by an R value of 1 or 
close to 1.  
 
 
Figure 2-3 : Schematic of a microarray chip 
 
According to the Wilcoxon signed rank test, two parameters are analyzed a) change 
in gene expression (up or down regulation) and b) the p value. If the p value is greater 
than 0.05, the gene will be excluded from the list. The fold changes between the control 
and sample genes will be measured and based on these results, a new set of genes, with 
highest fold changes, will be identified. The chip is normalized using the Robust Multi 
Averaging (RMA) software.166,167 This software allows users to normalize the 
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background and also negate misidentified mismatch data and also determine fold changes 
between the original gene and the up regulated or down regulated gene.   
 
2.7.2 Pathway Studies 
 
Pathway analysis tools help in searching and exploring the relationships between 
genes that are associated in any given pathological condition. The relationships then help 
researchers understand the functionality associated with these genes. These tools are 
structured in order to define the location of these genes in the cellular compartments. 
Moreover they define the interactions between genes to endogenous chemicals, drug 
targets and other genes within their network. This then provides a mechanistic 
understanding of all genes and their targets, thus illustrating the pathways that are 
involved in the given process. These networks and pathways are mostly pre defined and 
provide comprehensive information to the researcher. The Ingenuity Pathway Analysis 
software is a tool to understand the various pathways involved in the genes that have 
changed after the treatment process.163 It can provide information on the signaling 
pathway involved in the whole process. Other software, such as Spotfire, helps cluster the 
genes and thus form groups which helps in gene profiling.  
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CHAPTER III  
 
GENERAL METHODS 
 
3 GENERAL METHODS 
 
3.1 Cell Culture 
 
3.1.1 Harvesting Rat Mesenchymal Stem Cells 
 
Rat bone marrow was isolated by flushing rat femurs and tibias with 0.6 ml DMEM 
repeatedly until all of it is extracted. Clumps of bone marrow were gently minced using a 
20 gauge needle and a 10 ml syringe.  Cells were then be removed by Percoll density 
gradient. This bone marrow was then washed with PBS three times to remove all debris 
and then plated in a dish with MSC media, comprising 10% FBS and 1% antibiotic in 
low glucose DMEM, and incubated at 37ºC for three days.  
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The mesenchymal stem cells adhere to the plate leaving the endothelial cells in 
suspension. The floating endothelial cells were removed and the media was changed in 
order to obtain a pure population of MSC cells. After four passages, this culture was then 
sorted negatively for CD45 and CD34, by magnetic cell sorting to remove endothelial 
cell types and in order to obtain a double purified population of MSCs.  
 
3.1.2 Isolation of Cardiac Fibroblasts 
 
The left ventricles of 3 to 5 rats were pooled together, minced and placed in 100 
U/ml of collagenase XI and trypsin at 37 ºC for 10 minutes in a shaking incubator. The 
cell suspension was filtered out using gauze filtration and minced tissue was collected. 
The cell suspension was centrifuged at 2000 rpm for 10 minutes to sediment the cells. 
The cells were seeded in Ham’s modified DME medium supplemented with 10 % FBS 
and 1% antibiotic containing Penicillin and Streptomycin. Non adherent cells were 
removed after 2 hours of incubation and the adherent cells were washed twice with 
phosphate buffered solution (PBS). The resulting adherent fibroblasts were cultured in 
Ham’s modified DMEM medium supplemented with 10% FBS and 1% antibiotic 
containing Penicillin and Streptomycin on T75 flasks and incubated in 37ºC and 5% CO2.  
 
3.1.3 Stem Cell (Mesenchymal Stem Cell) culture 
 
Harvested mesenchymal stem cells were cultured on tissue culture plates. Cells were 
added to media comprising Dulbecco’s minimum essential medium supplemented with 
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10% fetal bovine serum and 1% antibiotic of penicillin and streptomycin. Cells were 
allowed to adhere to the bottom of the plate and proliferate in a 5% CO2 and 37° C. 
Media was changed every 2 days. When the plate was confluent, cells were detached 
from the bottom of the plate by washing twice with Phosphate buffered solution, and then 
incubated for 5’ at 37°C with trypsin EDTA. Cells were pipetted to break down clumps 
mechanically and then re-plated at a concentration of 1 million cells per plate in the 
specific medium.   
 
3.1.4 Cardiac Fibroblasts culture 
 
Cardiac fibroblasts were cultured on tissue culture plates in a similar fashion as 
described for mesenchymal stem cells but with a specific cardiac fibroblasts media 
comprising equal parts of Dulbecco’s minimum essential medium and F12 medium 
supplemented with 10% fetal bovine serum, 1% antibiotic solution with penicillin and 
streptomycin, and 1% L-glutamine.  
 
3.1.5 Cell Freezing  
 
Cells were detached from the tissue culture plate using Trypsin-EDTA. A pellet of 1 
million cells was collected by centrifuging the cell solution (Cells in Trypsin) at 2000 
rpm for 5 minutes. Each cell pellet was dissolved in 1 ml of DMSO (dimethyl sulfoxide) 
and Fetal Bovine Serum at a ratio of 6:4 (600 µl of DMSO and 400µl of FBS). These 
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were then transferred to a Nunc cryovial and slowly frozen at -80°C for 1 week and then 
in liquid nitrogen for long term storage.  
 
3.2 Plasmid Constructions 
 
3.2.1 pCMV 
 
The pCMV Luc plasmid was generated by digesting the Luciferase gene from a 
pGL3 vector (Promega), using the following primers: Forward: 5’- GAATTCGTCG 
ACTATGGAAGACGCCAAAAACATAAAGAAAGGC-3’; Reverse: 5’-TCTAGAAAG 
CTTTTACACGGCGATCTTTCCGCCCT TC-3’, and subsequently ligating it onto a 
pcDNA3.1 vector (Invitrogen, Carlsbad, CA). The Forward Primer has the restriction 
enzymes EcoRI & SalI; the Reverse Primer has HinDIII and XbaI. The resulting PCR 
product was digested with EcoRI and XbaI, gel-purified and ligated into an EcoRI-XbaI 
digested pcDNA3.1+ (Invitrogen) backbone.  
 
3.2.2 pCMVe 
 
The pCMVe Luc vector was a kind gift from Copernicus. This plasmid was 
generated by ligating a Luc gene onto a pcDNA3.1 vector with a Kozak sequence and an 
RU5 sequence at the 5’ end of the plasmid, followed by a polyA tail.  
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3.2.3 pMHC 
 
The luciferase gene from pCMV vector was digested and ligated into a pBSK.αMHC 
vector (a kind gift from Jeffery Robbins Lab at  the University of Cincinnati Medical 
Center, Children’s Hospital Medical Center) to generate the  pMHC Luc vector. The 
MHC promoter is a mouse alpha myosin heavy chain promoter in pBluescript SK (+) 
vector (Stratagene, Agilent Technologies, La Jolla, CA) with a 23bp linker region and a 
Human Growth Hormone Poly A tail (hGH).  
 
3.2.4 pMHCe 
 
This plasmid was generated by ligating a Luc gene onto an αMHC vector with a 
Kozak sequence and an RU5 sequence at the 5’ end of the plasmid, followed by a polyA 
tail.  
 
The Luc gene was sub cloned out of the vector and the SDF-1 cDNA was inserted to 
generate the pCMV SDF-1, pCMVe SDF-1 and the pMHC SDF-1 vectors respectively. 
For the SDF-1 plasmids, the hSDF-1 gene was cloned from the mRNA of human foreskin 
fibroblasts using the primers, Forward: 5’- GCTAGCGTCGACATGAACGC 
CAAGGTCGTGGTCGTGCTGGTC-3’; Reverse: 5’-AAGCTTTTACTTGTTTAAGGC 
TTTCTCCAGGTAC TCCTGAAT-3’. 
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3.2.5 Plasmid Amplification and Validation 
 
The DNA was amplified using 250mL of LB Broth (Ampicillin) resistance and 50uL 
of the frozen bacteria plasmid stock. It was cultured overnight in a shaking incubator at 
37oC at 225rpm.  The DNA was isolated from the bacterial prep using the PureLink 
HiPure Plasmid Filter Maxiprep Kit (Invitrogen, Carlsbad, CA) as per the manufacturer’s 
instructions. The DNA was then measured at 260/280nm for concentration using a 
Nanodrop 3000 fluorospectrometer (Thermo Fischer Scientific, Waltham, MA). 
 
The CMV driven Luc plasmids, pCMV-Luc and pCMVe Luc were transfected onto 
293FT cells and the αMHC driven Luc plasmids, pMHC Luc were transfected onto H9C2 
cardiomyoblasts at 50% confluence at 300,000 cells per well in a 6 well plate using the 
FUGENE Transfection kit (Roche Basel, Switzerland) as per the manufacturer’s 
instructions. The cells were exposed to luciferin at 10µg per ml of PBS per well and the 
chemiluminescence emitted was quantified using a cooled couple device camera from the 
Xenogen Imaging Systems. 
 
3.3 Animal Handling 
 
All animals were maintained in the AAALAC approved rodent facility of the 
Cleveland Clinic Foundation that is staffed by a full time veterinarian and trained 
technicians.  The Animal Research Committee of the Cleveland Clinic Foundation 
reviews and approves all protocols.  All animals were maintained under sodium 
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pentobarbital anesthesia by i.p. injection during the surgical procedures. Once surgery is 
complete, bupivacaine (0.5%), a local anesthetic was injected along the sternal wound 
which provided analgesia for ~18 hours. The animals were treated with Buprenorphine 
after the procedure at a concentration of 0.3 mg/kg up to 3 days after surgery. For 
euthanizations, the animals were treated with an overdose of sodium pentobarbital at the 
time of sacrifice.  This mode of euthanasia is consistent with the recommendations of the 
Panel on Euthanasia of the AVMA.  We routinely use Buprenorphine as an analgesic in 
our protocols.   
 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee and we followed the guidelines provided by them. All animals were 8 week 
old, weighing 200-225 grams, Lewis rats (Jackson Laboratories Bar Harbor, ME) for the 
chronic heart failure study. 
 
3.3.1 LAD Ligations 
 
Briefly, LAD ligation was performed in rats anesthetized with sodium pentobarbital, 
50 mg/kg.  Animals were intubated and ventilated with room air at 100 breaths per 
minute using a rodent ventilator (Harvard Apparatus Holliston MA).  The chest was 
sterilized with ethanol, and a sternotomy was performed. The left atrium was retracted 
and the proximal LAD was identified visually.  The proximal LAD was ligated using 6-0 
prolene.  We were able to verify ligation of the LAD by blanching and dysfunction of the 
anterior wall. The sternum and then skin was closed with 4-0 prolene with interrupted 
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sutures.  Any residual pneumothrorax was reduced using negative pressure generated by 
a 20G needle placed in the closed chest, attached to a 10 ml syringe.  The rat was then 
weaned from the ventilator over the next 10-15 minutes. 
 
3.4 Tissue Fixation and Staining 
 
3.4.1 Harvesting Rodent Organs 
 
At the time of necropsy, the animals were perfused with saline to remove all residual 
blood from their circulation and histochoice to fix the tissues immediately. The hearts 
were harvested and again fixed in histochoice for 7 days.  
 
3.4.2 Paraffin Embedding 
 
Harvested tissues were then processed by a series of dehydration steps and then 
washed in hot paraffin. Plastic labeled blocks were filled with hot paraffin and the tissues 
were embedded into them. This was allowed to cool at 4°C for a couple days. 
 
3.4.3 Embedding in OCT for frozen sections 
 
At the time of necropsy, animals are perfused with saline alone, and then organs are 
harvested. The tissues are again washed three times in ice cold PBS and then embedded 
in the OCT (Optimum Cutting Temperature) compound and placed on dry ice. This is a 
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gel at room temperature but freezes on dry ice. This snap frozen tissue, embedded in 
OCT is stored at -20°C for a week.  
 
3.4.4 Masson’s Trichrome Staining 
 
Tissues embedded in paraffin blocks are cut into 5 micron slices using a microtome. 
These slices are then mounted on transparent slides and stained with the Masson’s 
Trichrome dye in a series of steps involving dehydration and staining with the dye for 
collagen and heart muscle. Mason’s trichrome is used to quantitate the collagen content. 
Fibrosis size or scar tissue was deduced by the percentage of area with collagen as 
compared to the total area.  
 
3.4.5 Immunohistochemistry 
 
Tissues were fixed in formalin and embedded in paraffin blocks according to 
established protocols. Antigen retrieval was performed using 10 mM sodium citrate 
buffer (pH 6.0) and heat at 95°C for 5 min. The buffer was replaced with fresh buffer and 
reheated for an additional 5 min, then cooled for 20 min. The slides were washed in 
deionized water three times for 2 min each. Specimens were then incubated with 1% 
normal blocking serum with goat and donkey serum in PBS for 60 min to suppress 
nonspecific binding of IgG. Slides were then incubated for 60 min with the primary 
antibody at a dilution specified by the manufacturer in blocking buffer with serum. Slides 
were then washed with phosphate-buffered saline (PBS) and incubated for 45 min, with 
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secondary antibody at a dilution specified by the manufacturer in blocking buffer with 
serum in a dark chamber. After washing extensively with PBS, coverslips were mounted 
with aqueous mounting medium. (Vectashield Mounting Medium with DAPI, H-1200; 
Vector Laboratories, Burlingame, CA, USA).  
 
3.5 Isolation of total RNA 
 
RNA from tissue samples were isolated using the Trizol reagents. Briefly, the tissues 
were homogenized in Trizol in dry ice and chloroform was added to this. The aqueous 
phase obtained was collected and mixed with isopropanol and centrifuged to collect the 
samples. RNAgents denaturing solution (Qiagen, Hilden, Germany) was then added to 
this to dissolve the pellet. Samples were again collected with isopropanol and are 
centrifuged. This sample was further treated with 75% ethanol and centrifuged to collect 
samples. The supernatant was discarded without disturbing the pellet and the pellet is 
dissolved in DEPC water for future use. Further clean up of the RNA was done with the 
use of the Qiagen kit as per the manufacturer’s instructions.  
 
3.6 Preparation of cRNA 
 
First-strand cDNA was synthesized using Oligo dT and Superscript II RT (Invitrogen, 
Grand Island, NY). Alternatively, cDNA can be prepared using OVATION RNA 
Amplification System (NuGen Technologies, Inc., San Carlos, CA). cDNA amplification 
products were fragmented and chemically-labeled with biotin to generate biotinylated 
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cDNA targets. Each Affymetrix gene chip for rat genome was hybridized with 
fragmented and biotin-labeled target (2.5 μg) in 200 μl of hybridization cocktail. Target 
denaturation was performed at 99°C for 2 minutes, followed by hybridization for 18 
hours. Arrays were washed and stained using Genechip Fluidic Station 450, and 
hybridization signals were amplified using antibody amplification with goat IgG (Sigma-
Aldrich) and anti-streptavidin biotinylated antibody (Vector Laboratories, Burlingame, 
CA). 
 
3.7 Imaging 
 
3.7.1 Xenogen IVIS 
 
The animals were routinely measured for luciferase expression using a cooled 
coupled device camera from the Xenogen Imaging Systems. The animals were 
anesthetized using 2% isofluorane. Luciferin was injected intra peritoneally at a 
concentration of 125 mg/kg of the animal. As Luciferin is light sensitive, care was taken 
to minimize the amount of light in the room. After 10 minutes, within which time the 
luciferin would have been flushed to all parts of the body, real time images were obtained 
to determine the luciferase expression of the gene, as expressed by a chemiluminescence 
emitted by the luciferase protein in the presence of luciferin.  
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3.7.2 Echocardiography 
 
We performed 2D-echocardiography on rats using a 15-MHz linear array transducer 
interfaced with a Acuson Sequoia C256 (Siemens, Munich, Germany).  The animals were 
sedated with ketamine, the chest was shaved, and the sedated animal maintained in a 
supine position. For quantification of LV dimensions and wall thickness, we digitally 
record 2D clips and m-mode images in a short axis view from the mid-LV just below the 
papillary muscles.  This anatomical location was chosen to consistently obtain 
measurements from the same anatomical location in different mice.  Measurements were 
made offline using ProSolv (Indianapolis, IN).  Each measurement in each animal was 
made 6 times, from 3 randomly chosen m-mode clips out of 5.  
As a measure of left ventricular functions, shortening fractions was calculated from 
M mode studies.  
Shortening fraction: (LVEDD-LVESD)/LVEDD *100 where, 
LVEDD: Left ventricular end diastolic dimension 
LVESD: Left ventricular end systolic dimension 
Dimensions were measured between the anterior and the posterior walls from short axis 
view just below the papillary muscle. Left ventricular mass was calculated by  
Left Ventricular Mass = 1.05 * ((Anterior Wall Thickness+LVEDD+Posterior Wall 
Thickness)3 –LVEDD3) 
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3.7.3 Confocal Microscopy Analysis 
 
Tissues were analyzed using an upright spectral laser scanning confocal microscope 
(Model TCS-SP; Leica Microsystems Heidelberg, Germany) equipped with blue argon 
(for DAPI), green argon (for Alexa Fluor 488), and red krypton (for Alexa Fluor 594) 
lasers. Data were collected by sequential excitation to minimize “bleed-through.” Image 
processing, analysis, and the extent of co-localization were evaluated using the Leica 
Confocal software. Optical sectioning was averaged over four frames, and the image size 
was set at 1,024 x 1,024 pixels. No digital adjustments were made to the images. 
 
3.8 Nanoparticle Formulation 
 
Nanoparticles containing BSA and 6-coumarin were formulated using a double 
emulsion-solvent evaporation technique. An aqueous solution of BSA (60 mg/ml, 1 ml) 
was emulsified in a PLGA solution (180 mg in 6ml chloroform) containing 6-coumarin 
(100µg) using a probe sonicator (55W for 2 min) (Sonicator® XL, Misonix, NY). The 
water-in-oil emulsion formed was further emulsified into 50 ml of 2.5% w/v aqueous 
solution of PVA by sonication (55W for 5 min) to form a multiple water-in-oil-in-water 
emulsion. The multiple emulsion was stirred for ~18 h at room temperature followed by 
for 1 h in a desiccator under vacuum to remove the residual chloroform. Nanoparticles 
were recovered by ultracentrifugation (35,000 rpm for 20 min at 4°C, OptimaTM LE-
80K, Beckman, Palo Alta, CA), washed two times with distilled water to remove PVA, 
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un-entrapped BSA and 6-coumarin, and then lyophilized (−80°C and <10µm mercury  
pressure, SentryTM, Virtis, Gardiner, NY) for 48 h to obtain a dry powder. 
 
3.8.1 Conjugation of nanoparticles with RR peptide 
 
Nanoparticle surface was activated by the epoxy compound, Denacol®, followed by 
conjugation of the activated NPs to RR-peptide in the second step. Briefly, 60 mg of NPs 
were sonicated in 4 mL of borate buffer (50 mM, pH 5.0) for 30 s on an ice-bath. This 
was followed by the addition of 40 mg of Denacol® that was also dissolved in an equal 
volume of buffer and the reaction was allowed to take place for 30 min at 37 °C with 
gentle stirring in the presence of 50 mg of zinc tetrahydrofluroborate hydrate, which 
acted as a catalyst. NPs were separated by ultracentrifugation at 30,000 rpm at 4 °C for 
20 min followed by three washings with borate buffer to remove any unreacted Denacol®. 
To conjugate RR-peptide, epoxy activated NPs were resuspended in 4 mL of borate 
buffer and mixed with a solution containing 200 μg of RR peptide in the same buffer. The 
reaction was allowed to proceed at 37 °C for 2 h with constant stirring. The unreacted 
peptide was then removed by ultracentrifugation as discussed above; the final NP 
suspension was lyophilized for 48 h to obtain a dry powder. 
 
3.8.2 High Performance Liquid Chromatography 
 
The mobile phase used for the HPLC analysis was acetonitrile water solution at a 
ratio of 65:35 supplemented with 0.005M n-heptane sulfonic acid salt. The column used 
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was a C8 column (Waters Technologies). The mobile phase was allowed to circulate 
through the column and the samples were dissolved in 100% methanol. Samples were 
allowed to pass through the column at a rate of 0.8 ml/minute for 5 minutes. All samples 
were in triplicates. Standard curves were generated with increasing concentrations of 6 
Coumarin extracted with methanol overnight. Excitation and emission wavelengths were 
at 420 and 490 nm.  
 
3.9 Statistical Analysis 
 
All results are expressed as mean + s.e.m. Statistical analysis was performed using 
the Students t-test.  
65 
 
CHAPTER IV  
 
 IN VIVO BIO-FLUORESCENCE IMAGING FOR GENE 
EXPRESSION 
 
4 IN VIVO BIO-FLUORESCENCE IMAGING FOR GENE EXPRESSION 
 
4.1 Introduction 
 
Gene therapy has evolved as a viable method to deliver therapeutic genes, such as 
VEGF, FGF to ischemic myocardium following myocardial infarction. However, this is 
limited in its approach as there are not enough bio assays that can quantify the amount or 
the presence of these proteins in the injured tissue. Moreover, the expression of these 
plasmids is mostly studied ex vivo, wherein the tissue is excised and the level of reporter 
molecules are identified via various assays, such as optical microscopy (confocal), PCR 
analysis, flow cytometry, microarray analysis, and others. However, this method provides 
information for a single time point and for temporal analysis several animals are used, 
with one group of animals being sacrificed for each time point. These studies also vary
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between animal groups, and have discordance due to technical errors generated during 
intra myocardial injections. A real time in vivo quantification of gene expression can 
provide a more cost effective and more accurate data between animal groups.   
 
Several sophisticated imaging modalities can be used to detect physiological changes, 
as a response to gene therapy, including magnetic resonance imaging MRI, positron 
emission tomography PET, single photon emission computed tomography SPECT and 
others.168, 169 However these modalities are extremely complicated, are not well suited for 
small animals, and are highly expensive and thus non feasible for initial studies.  
 
Bioluminescent reporters, however, can be used as a tool to determine real time 
information on gene expression for plasmid expression studies. Bioluminescent reporters 
can provide real time, in vivo monitoring data for gene expression by emitting 
chemiluminescence at particular wavelengths. In the past, such studies were only possible 
with transparent or translucent objects, however, recent studies using a firefly Luciferase 
gene has been shown to provide non invasive quantification of expression due to its 
bioluminescent light source internally.170  Luciferase, derived from the firefly, is a 
photoprotein used in several molecular biology studies, including in vitro in cells studies, 
tumor studies, and gene expression studies.171-173   
 
This study aimed to design and validate a plasmid for effective gene therapy capable 
of expressing and sustaining expression in rodent hearts. We wanted to evaluate if optical 
imaging could provide detailed information about changes in gene expression, with 
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modifications to the plasmid design. Therefore, we designed a plasmid that encoded for 
the gene, Luciferase. This protein generates bioluminescence via a reaction in the 
presence of a substrate luciferin and oxygen, in order to produce photons of light. Light 
thus produced can be imaged via a sensitive detector present in a cooled coupled camera 
device.  
 
We injected plasmids encoding Luciferase into rats that had chronic heart failure. We 
then serially measured the light emitted from it in the presence of an i.p. injection of 
luciferin. This was quantified and analyzed in order to understand the gene expression 
profile of this plasmid. We noticed that this profile changed when the gene was enhanced 
with transcriptional enhancers boosting the amount of light and the duration that the light 
was emitted. Utilizing a cooled camera to detect bioluminescence can help understand the 
gene expression profile in gene therapy and eliminate the need for complicated bioassays.  
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Mechanism of Biofluorescence Imaging using the IVIS 100 
 
 
Figure 4-1 : Illustration of the mechanism involved in bioluminescent imaging.  
Adapted from www.caliperls.com 
 
When the luciferin protein interacts with oxygen it emits light but this process is 
extremely slow. In the presence of oxidative Luciferase, this reaction occurs almost 
immediately allowing this light to be quantified. The animal or cells that possess the 
Luciferase (Luc) gene are placed in a light tight box. An i.p. injection of luciferin is 
administered and this is allowed to circulate through the body. When luciferin interacts 
with oxygen in the presence of Luciferase, it emits chemiluminescence, which is captured 
by a highly sensitive charged cooled camera device. The signal here needs to be adjusted 
for autoluminescence and scattered luminescence.  
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4.2 Methods: 
 
4.2.1 Experimental Plan 
 
 
 
 
 
Rats were infarcted via LAD ligation and the hearts were allowed to modify to a 
chronic heart failure stage. 4 weeks after LAD ligation, the chests were re-opened in 
order to inject the plasmid into the border zone of the left ventricle. Rats were imaged 
using the IVIS system (Xenogen, CA) in the presence of an i.p. injection of luciferin 
serially till no chemiluminescent image was observed for three days in a row.  
 
4.2.2 Optical Imaging System 
 
All studies were performed using the IVIS 50 small animal scanner (Xenogen, 
Alemeda, CA) using the Luciferase filter set to match the emission characteristics of the 
chemiluminescence emitted from the Luciferase Luciferin reaction. Acquisitions were 
performed 10 minutes after an i.p. injection of luciferin to allow for maximum circulation. 
Illumination parameters (exposure time of 1 minute, medium lamp voltage = medium, 
f/stop of 2, and binning of 2) were selected for each acquisition. For in vitro studies, cell 
samples were placed in a black bottomed 6 well plate. Whole-body real-time scans of 
Rats are 
infarcted 
1 month (CHF) Chest is reopened  
Plasmid of choice  
is injected  
100µg / site * 4 sites 
In the border zone 
Luciferin injected 
intra peritoneally Imaged using 
Xenogen cooled 
camera device 
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anesthetized rats were acquired in prone and supine position, every day following 
myocardial injection of the Luciferase gene. 
 
4.2.3 Image analysis 
 
Images were acquired and analyzed using Living Image 2.5 software (Xenogen, 
Alameda, CA, SA) integrated with Igorpro (Wavemetrics, Lake Oswego, OR, USA). The 
digitized image intensity is expressed in arbitrary units.  
 
For the in vitro experiments, image analysis involved the designation of regions-of 
interest (ROI) as the circular area of the well containing the cell concentrations to extract 
the average intensity (sum of the intensity of all pixels within this ROI divided by the 
number of pixels). For the in vivo experiments, image analysis involved the definition of 
the ROI in each location of enhanced fluorescence as the area having intensity larger than 
50% of the peak signal intensity. This ROI was manually selected.  
 
4.2.4 Plasmids Used 
 
The pCMV, pCMVe and pMHC plasmids expressing the Luc gene was used for this 
study. Detailed descriptions of these plasmids are described above. (Chapter 3) 
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4.2.5 In Vitro Expression 
 
Plasmids were transfected into HEK293A cells or H9C2 cardiomyoblasts at 50% 
confluence at 300,000 cells per well in a 6 well plate using the FUGENE Transfection kit 
(Roche Basel, Switzerland) as per the manufacturer’s instructions. The cells were 
exposed to luciferin at 10 µg per ml of PBS per well and the chemiluminescence emitted 
was quantified using a cooled coupled device camera from the Xenogen Imaging Systems. 
 
4.2.6 In Vivo Expression 
 
8 week old male Lewis rats weighing 225-250 grams underwent LAD ligation, as 
previously described. 4 weeks later, the chests were re opened and the plasmid was 
injected, intra myocardial at 100 µg / 100 µl of plasmid in phosphate buffered solution 
(PBS) at 4 sites in the border zone of the infarct using a 30 gauge needle. Animals were 
imaged serially, one day post surgery, using the IVIS system.  Five animals were used per 
group for each plasmid type.  
 
4.3 Results  
 
4.3.1 Plasmid expression in H9C2 cell lines 
 
The inefficiency of physical delivery of non-viral plasmid DNA to cells has been 
well documented. One of the strategies employed to circumvent low transfection 
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efficiencies has been to identify vector components that yield either high levels of protein 
expression or enable target specific expression using tissue-specific promoters. We tested 
three different plasmids in the H9C2 myoblast cell line to identify a vector that would 
produce sufficient cardiac cell expression over approximately two weeks. Plasmids were 
constructed with either the ubiquitous CMV promoter or cardiac-specific αMHC 
promoter and the luciferase reporter gene (pCMV, pMHC and pCMVe, Figure 4-2A). We 
observed that CMV-driven promoters (pCMV and pCMVe) exhibited higher luciferase 
expression (1.3x107 arb units and 2.3x107 arb units) compared to the cardiac-specific 
αMHC-driven plasmid (pMHC, and pMHCe at 1.1x106 and 9.2x106 arb units). As 
expected, the RU5 translational enhancer in pCMVe increased expression over pCMV 
and pMHC plasmids (Figure 4-2B).  
 
Figure 4-2: Plasmid design and in vitro expression profile.  
A) A schematic of the gene design is shown here. The promoters, a ubiquitous CMV, or a 
cardiac specific αMHC present in the 5’ region are used to drive the gene expression. 
Transcriptional enhancers, such as Kozak sequences and RU5 regions are used to boost 
the gene expression by multiple folds. B) The in vitro expression of luciferase activity is 
shown here. H9C2 cells were transfected with CMV and αMHC driven plasmids at 
300,000 cells per well. Transcriptional enhancers, such as Kozak sequences and RU5 
regions increase gene expression by multiple folds. 
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4.3.2 Evaluation of Gene Expression in rodents 
 
We assessed in vivo vector expression in adult Lewis rats infarcted via a left anterior 
descending artery (LAD) ligation followed by direct cardiac injection with 100 µl of 1 
mg/ml pCMV, pMHC or pCMVe-luc in saline into the border zone of the infarcted 
myocardium at the time of infarct. Control rats were injected with saline. Gene 
expression was quantified by measuring chemiluminescence following i.p. injection of 
luciferin three days after direct cardiac injection (Figure 4-3). The presence of the signal 
in the heart alone, rules out the possibility of the naked plasmid being flushed into the 
liver, or being washed away into the circulatory system 
 
 
Figure 4-3 : Gene expression in vivo in 8 week old rodents 
Animals were injected with CMV αMHC plasmids expressing the Luc gene and the 
images were obtained after 3 days. The luciferase gene expresses the protein which emits 
chemiluminescence in the presence of an i.p. injection of luciferin. This intensity is 
measured using a cooled coupled camera device. The greatest intensity was obtained with 
the gene vector with transcriptional enhancers.   
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4.3.3 Dose-response of cardiac gene transfer 
 
To determine the optimal plasmid dose required for efficient myocardial transfection, 
we injected naked plasmid encoding luciferase (pCMV-luc) immediately after ligation of 
the LAD in Lewis rats at doses ranging from 0 to 500 μg in 100 μl PBS. A dose-response 
curve was generated for vector expression.  The peak expression increased up to a dose of 
100 µg and saturated at higher doses (Figure 4-4).  Therefore, a dose of 100 μg was used 
in all subsequent experiments. 
 
 
Figure 4-4 : Dose curve to determine optimal amount of plasmid in vivo 
Infarct model of rodents were injected with CMV pcDNA3.1 Luc at varying doses of 0 
µg to 500 µg in the border zone. The chemiluminescence emitted was measured every 
day for 5 days after the injection. The gene expression saturated at 100ug. n=3   
 
 
 
75 
 
4.3.4 Time course of vector expression in the heart 
 
Next we determined duration of expression after cardiac gene transfer with pCMV, 
pCMVe and pMHC vectors.  All plasmids expressed luciferase in infarcted cardiac tissue. 
Expression from the CMV based plasmids expressed for a short period of 5 days, 
whereas plasmid pMHC expressed for a longer period of 32 days. Adding elements to 
increase transcriptional and translational efficiency significantly affected the expression 
profile, with pCMVe expression lasting 15 days. Changing the promoter or adding 
elements to increase translational efficiency significantly affected the duration of 
expression (Table 4-1). 
 
Promoter Backbone Model Days of expression 
αMHC pBS Infarcted rats 32 
αMHC pBS  Infarcted rats 40 
CMV pCDNA 3.1  Infarcted rats 5 
CMV pCDNA 3.1  Infarcted rats 16 
 
Table 4-1 : Comparison of maximum expression time between the plasmids.  
CMV and αMHC plasmids exhibited different expression profiles when injected in 
rodents. CMV plasmids had shorter expression time as compared to αMHC plasmids. 
Translational enhancers boosted expression time.  
 
4.3.5 Comparison of peak magnitude between the different plasmids 
 
The magnitude of luminescent intensity was determined for the three plasmids 
(pCMV, pCMVe and pMHC). We observed that pCMV peaked at day 3. pMHC showed 
maximum expression on day 7 and continued for 30 days. The αMHC promoter had a 
smaller magnitude of luciferase expression when compared to CMV promoters. 
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Compared to pCMV, the RU5 translational enhancer in the CMV plasmid (pCMVe) 
increased peak expression almost 10-fold. The pMHCe plasmid also improved peak 
magnitude as compared to pMHC plasmid to almost 10 fold. (Figure 4-5) 
 
 
Figure 4-5 : Expression profile between various plasmid designs in vivo 
Animals were injected with the four different plasmids and the gene expression was 
monitored by quantifying the chemiluminescence intensity emitted. αMHC pBS Luc had 
the longest expression time, 32 days, and KCPIR Luc had the maximum peak expression, 
2.7x107.  
 
 
4.3.6 Role of promoters and backbones in plasmid design 
 
The vectors backbones used were pcDNA 3.1, which is a standard vector used in 
most studies. pBS is the smallest vector and therefore provides greater uptake into the 
cells. pKCPIR is a modified pcDNA 3.1 backbone which has a transcriptional enhancer 
and an intron/exon unit inserted into the pcDNA backbone, and a modified pBS plasmid 
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with the enhancer elements. On comparing pCMV backbones, pMHC backbones, 
pCMVe backbones, and the pMHCe backbones, we observed the longest expressions 
were obtained by using either the pBS backbone used in the pMHC and the pMHCe 
plasmid. The length of plasmid expression is determined by the backbone and does not 
change significantly with the use of a translational enhancer element added to this. (Table 
4-1). 
 
4.3.7 Role of Transcriptional Enhancers in plasmid design 
 
On comparing the overall magnitudes between plasmids, it can be seen that the role 
of transcriptional enhancers is to boost the magnitude of expression. Translational 
enhancers slow down ribosomal units so that the chance of the occurrence of translation 
is increased.  Between the pCMV and pCMVe plasmids, the expression was enhanced by 
more than 6 fold. Similarly the use of enhancer elements in the pMHC plasmid boosted 
the expression by more than twice. (Figure 4-6)  
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Figure 4-6 : Peak expression profile between various plasmids in vivo 
Overall peak magnitudes describe the amount of gene expression collected over the time 
course of the expression period. Enhanced CMV plasmids exhibited the largest amount of 
expressions collected overall.  
 
4.4 Discussion 
 
The use of gene therapy to deliver therapeutic proteins has been utilized for 
providing cardiac benefit to ischemic myocardium. However, the use of viral vectors 
poses a threat to the host due to immunological responses and toxic concerns. The use of 
non viral gene therapy for the delivery of proteins is becoming an attractive option to 
reduce immunological responses and eliminate toxic concerns. The limitation of low 
transfection efficiencies, associated with non viral mediated gene transfer can be 
overcome with the use of translational enhancers. The need to determine the expression 
of a gene in vivo, without the excision of the tissue, to provide real time, accurate data 
has become necessary and optical imaging with the help of biofluorescence quantification 
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provides the tools to do so. In addition, optical imaging allows for data to be collected 
from the same animal over time thus reducing the number of animals required for the 
study, and eliminating variations between animals.170   
 
To date, no study has been performed with optical imaging as a means to understand 
gene expressions. Our expression studies demonstrated that expression of the pCMV 
plasmid peaked at day 2 post gene transfer and decreased over the following two weeks. 
These findings are consistent with previous literature showing a peak in CMV-driven 
gene expression, 2 days after injection in the rat heart.169,174 Peak expression in the 
presence of the RU5 element (pCMVe) was 10-fold greater than that seen in the non-
enhanced CMV plasmid (pCMV).   
 
It is noteworthy that direct injection of plasmids into the infarct border zone led to 
the transfection of cardiac myocytes.  In our studies with plasmid delivery restricted to 
cardiac myocytes, using the cardiac specific αMHC promoter, there was a delay of 4 days 
after plasmid injection, prior to any evidence of significant expression.  Furthermore, the 
magnitude of expression was 10-fold less than that observed with the pCMV.  Although 
the signal was low, expression persisted for 32 days. Combining the αMHC promoter 
with the RU5 translational enhancer results in significant plasmid expression for up to 1 
month post-injection. Replacing the biofluorescent gene to a therapeutic gene, in the 
same plasmids will be able to provide expression similar to the expression observed here, 
thus optical imaging proves to be a useful tool for gene expression profiling.  
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CHAPTER V 
 
STROMAL DERIVED CELL FACTOR-1 GENE TRANSFER FOR 
HEART FAILURE 
 
5 SDF-1 GENE TRANSFER FOR HEART FAILURE 
 
5.1 Introduction 
 
We previously identified Stromal cell-Derived Factor-1 (SDF-1, a.k.a. CXCL12) as a 
chemokine that is transiently expressed post-tissue injury to promote stem cell homing to 
the myocardium.69 SDF-1 enhances tissue repair by preventing cell death and recruiting 
blood borne and tissue specific stem cells to the damaged region.69 SDF-1 is a naturally-
occurring chemokine that is rapidly increased after myocardial infarction for a period of 
4-5 days.69,175 SDF-1 triggers a number of protective molecular cascades that are both 
anti-inflammatory81 and anti-apoptotic to preserve cardiac tissue after injury.176  
Furthermore, SDF-1 is a strong chemoattractant of stem cells and progenitor cells that 
promote tissue preservation and blood vessel development. The tissue-preserving and 
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reparative effects of SDF-1 led us to investigate the potential role of SDF-1 in treating 
ischemic cardiovascular disease.   
 
More recently, we have demonstrated that the over-expression of SDF-1 in 
myocardial tissue leads to recruitment of endogenous cardiac stem cells to the infarct 
border zone.61 Since our original findings several groups have expanded the molecular 
mechanisms by which myocardial expression of SDF-1 or its receptor CXCR4 leads to 
preservation of cardiac myocytes and improvement in cardiac function in an acute 
myocardial infarction setting.74,177 The benefit from adult stem cell therapy, for 
preventing and treating cardiac dysfunction, is due to paracrine factors; therefore, the 
results of cell therapy can be achieved by gene transfer. 
 
We hypothesized that re-establishing stem cell homing by increasing SDF-1 
expression via non-viral gene transfer into the peri-infarct tissue, late after myocardial 
infarction, would re-establish myocardial healing through recruitment of bone marrow 
derived stem cells and lead to increases in vascular density and cardiac function.69 To 
date, we have re-established SDF-1 expression through a cell-based gene transfer 
approach using stably transfected fibroblasts,69 mesenchymal stem cells,35 or skeletal 
myoblasts transfected with an adenovirus encoding SDF-1 ex vivo.66, 178  SDF-1 protein, 
in combination with a slow release matrix, has been shown to improve cardiac function in 
a model of ischemic cardiomyopathy.179 While these data would suggest that SDF-1 
alone may be sufficient to improve cardiac function, such a conclusion is premature, 
since matrix alone has been shown to induce ventricular remodeling.180, 181 The goal of 
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this study was to determine if re-establishing myocardial SDF-1 expression without the 
concomitant delivery of cells is a viable strategy for increasing myocardial vascular 
density and cardiac function in the setting of ischemic cardiomyopathy. 
 
In order to deliver SDF-1 to the myocardium, we injected naked plasmid DNA 
encoding hSDF-1 into the infarct border zone.  In prior studies, this strategy has proven 
to be safe and non-toxic, and is not associated with the toxicities and loss of function that 
have been observed with adenoviral injection in the infarct border zone.182 We 
characterized plasmid expression in cardiac tissue using a luciferase bioluminescence 
reporter system,109 since previous non viral gene transfer studies demonstrated low 
transfection efficiency with this approach. We tested plasmid dose, effect of transcription 
enhancers, and ubiquitous versus cardiac-specific promoters to increase expression of this 
therapeutic gene. We identified an optimal plasmid formulation, using a biofluorescence 
reporter and used a similar design for this gene as well. We injected plasmid encoding 
SDF-1 into the heart one month after myocardial infarction. This led to a significant 
increase in cardiac function four weeks post-injection that could be attributed to 
significant increase in vessel density and a trend towards reduction in scar tissue. The 
degree of functional improvement correlated with the level of vector expression.  
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5.2 Methods: 
 
5.2.1 Experimental Plan 
 
 
 
 
 
 
 
 
Rats were infarcted via LAD ligation, and the hearts were allowed to modify to a 
chronic heart failure stage. 4 weeks after LAD ligation, the chests were re-opened in 
order to inject the hSDF-1 plasmid into the border zone of the left ventricle dissolved in 
100µg/100µl of PBS, at 4 sites spanning the infarct. Rats were imaged using the 
ultrasound echocardiography, before the injections, and 2 weeks, 4 weeks and 8 weeks 
post treatment. Hearts were then excised and characterized for vessel density, and fibrosis 
extent, via histochemistry studies.   
 
5.2.2 Plasmids Used 
 
The pCMV, pCMVe and pMHC plasmids expressing the hSDF-1 gene was used for 
this study. Detailed descriptions of these plasmids are described above. (Chapter 3) 
Rats are infarcted 
via LAD ligation 1 month CHF 
Chest is reopened, 
plasmid is injected 
100µg/site * 4 sites 
In the border zone 
SDF-1plasmid 
Echo at baseline, 
4 and 8 weeks 
Hearts are 
harvested 
Hearts characterized with 
H&E staining and antibody 
staining 
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5.2.3 Intramyocardial Gene Delivery  
 
8 week old male Lewis rats weighing 225-250 grams underwent LAD ligation, as 
previously described. To inject the DNA, the chest was reopened four weeks post MI, 
applying the same procedure as above.  100 µg of DNA solution in 100 µl of saline per 
injection site was injected using a 30 gauge needle, for a total of 4 injection sites around 
the border zone. The border zone was identified by the blanched region around the LAD 
identified by dyskinetic motion of the anterior wall. The DNA was injected into the wall 
and distention of the tissue was observed when the DNA was injected. The chest was 
closed as mentioned above for the LAD ligation. 
 
5.2.4 Echocardiographic Analysis 
 
We routinely perform 2D-echocardiography on rats, pre injection, 2 weeks, 4 weeks 
and 8 weeks post injection, using a 15-MHz linear array transducer interfaced with a 
Acuson Sequoia C256 (Siemens, Munich, Germany).  The animals were sedated with 
ketamine, the chest was shaved, and the sedated animal maintained in a supine position. 
For quantification of LV dimensions and wall thickness, we digitally record 2D clips and 
m-mode images in a short axis view from the mid-LV just below the papillary muscles.  
This anatomical location was chosen to consistently obtain measurements from the same 
anatomical location in different mice.  Measurements were made offline using ProSolv 
(Indianapolis, IN).  Each measurement in each animal was made 6 times, from 3 
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randomly chosen m-mode clips out of 5. As a measure of left ventricular functions, 
shortening fractions was calculated from M mode studies.  
 
5.2.5 Immunohistochemistry 
 
8 weeks after the injection of the plasmid, the animals were perfused with saline and 
histochoice and the hearts were harvested. Tissues were fixed in histochoice and 
embedded in paraffin blocks according to established protocols. Antigen retrieval was 
performed using 10 mM sodium citrate buffer (pH 6.0) and heat at 95°C for 5 min. The 
buffer was replaced with fresh buffer and reheated for an additional 5 min, then cooled 
for 20 min. The slides were washed in deionized water three times for 2 min each. 
Specimens were then incubated with 1% normal blocking serum with goat and donkey 
serum in PBS for 60 min to suppress nonspecific binding of IgG. Slides were then 
incubated for 60 min with rabbit polyclonal von Willebrand factor (Abcam Cambridge, 
MA) at 1:100 dilutions in blocking buffer with serum. Myosin was stained with mouse 
monoclonal left ventricular myosin (Millipore, Billerica MA) at a dilution of 1:10 in 
blocking buffer with serum. Optimal antibody concentration was determined by titration. 
Slides were then washed with phosphate-buffered saline (PBS) and incubated for 45 min, 
with IgG donkey anti-rabbit Alexa fluor 594 (Molecular Probes, Invitrogen, Carlsbad, 
CA) at 1:800 dilution in blocking buffer with serum and IgG goat anti-mouse Alexa Fluor 
488 (Molecular Probes, Invitrogen, Carlsbad CA) at 1:800 dilution in blocking buffer 
with serum respectively in a dark chamber. After washing extensively with PBS, 
coverslips were mounted with aqueous mounting medium. (Vectashield Mounting 
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Medium with DAPI, H-1200; Vector Laboratories, Burlingame, CA, USA). For arteriole 
imaging, a mouse monoclonal α-sarcomeric actin antibody was used at a 1:200 dilution 
(Sigma). 
 
5.2.6 Masson’s Trichrome Staining 
 
8 weeks after the injection of the plasmid, the animals were perfused with saline and 
histochoice and the hearts were harvested. The hearts were fixed in histochoice for 7 days 
and then embedded in paraffin. Hearts were then sectioned and stained with Masson’s 
Trichrome staining for identifying the infarct. Mason’s trichrome was used to quantitate 
the collagen content. Fibrosis size or scar tissue was deduced by the percentage of area 
with collagen as compared to the total area. 
 
5.3 Results: 
 
5.3.1 Intra-myocardial injection of SDF-1 plasmid increased vessel density 
 
Previous studies have shown that SDF-1 expression is increased after MI and recruits 
stem and/or progenitor cells to promote tissue preservation and promote vasculogenesis. 
We tested whether non-viral gene transfer of vector expressing SDF-1 would improve 
vasculogenesis following myocardial infarction. As described above, rodents were 
infarcted via LAD ligation and received direct injection of SDF-1 plasmid DNA one 
month post myocardial infarction. Myocardial sections obtained from animals that 
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received SDF-1 gene transfer, 8 weeks after injection, were stained with antibodies 
against von Willebrand Factor (vWF) to assess vasculogenesis (Figure 5-1). We observed 
a statistically significant increase in blood vessel density in the infarct zone in the animals 
that received pCMVe-hSDF-1 and pCMV-hSDF-1, as compared to saline controls (p<0. 
0001). The infarct border zone and infarct zone, on average, had a higher blood vessel 
density in the pCMVe-hSDF-1 group (21 vessels/mm2) and pCMV-hSDF-1 group (17 
vessels/mm2) than those in the saline group (6 vessels/mm2) (n=7 in all groups) (Figure 
5-2). The vessels observed by vWF staining were also co-stained with α-smooth muscle 
actin. A co-localization of endothelial cells and actin filaments was observed (Fig 5-3), 
which further established the fact that the blood vessels observed were arterioles and 
arteries, and not capillaries. 
 
Interestingly, the pCMVe vector that had the highest peak expression did not induce 
significantly greater vasculogenesis than the lesser expressing unenhanced pCMV vector.  
This result suggests that delivering a minimum threshold amount of SDF-1 was necessary 
to induce vasculogenesis but that more SDF-1 did not induce more. 
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Figure 5-1: Vessel density count (vessels / mm2) in rodents that received SDF-1 gene 
Double staining with von Willebrand Factor and ventricular myosin showing blood 
vessels and myocytes respectively in the infarct zone after injection with saline as 
control, or plasmids; CMV pcDNA SDF-1 and CMV KCPIR SDF-1 (n=7 in all groups) 
are represented above. The number of arterioles observed in the SDF-1 treated groups is 
significantly greater than the controls. (p<0.001) 
Red: vWF; Green: Myocytes; Blue: Dapi. Magnification = 20x 
 
 
 
Figure 5-2 : Increase in blood vessels following SDF-1 gene therapy 
Vessel density was significantly increased in the SDF-1 treated animals compared to 
saline controls.CMV KCPIR-SDF1, 21 ± 1.82 vessels/mm2; CMV pcDNA-SDF1 17 ± 
1.48 vessels/mm2, and PBS 6 ± 0.73 vessels/mm2. *, p<0.001. 
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Figure 5-3 : Actin staining to determine the vessels to be arterioles 
Immunohistochemistry with vWF and α- sarcomeric actin staining showing blood vessels 
and actin staining in the infarct zone, 8 weeks after injection with CMV KCPIR SDF-1 
(n=7). The positive staining identifies the blood vessels as mature arterioles and not 
capillaries. Red: actin; Green: vWF for vessels, Blue: Dapi. Magnification = 20x 
 
5.3.2 SDF-1 plasmid therapy improves ventricular function in ischemic rats 
 
We hypothesized that the SDF-1 plasmids that induced vasculogenesis would also 
improve cardiac function post-MI.  To test this hypothesis, ischemic hearts were injected 
with hSDF-1 pDNA vectors. Pre-injection (one month post infarct), all rats had fractional 
shortening (FS) < 30%. 4 weeks post-injection, control animals had a decrease in 
fractional shortening by 35.9%. In contrast, the pCMV-SDF1, and pCMVe-SDF1 groups 
showed statistically significant improvements of 4.62% and 24.97% respectively, by 4 
weeks, (p < 0.01) compared to control. In contrast, a cardiac-specific promoter, αMHC-
driven plasmid (pMHC-hSDF1) treated animals did not improve function compared to 
control animals exhibiting a decline in FS of 32.65% (Figure 5-4). Importantly, the 
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improvement in cardiac function correlated with an increase in blood vessel density 
strongly suggesting a link between vasculogenesis and cardiac functional improvement. 
However, the greater benefit seen with the pCMVe compared to pCMV suggests that 
there are other mechanisms in play as well since pCMVe did not induce significantly 
greater vascular density compared to pCMV.  SDF-1 gene transfer induced cardiac 
benefit was sustained at 8 weeks, as the animals that received the CMV-driven plasmids 
continued to demonstrate improved cardiac function compared to saline control and 
αMHC vector groups (Fig 5-5).  
 
Other parameters of cardiac function, such as the thickening of the anterior and 
posterior walls, trended toward significant improvement (i.e. an increase in wall thickness) 
in the pCMVe-hSDF1 treated animals. No significant change was observed in the 
pCMV-hSDF1 treated animals, the pMHC-SDF1 treated animals or the saline control 
animals. There was no change in left ventricular mass in any group. (Figure 5-6). Since 
the animals treated with the plasmid producing the highest peak expression had the 
largest cardiac benefit, these data suggest the importance of the magnitude of hSDF-1 
vector expression rather than the length of plasmid expression in determining 
improvement in cardiac function.  
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Figure 5-4 : Functional benefit observed in vivo with SDF-1 plasmid treatment 
Pre-injection, (one month post infarct) all rats had a Fraction of Shortening % (FS%) < 
30%. 4 week post injection, the control group (n=10) decreased in FS. In contrast, both 
CMV-driven plasmids showed a statistically significant improvement of 5% (CMV-SDF-
1) (n=9) and 25% (CMVe-SDF-1) (n=10) respectively (p<0.02). The cardiac-specific 
promoter plasmid (αMHC- SDF1) (n=5) did not improve function compared to control. 
 
 
 
Figure 5-5 : Sustenance of benefit for 8 weeks post treatment 
The improvement in cardiac function following plasmid injection is sustained 8 weeks 
after injection. CMV driven plasmids depict an increase in cardiac function as compared 
to saline controls and αMHC driven plasmids. 
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Figure 5-6 : Other physiological parameters associated with benefit 
Other physiological parameters such as left ventricular mass, anterior wall and posterior 
wall thickening between rodents from the different treatment groups are assessed here. 
These parameters are symptomatic with ventricular remodeling. 
 
 
5.3.3 SDF-1 gene transfer reduced fibrotic tissue in the infarct zone 
 
We performed Masson’s Trichrome staining to determine the infarct size, 
represented by fibrotic tissue, 4 weeks after treatment with plasmids. The infarct size was 
reduced in the animals that received SDF-1 plasmid when compared to the saline animals. 
The fibrotic area was smaller in the pCMVe-SDF1 group (16.92%) and pCMV-SDF1 
group (17.81%), than in the saline group (23.82%) (n=7 in all groups). These results 
exhibit a strong trend towards reduction in cardiac fibrosis following SDF-1 treatment 
(p=0.08) (Figure 5-7).  
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Figure 5-7 : Masson’s Trichrome staining to determine infarct sizes in vivo 
SDF-1 gene therapy reduces infarct size, 8 weeks after treatment in chronic heart failure. 
The left ventricular fibrotic area was significantly smaller in the SDF1 groups (compared 
to the saline group. (n=7 in all groups) 
 
 
 
Figure 5-8 : Decrease in fibrotic scar following SDF-1 treatment 
The left ventricular fibrotic area was significantly smaller in the CMV KCPIR-SDF1 
(16.92 ±2.82 %) and CMV pcDNA-SDF1 groups (17.81 ±2.59 %), compared to the 
saline group (23.82 ±4.47 %). (n=7 in all groups) 
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5.4 Discussion 
 
Regenerative medicine has significant potential for the treatment of ischemic cardiac 
disease because, unlike current treatments that focus on either alleviating symptoms or 
reducing cardiac work load, regenerative medicines provide an opportunity to repair and 
retain function in degenerating organs.  Non-viral gene delivery, or the application of 
naked plasmid DNA to express a therapeutic protein at a specific site, is a simple delivery 
method that has been tested clinically in ischemic patients for over 15 years. A 
substantial body of literature, both preclinical and clinical, has demonstrated that non-
viral vector delivery of therapeutic genes is safe and effective. The safety profile of non-
viral gene delivery is also attractive when compared to viral vector therapy delivery 
because it does not produce a significant inflammatory response that viral vector delivery 
can cause; nor is there concern for antibody response to the vector due to prior viral 
exposure in the patient.  
 
Cardiovascular gene therapy has been found to be a safe strategy to obtain transient 
protein expression in the heart.  Skeletal and cardiac muscle have been shown to take up 
and express plasmid encoded genes as well as transgenes incorporated into viral 
vectors.183, 184 While viral vectors yield increased transfection efficiencies compared to 
non-viral strategies, they induce inflammatory responses that may result in unwanted side 
effects and preclude repeat administrations.185 In vitro and in vivo studies have shown 
that despite lower gene transfer efficiency with non-viral methods, site-specific 
administration of the gene still results in physiological effects within the tissue.186, 187 
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Some advantages of non-viral gene transfer are the ability for repeat administration of 
therapy and the potential for transient protein expression. Several clinical trials have 
demonstrated safety and efficacy for non-viral gene therapy in ischemic cardiovascular 
disease.110  
 
We previously identified Stromal cell-Derived Factor-1, or SDF-1, as a naturally-
occurring protein that is rapidly produced in response to ischemic tissue injury.175 SDF-1 
induction stimulates a number of protective anti-inflammatory pathways, is increased in 
the myocardium after a heart attack, but only lasts for a matter of days, and therefore the 
protective response quickly fades. This short duration of SDF-1 action reduces the 
potential for tissue repair. A non-viral plasmid producing SDF-1 for treatment of heart 
failure provides a potentially safe means through which to obtain longer, albeit transient 
(< 15 day) therapeutic protein production in the heart while allowing for the possibility of 
repeat injections.  
 
In this study, we have demonstrated that the delivery of SDF-1 plasmid to the infarct 
border zone, 1 month after myocardial infarction, led to an increase in vascular density 
and improvement in cardiac function that was sustained 8 to 10 weeks after gene transfer.  
Our expression studies demonstrated that expression of our optimized plasmid peaked at 
day 2 post gene transfer and decreased over the following two weeks. These findings are 
consistent with previous literature showing a peak in CMV-driven gene expression, 2 
days after injection in the rat heart.169, 174 Peak expression in the presence of the RU5 
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element (pCMVe) was 10-fold greater than that seen in the non-enhanced CMV plasmid 
(pCMV).   
 
The degree of functional changes with any given plasmid encoding hSDF-1 
correlated with the level of luciferase expression achieved with that plasmid construct.  
We observed continued decline in cardiac function in the animals that received saline or 
the low expressing αMHC plasmid (pMHC).  Four weeks after plasmid injection (8 
weeks after MI) there was a decline in cardiac function in both these groups, which 
correlated with low expression profiles. Both CMV vectors resulted in an increase in 
cardiac vascular density.  However, the animals that received the CMV plasmid with 
enhancer elements (pCMVe) increased cardiac function to a greater extent than those 
animals that received the CMV plasmid alone (pCMV).  
 
Increased SDF-1 expression in the infarct border zone also led to a decrease in 
myocardial fibrosis at 8 to 10 weeks after plasmid injection. Similar to the change in 
vascular density, there was an inverse correlation between the degree of myocardial 
fibrosis and SDF-1 expression, suggesting that the mechanisms behind scar remodeling 
may be crucial to the understanding of the therapeutic response to SDF-1. These data 
suggest that SDF-1 treatment attenuates the progression of chronic ischemic heart failure 
and may partially reverse manifestations of the disease by increasing vasculogenesis, 
reducing scar formation and attenuating pathological cardiac remodeling after MI. 
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CHAPTER VI 
 
IDENTIFICATION OF TARGETING PEPTIDES 
 
6  IDENTIFICATION OF TARGETING PEPTIDES 
 
6.1 Introduction 
 
Gene therapy has evolved as a viable therapeutic option for treating patients with 
chronic conditions. We have optimized and established a vector system for delivering 
plasmid hSDF-1 to the myocardium in order to provide significant cardiac benefit, due to 
improved angiogenesis in the cardiac tissue. However, we injected this plasmid into the 
myocardial wall, thus requiring an invasive procedure in order to deliver the therapeutic 
gene. Injecting the plasmid directly into the myocardium, ensures maximum efficacy of 
the therapeutic gene, as it is delivered into the micro environment associated with the 
damaged tissue, therefore, improving the chances of the gene being taken up by these 
cells. However, delivery of naked plasmid into the tissues, increases the probability of 
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being subject to endosomal degradation. Therefore, only a smaller portion of the plasmid 
injected is taken up by the cells and then translated to the therapeutic protein. In order to 
protect the genes from degradation, scientists have studied various techniques to package 
the plasmid and safely deliver it to organs.188,189 However, although this technique 
protects the DNA from being degraded, it does not eliminate the need for invasive 
surgery.  
 
Systemic delivery of the plasmid, packaged into safe compartments is an optimal 
solution. Recent advances in identifying various polymeric carriers capable of 
encapsulating the DNA safely have spurred research into identifying efficient targeting 
ligands to direct the polymeric vectors to the organs of interest.  
 
Phage libraries are able to provide a comprehensive list of peptide sequences that 
specifically bind to particular molecules. A large number of phage particles 
(approximately 1010-12) are exposed to a specific molecule, a certain organic compound, 
sugar molecule, or even cells in culture, to identify the few that bind to them.160 An 
extension of this technique, is in vivo phage panning, where a similar number of phage 
particles are infused via a vein into an animal, to identify the few ones that specifically 
bind to the targeted organ.158 These have shown to traverse intestinal mucosal layers, skin 
layers to target cells within them.152 They have been used to identify targets for tumor 
cells, identify targets to the brain via an intra nasal pathway, and reach amyloid plaques 
with the help of antibodies.150, 153, 155, 190 Infusion of phage display libraries within M13 
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bacteriophage may be useful in identifying specific ligands in the infarct region of the 
heart.  
 
In this study, we hypothesized that delivering a large number of phage particles, with 
multiple copies of various peptides in the library, can lead us to one or a few targets to 
the infarcted zone in the heart.  The main focus was to identify one or a few ligands that 
have a high affinity for infarct tissue and are specific to the heart. This can then be used 
to tag polymeric devices, or the naked plasmids to infuse therapeutic genes to the 
ischemic myocardium.  
 
We infused the circular C7C peptide library in M13bacteriophages into rodents that 
exhibited chronic heart failure. 1.5 hours post infusion we removed the heart, separated 
the infarcted and border region, and eluted the phages in this region of the heart. This was 
amplified and panned for a second round. After 3 rounds of panning and sequencing of 
the peptides with affinity to the infarcted region of the heart, we identified the sequence 
to be a 7 peptide sequence of RQPRMKR (RR peptide) flanked on either sides by 
cysteines to provide a circular CRQPRMKRC ligand with selective affinity to the heart. 
On infusing this peptide tagged with a fluorescent label, we confirmed the targeting 
nature of this peptide with immunohistochemistry studies.  
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6.1.1 Mechanism of phage panning 
 
The Ph.D. C7C library consists of random 7-mer peptides flanked by cysteines in 
order to conserve the 7-mer peptide by giving it a circular conformation. The cysteine 
residues are oxidized during phage assembly, and thus allow for a di-sulfide link that 
brings the 7-mer peptide to a circular construct, conserving its sequence. These 7-mer 
peptides are fused to the minor coat protein of the M13 bacteriophage via a linker 
sequence Gly-Gly-Gly-Ser. These variant libraries are expressed on the outside of the 
phage, while the genetic material encoding the 7 mer is inside the phage particle. The 
presence of the peptide on the surface, bound to the phage, creates a link that can bind the 
phage to selective targets, antibodies, receptors enzymes etc.  
 
In vitro phage panning is carried out when multiple copies of each variant peptide is 
exposed to a surface antigen, the unbound phage is washed away and the resulting phage 
is eluted, amplified and exposed to a second surface with the antigen. Each such round is 
called panning. After 3 to 4 rounds of panning, an exclusive sequence is identified by 
DNA sequencing and ELISA, which binds to the antigen.132, 150, 151 
 
In vivo phage panning refers to an extension of the in vitro phage panning, to identify 
potential ligands that bind to organs. Phage with its variant libraries is circulated through 
an animal, following infusion via a vein. The organs are harvested and the bound phage is 
eluted, amplified and identified.155 
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Figure 6-1 : Mechanism of in vivo phage panning technique in rodents. 
Adapted from Nature Reviews Cancer 2, 83-90 (February 2002) 
 
6.2 Methods: 
 
6.2.1 Phage Panning 
 
M13 phage library Ph.D.-7 (M13-based, complexity 2.8×109 transformants; New 
England BioLabs, Schwalbach, Germany) which displays random 7-mer peptides at the 
N-terminus of the pIII protein (high stringency: only 3–5 copies per phage particle) was 
used. 1.2×1011 pfu of phage library in 200 µl saline was delivered to three anesthetized 
Lewis rats (8–12 weeks old), one month post infarction via LAD ligation. LAD ligation is 
described above.  These animals were sacrificed 1.5 hours post infusion. Following 
careful dissection to avoid any possible puncture of gastro-intestinal tract and 
exsanguinations by cutting jugular veins, the rats were perfused through the heart with 
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120 ml of saline to remove all blood. The hearts were removed and washed in ice cold 
saline. Tissues were weighed and, homogenized in 2 ml of tissue suspension buffer 
(DMEM, with 1% BSA and 10% protease inhibitors). Bound phage was eluted from this 
with glycine and stabilized with Tris. This was amplified with E Coli. 1.2×1011 pfu of 
amplified phage was re-infused via tail veins. This process was repeated three times. At 
the end of the 3rd round, eluted phage was sequenced and identified.  
 
6.2.2 Peptide Synthesis and Analysis 
 
The RQPRMKR peptide was synthesized by the Protein Core lab at the Cleveland 
Clinic and confirmed by mass spectrometry. This peptide was tagged with a His tag. A 6-
His peptide was attached to the N terminal end, thus synthesizing a 6-His-RQPRMKR 
peptide (RR peptide). 
 
Rats were infarcted via LAD ligation, as described before. One month post ligation, 
the RR peptide was infused via the tail vein. 1.5 hours later, the animal was sacrificed 
and the heart, lung, liver, spleen and kidney was excised, and washed in ice cold PBS.  
 
6.2.3 Immunohistochemistry 
 
Organs were embedded in OCT compound and were frozen immediately. The tissue 
samples were stored for long periods of time at -80°C. Frozen samples were cut in a 
cryotome at 5micron thickness and mounted on slides. Tissue specimens were fixed with 
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paraformaldehyde and incubated with 1% normal blocking serum with goat and donkey 
serum in PBS for 60 min to suppress nonspecific binding of IgG. Slides were then 
incubated for 60 min with mouse monoclonal anti His antibody (Abcam Cambridge, MA) 
at 1:200 dilutions in blocking buffer with serum. Slides were then washed with 
phosphate-buffered saline (PBS) and incubated for 45 min, with IgG goat anti-mouse 
Alexa fluor 488 (Molecular Probes, Invitrogen, Carlsbad, CA) at 1:800 dilution in 
blocking buffer with serum in a dark chamber. After washing extensively with PBS, 
coverslips were mounted with aqueous mounting medium. (Vectashield Mounting 
Medium with DAPI H-1200; Vector Laboratories, Burlingame, CA, USA).  
 
6.3 Results 
 
6.3.1 Identification of targeting peptide 
 
In vivo phage panning was performed in rats with LAD ligation, one month post 
infraction. Infarction in the hearts was confirmed by echocardiography. 1.2x1012 particles 
was infused via the tail vein. 1.5 hours later, when the particles have had enough time to 
circulate through the body, hearts were excised. The blanched region was identified as 
the infarct zone. The region in between this zone and the healthy tissue is termed the 
border zone. Tissue sections were washed in ice cold saline, and the blanched region was 
sectioned out. Tissues were homogenized and the phage was eluted. Phage was 
sequenced using primers provided in the kit. Three colonies were picked after each round 
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of panning. After three rounds of panning, a common sequence of Arg-Glu-Pro-Arg-Met-
Lys-Arg (RQPRMKR) was identified. (Figure 6-2) 
 
 
Figure 6-2 : Phage panning to determine a targeting sequence to the ischemic heart 
Colonies obtained from rodents (n=3) after each panning cycle were sequenced to 
identify the phage that bound to the ischemic hearts in their respective cycles. The first 
pan identified multiple sequences but after the third round a common sequence was 
identified.  
 
 
6.3.2 Synthetic Peptide Formulation and Analysis 
 
This peptide was synthesized at the CC Proteomics Core lab. The peptides were 
synthesized with a fluorescent tag attached to one end. A (His)6 – RQPRMKR peptide 
was synthesized and the purity was checked by reverse phase liquid chromatography. The 
mass was determined using a mass spectrometer and was recorded at 1794.60 units using 
a 4700 Reflector Spectrometer. 
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6.3.3 In Vivo Expression Profile of the RR peptide 
 
The RR peptide tagged with His was infused at 200 µg of peptide in 200 µl of PBS 
into tail veins in rodents, one month after LAD ligation. Prior to infusion, rats hearts were 
imaged via echocardiography to ensure an akinetic wall motion and a loss in fractional 
shortening (<30%). The rats were then perfused with saline, and the organs were excised 
and embedded in OCT compound. Sections were made and the tissue samples were 
stained with fluorescent antibody markers against His and Dapi for nuclear detection. 
Heart sections were stained positive against the His antibody, thereby confirming the 
presence of the (His)6 – RR peptide. All other organs, lungs, spleen, liver and kidney 
were stained negative for His, thus confirming the absence of this peptide in all other 
organs. (Figure 6-3) 
 
The RR peptide specifically targets the heart tissues and has high affinity to the 
infarct region. This peptide may be used as a targeting molecule to direct therapeutic 
drugs and genes to the infarct region.  
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Figure 6-3 : Specificity of peptide interaction with heart tissues 
Rodent hearts were frozen and then stained for His antibody. A “His” tag was attached to 
the peptide sequence thus a positive His stain correlated with a positive peptide 
identification. Peptides were infused via the tail vein and translocated to the heart tissue 
specifically.  
 
 
6.3.4 BLAST Analysis of the targeting peptide 
 
The RQPRMKR sequence with the genomic code of agg cag ccg cgc atg aag cgg 
was compared against all the known sequences n the rat genome using the BLAST 
software. There were some similarities in the sequence code with other known protein 
sequences such as FAS Associated Factor -1 (FAF-1) which has the sequence 
qiverqprmldfrveyrdrn and another protein, Sodium-dependent phosphate transporter 1 or 
Solute carrier family 20 member 1 a.k.a. Phosphate transporter 1 (PiT-1) which has a 
sequence wffvcprmkrkierevkssp. But neither of these sequences possesses all the 7-mer 
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sequence, therefore a conclusive evidence of either of these two proteins is lacking. 
(Figure 6-4)  
 
 
Figure 6-4 : BLAST Analysis of the peptide sequence with other known proteins 
BLAST analysis provides a comparison between a known peptide sequence to the whole 
genome to identify potential peptide targets or proteins associated with the peptide. 
Analyzing the targeting peptide against the rat genome using the BLAST software 
provided two potential protein targets, FAF-1 and PiT-1.  
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6.4 Discussion 
 
Targeting peptides are an essential component in delivering genes or encapsulated 
drugs to the organ of interest. There has been a growing body of researchers trying to 
develop micro particles, and other polymeric compounds to devise novel means to 
encapsulate genes and drugs to protect their safety from degradation.191 However, on the 
other hand, research involving the identification of targeting ligands has been slow to 
progress. This is partly due to the lack of effective libraries required for screening of 
ligands. Previously, researchers studied various angiogenic and inflammatory pathways 
that were triggered during injury to build a library of possible ligands and then screened 
them to identify effective ones. This poses a problem with missing out on ligands that 
were not included as part of the list.159  
 
The PhD library, using phages has revolutionized the screening for target compounds 
to complex diseases, such as cancer.155 The PhD libraries provide every possible 
combination of the whole genome, and thus are useful in identifying ligands that may be 
involved in targeting.150 However, the repeated panning cycles, are responsible for the 
high selectivity in this process. The prepared libraries have sufficient complexity to 
produce multiple DNA sequences encoding the same consensus peptide motifs. These 
libraries are used for various purposes, ranging from epitope mapping, material-specific 
peptide identification, in vitro testing and identification, small molecule discoveries, 
enzyme substrates and various in vivo applications.148, 149, 151, 154, 160 The Ph.D. libraries 
have been used extensively for discovery of peptide antagonists of VEGF-mediated 
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angiogenesis, trans-dermal trafficking and trans-intestinal trafficking peptides, and cell 
targeting peptides.151, 152, 155  
 
In our study we have identified and confirmed a peptide sequence of RQPRMKR, 
with some unknown binding sites that may relate to the FAF-1 peptide or the PiT-1 
peptide. This sequence was identified after three different panning rounds. This peptide 
was synthetically made and tagged with a fluorescent label of 6-His. This peptide 
sequence was specific among 1.2x1011 pfu of phage and demonstrated specificity to the 
heart tissue as compared to the various other organs. When used as a tagging peptide to 
nanocarriers, this peptide will be capable of transporting the carriers to the heart alone, 
and thus reduce risks of secondary organ complications.  
 
This study now opens the doors towards the application of this targeting peptide in 
multiple applications involving the failed heart, thus providing the solution to systemic 
delivery of drugs for patients, who are incapable of undergoing a surgical procedure.  
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CHAPTER VII 
 
ENGINEERED NANOPARTICLES AS CARRIERS FOR SYSTEMIC 
DELIVERY 
 
7  NANOPARTICLES AS CARRIERS FOR SYSTEMIC DELIVERY 
 
7.1 Introduction 
 
Gene therapy has evolved as a promising option to deliver pro-angiogenic proteins to 
infarct zones, thus providing cardiac benefit. We have identified a gene design without 
viral promoters, using the ubiquitously-expressing CMV promoter and transcription 
enhancers, to improve the length and magnitude of gene expression as compared to 
traditional naked plasmid deliveries. Using this design we delivered therapeutic levels of 
Stromal Derived Cell Factor-1 (SDF-1) (which is pro-angiogenic) in rodents and pigs 
with chronic heart failure, by direct injection in the border zone, thereby improving 
cardiac function. To target cardiac myocytes in the infarct zone, we also generated a 
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vector with a cardiac-specific αMHC promoter. On assessing the gene expression, in vivo, 
we observed that non-enhanced αMHC driven plasmids have low magnitudes of 
expression which could be increased 10-fold, to therapeutic levels, with transcriptional 
enhancers. This therapy is safe, effective, and the benefits can last long after the 
expression of the gene is lost.  We have also studied and identified targeting peptides that 
allow for systemic targeting to the heart.  
 
However, the need for improving penetration of the genes into the cells has long 
been a challenge. Studies with cell penetrating peptides, such as TAT, VP22, etc have 
shown improvements in cell penetration of therapeutic drugs.192-195 Encapsulations of 
drugs and plasmids within polymeric devices have been studied extensively. The need for 
biodegradable particles, to encapsulate drugs, and deliver them safely to injured tissue, in 
an active form, has been the reason for the development and growth of nanoparticulate 
systems. PLGA (poly lactide co glycolide) is a poly ester with growing interest due to its 
stability, ability to bind targeting ligands to the surface, regulated control of release of the 
encapsulated plasmid in the cytoplasm, ability to be degraded in vivo, following the 
release of the plasmid, and approval for use in human trials by the FDA.114, 118  Our focus 
was to engineer a polymeric carrier that is capable of targeting the ischemic myocardium 
and delivering therapeutic drugs to it. PLGA polymeric devices may be able to 
encapsulate therapeutic genes and deliver them safely to tissues via the systemic 
circulation.  
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We hypothesized that encapsulating the gene of interest into PLGA polymeric 
particles, tagged with the RQPRMKR (RR) peptide will be able to provide a targeting 
encapsulated drug capable of homing to the ischemic myocardium via systemic delivery. 
The targeting peptide, RR, when tagged to the polymeric complex, will be viable and in 
its active form, and will be able to direct the polymeric complex to the injured 
myocardium. The PLGA polymer will then be able to release the encapsulated material 
into the area of injury.  
 
To understand the behavior of encapsulated drugs in vivo, and to determine the 
efficacy of this system, various strategies have been studied in the past. Fluorescent 
nanoparticles with polystyrene have been used as models to understand tissue uptake and 
trafficking.196 Other strategies have employed gold colloidal particles that can be viewed 
by transmission electron microscopy due to its dense matter.197 6 Coumarin (6C) is a 
lipophilic fluorescent dye that can be viewed by confocal microscopy, and its 
fluorescence activity can be accurately measured by High Performance Liquid 
Chromatography (HPLC) analysis.127,198 Our focus was to design a nanoparticulate 
carrier capable of encapsulating 6C, a fluorescent dye, and delivering it to the 
myocardium, with the help of a tagging peptide. The uptake and in vivo trafficking would 
then be monitored to determine the dose, time, and other aspects associated with this 
delivery system. 
 
In order to determine the release and uptake of nanoparticles in vitro, we added 
nanoparticles with or without the homing peptide to cardiac fibroblasts seeded on 6 well 
113 
 
plates. As expected, we did not see a difference in fluorescence between the two groups. 
The uptake took place in about 30 minutes and stayed for more than 24 hours. In vivo, we 
observed a greater uptake of nanoparticles, as determined by the amount of fluorescence 
in various organs, in the injured myocardium, as opposed to the healthy myocardium. RR 
peptide helps target the encapsulated material to the injured myocardium.  
 
On replacing the 6C dye with a therapeutic gene, such as SDF-1 we may be able to 
show improved cardiac benefit via systemic delivery, capable of translating this complex, 
to patients with chronic heart failure.  
 
7.2 Methods 
 
7.2.1 Materials  
  
BSA (Fraction V) and PVA (average molecular weight, 30,000–70,000) were 
purchased from Sigma (St. Louis, MO). 6-Coumarin was purchased from Polysciences 
(Warrington, PA). PLGA (50:50 lactide–glycolide ratio, 143,000 Da, viscosity 0.87dl/g) 
was purchased from Birmingham Polymers (Birmingham, AL). RR-peptide of the 
sequence (His)6- Arg-Glu-Pro-Arg-Met-Lys-Arg (molecular weight 1784) was custom 
synthesized by Cleveland Clinic Proteomics Core(Cleveland, OH). Denacol_ EX-521 
(Pentaepoxy, molecular weight 742) was a gift from Nagase Chemicals Ltd (Tokyo, 
Japan). Zinc tetrahydrofluroborate hydrate, poly(vinyl alcohol) (PVA, average molecular 
weight 30,000–70,000), dextran, boric acid, and ethanol were obtained from Sigma 
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Chemical Co. (St. Louis, MO). Chloroform was obtained from Fisher Scientific 
(Pittsburgh, PA). 
 
7.2.2 Formulation of 6C loaded PLGA nanoparticles 
 
Nanoparticles containing BSA and 6-coumarin were formulated using a double 
emulsion-solvent evaporation technique as described previously. An aqueous solution of 
BSA (60 mg/ml, 1 ml) was emulsified in a PLGA solution (180 mg in 6ml chloroform) 
containing 6-coumarin (100µg) using a probe sonicator (55W for 2 min) (Sonicator® XL, 
Misonix, NY). The water-in-oil emulsion formed was further emulsified into 50 ml of 
2.5% w/v aqueous solution of PVA by sonication (55W for 5 min) to form a multiple 
water-in-oil-in-water emulsion. The multiple emulsion was stirred for ~18 h at room 
temperature followed by for 1 h in a desiccator under vacuum to remove the residual 
chloroform. Nanoparticles were recovered by ultracentrifugation (35,000 rpm for 20 min 
at 4 °C, OptimaTM LE-80K, Beckman, Palo Alta, CA), washed two times with distilled 
water to remove PVA, unentrapped BSA and 6-coumarin, and then lyophilized (−80 °C 
and <10_m mercury pressure, SentryTM, Virtis, Gardiner, NY) for 48 h to obtain a dry 
powder. Dry lyophilized nanoparticle samples were stored in a desiccator at 4°C and 
were reconstituted in a suitable medium (buffer or cell culture medium) prior to an 
experiment. 
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7.2.3 Conjugation of targeting peptide:  
 
The peptide to be conjugated is the RQPRMKR peptide, identified via phage 
panning experiments. Prior to conjugation, the peptide is tagged with (His)6 residues in 
its N terminal. The peptide was conjugated to the nanoparticles in two steps.  
 
Step 1: Surface activation step: nanoparticles were suspended in borate buffer 
(50mM, pH 5.0) by sonication for 30 sec on an ice bath. This is followed by the addition 
of Denacol (40 mg), an epoxy that helps conjugation of the peptide on the surface and the 
catalyst zinc tetrahydrofluroborate hydrate (50 mg) also dissolved in an equal volume of 
buffer to the NP solution. This mixture was stirred gently for 30 minutes at 37C. NPs 
were separated by ultracentrifugation at 30000 rpm for 20 minutes at 4C. Any unreacted 
Denacol is removed by multiple wash steps.  
 
Step 2 : Conjugation of peptide: Surface activated NPs were suspended in borate 
buffer (4 ml) and stirred into a solution containing three different initial amounts of 
peptides; 250ug, 500ug and 1 mg in borate buffer. This reaction is carried out for 2 hours 
at 37C. The unreacted peptide was removed by ultracentrifugation and the final 
nanoparticles suspension was lyophilized for 48 hours.  
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7.2.4 Nanoparticle characterization 
 
Particle size and surface charge (zeta potential). 
 
Particle size and size distribution were determined by photon correlation 
spectroscopy (PCS) using quasi-elastic light scattering equipment (ZetaPlusTM equipped 
with particle sizing mode, Brookhaven Instrument Crop., Holtsville, NY). A dilute 
suspension (100µg/ml) of nanoparticles was prepared in double distilled water and 
sonicated on an ice bath for 30 s. The sample was subjected to particle size analysis. Zeta 
potential of nanoparticles in 0.001M double distilled water, was determined using 
ZetaPlusTM in the zeta potential analysis mode.  
 
7.2.5 In vitro expression and uptake of 6-coumarin 
 
Rat cardiac fibroblasts (abbreviated as rCFs,) cultured in DMEM Medium with 10% 
fetal bovine serum (Gibco, NY)  and 1% penicillin G and streptomycin (Gibco BRL, 
Grand Island, NY), were used for all the cell culture studies. The cells were seeded at 
200,000 cells per well/1 ml (50% confluency) in a 6-well plate and allowed to attach 
overnight. Nanoparticles were added at different doses in 1 ml of the medium and 
incubated for 2 days. Untreated cells (plain medium) were used as a control. At the end of 
the incubation period, cells were washed twice with phosphate buffered saline (PBS, pH 
7.4) to remove nanoparticles and 1 ml of fresh medium was added to each well. The 
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uptake of the nanoparticles in the cells was determined using optical microscopy studies, 
and high performance liquid chromatography (HPLC) analysis 
 
7.2.6 Extraction and quantitation of 6C fluorescence in cells 
 
Cells were washed with PBS three times and were solubilized in 1% Triton X 100 
solution. This suspension was stored at -80°C overnight and lyophilized for 48 hours. 
Lyophilized cell lysates were reconstituted in methanol (500ul) and incubated at 37°C for 
18 hours to extract the dye. Samples were centrifuged at 14000 rpm for 10 minutes at 4°C 
to remove cell debris. Supernatants were collected for HPLC analysis. A standard curve 
is obtained by adding 8 µg to 40 µg of nanoparticles in Triton X 100 solution and 
lyophilized as the cell samples.  
 
7.2.7 Confocal Microscopy Analysis 
 
rCFs were plated on coverslips in 6 well plates at 50,000 cells per well (50% 
confluency) in 1 ml of culture medium and allowed to attach for 24 h. Cells were then 
incubated with 6-coumarin loaded nanoparticle suspension (200µg/ml) in growth medium 
for 60 min. Cells were then washed twice with PBS and visualized with a Zeiss Confocal 
LSM410 microscope equipped with 488 nm excitation laser (Carl Zeiss Microimaging, 
Inc., Thornwood, NY).  
 
 
118 
 
7.2.8 In vivo Expression Analysis 
 
Rats were infarcted via LAD ligation, as described above. 4 weeks post infarction, 
nanoparticles with or without the tagging peptide was infused via the tail vein at 200 µg 
of particles per animal in 200µl of PBS. The nanoparticles were allowed to circulate 
overnight, after which the animals were sacrificed by de-sanguination by perfusion with 
saline, and the organs (heart and liver) were excised. Heart tissues were divided based on 
the region of infarct or the healthy region. The wet weight of the tissues was recorded. 
Samples were homogenized in 2 ml of distilled water using a tissue homogenizer. The 
homogenized samples were then lyophilized for 48 hours. The 6C dye from the 
homogenized tissue was extracted by shaking with 5 ml of methanol at 37°C for 24 hours 
at 100 rpm using an Environ orbital shaker. Standard curve was obtained by samples 
varying from 8 µg to 40µg of the nanoparticles in methanol. Tissue extracts were 
centrifuged at 14000 rpm for 10 minutes to remove cell debris. The supernatant was 
collected and this was used for HPLC analysis.  
 
7.2.9 HPLC Analysis 
 
A Shimadzu HPLC system (Shimadzu Scientific Instruments, Columbia, MO) fitted 
with an SCL-10A system controller, an SIL-10A auto-injector, LC-10AT pump, a RF-
10A XL   fluorescence detector, and Class VP chromatography data system software 
version 4.2 was used. A Nova pak C-8 column with spherical particles (4 mm) and pore 
size of 60A ° (Waters,  Milford, MA) and the mobile phase consisting of acetonitrile 
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/water (65:35) containing 5mM sodium salt of 1-heptane sulfonic acid (Aldrich, 
Milwaukee, WI) set at a flow rate of 0.8 ml/min were used to resolve the dye peak. 
Excitation and emission wavelengths were 450 and 490 nm respectively. A 20 ml aliquot 
of each sample was injected into HPLC. The retention time of 6-coumarin was 2.6 min. 
The amount of nanoparticles in different tissue samples was determined from a 
calibration curve plotted between the fluorescent intensity and the amount of  
fluorescently labeled nanoparticles that were treated similar to the tissue samples. There 
was no background peak for the control tissue (without nanoparticles). The assay is 
sensitive enough to detect as low as 5 ng nanoparticles in the tissue samples. 
 
7.3 Results 
 
7.3.1 Formulation of Nanoparticles 
 
Nanoparticles with 6 Coumarin as a fluorescent marker and BSA as a model protein 
were formulated. Nanoparticles had a typical protein loading of 20% (w/w). As in, 20 mg 
of BSA was present in 100 mg of nanoparticles.  
 
7.3.2 Particle Size Analysis and Zeta Potential 
 
Particle size distribution was analyzed by dynamic light scattering technique. The 
size of the unconjugated PLGA polymer encapsulating the 6C dye in BSA was found to 
be 0.095 microns or 95 ±12.3 nm. The conjugated PLGA polymer with the tagging 
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peptide on the surface had an average size of 103 ± 11 nm indicating uniform particle 
size distribution. When these particle sizes were analyzed before sonicating them, the 
mean particle size was 600 ± 350 nm indicating the importance of sonicating on these 
particles.  
 
The zeta potential, corresponding to the surface charge was recorded at -14.72 ± 0.95 
mV for the unconjugated particles and -11.04 ± 6.22 mV for the conjugated particles.  
 
Nanoparticles were resuspended easily after lyophilization to form a stable colloidal 
dispersion without any change in size or content. In previous studies, it has been shown 
that 99.4% of the entrapped dye remains associated with the nanoparticles even after 48 h 
of in vitro release study under constant conditions. 199Therefore, these nanoparticles serve 
as a good model formulation to study the tissue uptake in vivo in acute experiments. 
Furthermore, one can use these nanoparticles to quantitate the uptake as well as to study 
their localization in the cells/tissue by fluorescence microscopy  
 
7.3.3 In vitro Expression Analysis 
 
Dose Analysis 
 
Rat cardiac fibroblasts were cultured in DMEM Medium with 10% fetal bovine 
serum and 1% penicillin and streptomycin. The cells were seeded at 50,000 cells per well 
in 1 ml of culture medium (50% confluency) in a 6-well plate and allowed to attach 
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overnight. Nanoparticles with the conjugated peptides were added at different doses 
ranging between 10 µg of nanoparticles to 1 mg of nanoparticles per well in 1 ml of the 
medium and incubated overnight. At the end of the incubation period, cells were washed 
twice with phosphate buffered saline (PBS, pH 7.4) to remove nanoparticles and 1 ml of 
fresh medium was added to each well. The cells were then viewed using optical 
microscopy (Figure 7-1). 
 
When less than 100 µg of particles were added to the wells, the signal obtained was 
almost inconceivable. On the other hand a strong signal was observed at 500 µg of 
particles and 1 mg of particles per well. A minimum of 200 µg per well of particles are 
required for an observable signal. For future studies 200 µg of particles per well was used.  
 
 
 
Figure 7-1 : Dose response with un-conjugated nanoparticles encapsulating 6C 
Cardiac fibroblasts were cultured and nanoparticles encapsulating a fluorescent dye, 6C, 
were added to this in varying doses. The signal obtained correlates to the amount of 6C 
that released inside the cells. A 200µg dose was used for future studies.  
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7.3.4 Time for Uptake 
 
Rat cardiac fibroblasts were cultured in DME Medium with 10% fetal bovine serum 
and 1% penicillin and streptomycin. The cells were seeded at 50,000 cells per well / 1 ml 
of culture medium (50% confluency) in a 6-well plate and allowed to attach overnight. 
Nanoparticles with and without the conjugated peptides were added at 200 µg of 
nanoparticles per well in 1 ml of the medium and incubated for varying lengths of time 
varying between 30 minutes and 24 hours to determine the optimum time for uptake. 
Unconjugated nanoparticles were used as controls. At the end of the incubation period, 
cells were washed twice with phosphate buffered saline (PBS, pH 7.4) to remove 
nanoparticles and 1 ml of fresh medium was added to each well. The cells were then 
viewed using optical microscopy 
 
When the cells were analyzed at 30 minutes or less, no significant signal was 
observed. However, after 1 hour there was an observable signal that increased for upto 3 
hours, following which the signal remained constant for up to 24 hours. For future in 
vitro studies, nanoparticles will be added for a period of 2 hours before it is washed away. 
(Figure 7-2) 
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Figure 7-2 : Time response with un-conjugated nanoparticles encapsulating 6C 
Rat cardiac fibroblasts were cultured onto 6 well plated and 200µg of nanoparticles 
without any targeting peptide were added to this. The time taken for release of the 
nanoparticles into the cells and the endocytosis was determined by imaging cells ant 
various time points following the addition of nanoparticles. 6C signal was obtained 1 
hour following the addition and lasted for more than 24 hours.  
 
As expected, there was no significant difference in signal between the two 
nanoparticles types, whether conjugated or un-conjugated. Particles were added to the 
wells and did not have to target any specific cell type. In fact, there seemed to be a slight 
increase in particle uptake with un-conjugated particles. (Figure 7-3) Therefore in order 
to address this, a quantitative study was performed with conjugated and un-conjugated 
particles, at 200 µg of particles per well following 2 hours of uptake.  
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Figure 7-3 : Time response of nanoparticles with 6C conjugated with RR peptide  
Rat cardiac fibroblasts were cultured onto 6 well plated and 200µg of nanoparticles with 
targeting peptide were added to this. On imaging these cells at various time points, 6C 
signal was obtained 1 hour following the addition and lasted for more than 24 hours 
similar to the results obtained from un-conjugated nanoparticles 
 
 
7.3.5 HPLC Analysis with in vitro particle study 
 
Rat cardiac fibroblasts were cultured in the appropriate medium at 50,000 cells per 
well/1 ml of culture medium (50% confluency) in a 6-well plate and allowed to attach 
overnight. Nanoparticles with and without the conjugated peptides were added at 200 µg 
of nanoparticles per well in 1 ml of the medium and incubated 2 hours. Unconjugated 
nanoparticles were used as controls. At the end of the incubation period, cells were 
washed twice with phosphate buffered saline (PBS, pH 7.4) to remove nanoparticles and 
1 ml of fresh medium was added to each well and were solubilized in 1% Triton X 100 
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solution. This solution was lyophilized for 48 hours, and cell lysates were reconstituted in 
methanol (500ul) and incubated at 37°C for 18 hours to extract the dye.  Samples were 
centrifuged at 14000 rpm for 10 minutes at 4°C to remove cell debris. Supernatants were 
collected for HPLC analysis. A Standard curve was obtained by adding 8 µg to 40 µg of 
nanoparticles in Triton X 100 solution and lyophilized as with the cell samples.  
 
Following the HPLC analysis, the amount of fluorescent dye extracted from the un-
conjugated particles was 14.89 ±2.1 µg per well and the amount of 6C dye extracted from 
conjugated nanoparticles was 11.97 ± 3.24 µg per well. There is a slight decrease in the 
loading of conjugated particles that may be attributed to the slightly smaller sizes as 
compared to the un-conjugated particles. However, this difference is not significant. 
However, when unsonicated 6C unconjugated nanoparticles were used, this uptake 
dropped to almost half, indicating the importance of particle size on uptake. (Figure 7-4) 
 
 
Figure 7-4 : In vitro HPLC analysis to determine amount of 6C in cardiac 
fibroblasts  
Both conjugated and unconjugated nanoparticles had similar sizes. A quantitative 
analysis between the unconjugated and conjugated nanoparticles revealed similar 
amounts of nanoparticles being taken up by cardiac fibroblasts in culture. However, 
unsonicated nanoparticles that had a larger size exhibited lower uptake.   
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7.3.6 In vivo nanoparticle uptake in rodents 
 
4 weeks post infarction via LAD ligation in rodents, nanoparticles with or without 
the tagging peptide was infused via the tail vein at 200 µg of particles per animal in 
200µl of PBS. The nanoparticles were allowed to circulate overnight, and the organs 
(heart and liver) were excised. Heart tissues were divided between infarcted and healthy 
regions. The wet weight of the tissues was recorded. Samples were homogenized, 
lyophilized and the 6C dye from the homogenized tissue was extracted by shaking with 5 
ml of methanol at 37°C for 24 hours at 100 rpm. Tissue extracts were centrifuged at 
14000 rpm for 10 minutes to remove cell debris. The supernatant was collected and this 
was used for HPLC analysis. Standard curve was obtained by samples varying from 8 µg 
to 40µg of the nanoparticles in methanol. 
 
On analyzing the HPLC results, it was observed that infarcted tissue regions had 
more 6 C extracted from them, as compared to healthy tissues (n=3) (Figure 7-5). Also, 
the amount of fluorescence intensity observed in the infarcted region of the heart 
increased when nanoparticles with the homing peptide were infused as compared to when 
nanoparticles alone were used. This increase in fluorescence intensity was significant, 
with a p value of < 0.01 (Figure 7-6). When particles were conjugated with the ischemic 
heart targeting peptide, they travelled to the infarcted region of the heart.  
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Figure 7-5 : In vivo HPLC analysis between infarct and healthy regions of the heart  
On comparing infarcted tissue and healthy tissue for the amount of nanoparticles that 
released the fluorescent dye, 6C in them, we observed a greater amount of nanoparticles 
that targeted the infarct heart as compared to the healthy heart when a targeting peptide 
was used to conjugate the nanoparticles.  
 
 
Figure 7-6 : Difference in uptake in infarcted tissue with conjugation of 
nanoparticles 
A greater number of nanoparticles targeted the infarct heart when a targeting peptide was 
conjugated to the surface of the PLGA polymer. (n=5), p<0.05 
 * 
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7.4 Discussion 
 
Regenerative medicine aims to repair and retain the function of cardiac tissues 
following ischemia. The most viable of these therapeutic options is the use of genes that 
can trigger various other pathways responsible for alleviating the symptoms of cardiac 
failure. The use of non viral gene therapy is a safe and non toxic method of providing 
these genes to injured tissues, allowing them to repair and regenerate the tissue to 
mediate benefit in function. However, although non viral naked gene therapy may be a 
viable option in vitro, it is subject to degradation in vivo, by lysosomes in the 
cytoplasm.109 DNA plasmids have a polynucleotide structure and thus are negatively 
charged and hydrophobic in nature. This poses a challenge for traversing the tissue layers, 
and they are easily degraded in the system.191 In order to overcome this, genes need to be 
properly condensed to a size that can be taken up by cells. The encapsulation of these 
genes within polymeric carriers may provide an efficient, non toxic, yet safe delivery 
mechanism for sustained intra cellular delivery of these therapeutic agents. However this 
delivery platform has some limitations as the plasmid needs to be condensed to allow 
encapsulation within the nanoparticle. Following that, the whole assembly needs to be 
stable during formulation and in vivo. This complex should be capable of being targeted 
to the tissue or cells of choice by either a surface ligand or by possessing a specific 
promoter element in the plasmid, or both. And lastly, following intra cellular delivery, 
these encapsulated particles need to be released in their viable form else they will be 
sequestered and exited from the cells by lysosomal endosmosis.114  
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PLGA offers a viable, effective and safe delivery of therapeutic agents; drugs and 
genes, due to its capability release the encapsulated material intra cellular. Also, it is 
capable of attaching surface ligands and can thus be modified for specific tissue 
targeting.114,118 We wanted to test the efficacy and safety of PLGA polymers in being 
able to deliver a fluorescent dye within ischemic heart tissue and thus develop a model 
capable of delivering therapeutic genes responsible for cardiac regeneration.  
 
In this study we formulated PLGA nanoparticles via the double emulsion process 
and encapsulated a fluorescent dye, 6C that can be viewed via optical microscopy 
analysis. This dye is capable of being excited and emitted at certain wavelengths 
therefore the amount can be quantitated by using HPLC analysis. The surface of these 
particles was activated with PVA thus making it hydrophilic and being capable of 
attaching to surface ligands. We previously identified a peptide sequence RQPRMKR 
which is a specific ligand to ischemic cardiac tissues via phage panning studies. We 
tagged the surface of the PLGA nanoparticles with this ligand in order to mediate its 
delivery specifically to the ischemic heart.  
 
Intracellular levels of nanoparticles increased with dose and time, and an optimum 
200 µg of particles per well for a mean incubation time of 2 hours was selected for our 
study. In vitro studies with and without the surface ligands demonstrated that the size of 
the particles and not the ligands associated on its surface mediates the uptake into cells. 
The uptake of nanoparticles was proportional to the size of the particles, however, there 
was no significant difference between the particle uptake as the size between the 
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conjugated and un-conjugated particles was not very different from each other with 
average sizes around 100 nms.119 When un-sonicated particles, of an average size of 500 
nm were used the uptake changed dramatically, with the amount of extracted 6C from 
these cells reducing to more than half of the sonicated particles.  
 
In vivo studies with PLGA nanoparticles demonstrated the selective targeting of 
conjugated nanoparticles to the ischemic heart specifically, as compared to the healthy 
heart or the liver as a response to the targeting ligand on the surface. Un-conjugated 
particles did not get taken up by the heart tissues and instead were found to be flushed 
into the liver.  
 
This study provides a viable option for the encapsulation of a fluorescent agent and 
has demonstrated the intracellular characteristics, in vitro and in vivo associated with this. 
This can be used as a model for future studies, as a mechanism for the delivery and 
uptake of other genetic or drug therapies responsible for mediating benefit to the cardiac 
tissue.  
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CHAPTER VIII 
 
IDENTIFICATION OF NOVEL CARDIAC PATHWAYS IN 
REVERSE VENTRICULAR REMODELING FOLLOWING STEM 
CELL THERAPY 
 
8 IDENTIFYING CARDIAC PATHWAYS INVOLVED IN REVERSE 
VENTRICULAR REMODELING  
 
8.1 Introduction 
 
Cell therapy, especially stem cell therapy has emerged as a promising method for the 
repair and/or regeneration of ischemic myocardium following myocardial infarct. This 
includes the use of Hematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), 
and Multipotent Adult Progenitor Cells (MAPCs).31,36,37,200 MSCs have been extensively 
tested for the repair of diseases involved in the heart, brain, liver and the skin.13,48,201-204 
Various mechanisms have been demonstrated for cardiac repair mediated by MSCs, 
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some of which include differentiation of recruited or cardiac stem cells, fusion between 
host and recruited stem cells, promotion of angiogenesis and thus improved tissue 
perfusion.31,46,200,205 In the past, MSCs have been shown to differentiate to cells of the 
endothelial lineage providing for angiogenesis and thus improvement in micro 
circulation.205 Also, functional recovery of cardiac tissue following MSC engraftment has 
shown to be coupled with increase in various other paracrine factors, including Vascular 
Endothelial Growth Factor (VEGF), basic Fibroblast Growth Factor (bFGF), and 
Angiopoietin-I which induces the growth of blood vessels.34,49,53 However, due to the 
complexity involved in the mechanism of repair followed by mesenchymal stem cell 
therapy, the exact pathways that determine this change in functional improvement is not 
yet determined.  
 
Similar results obtained from the varied stem cell sources combined with limited 
evidence that these different cell types actually differentiate into cardiac myocytes has led 
to the conclusion that the majority of the improvement observed is not due to the 
regeneration of cardiac myocytes, but rather due to the paracrine factors released by the 
engrafted stem cells.52, 206   
 
Consistent with this hypothesis are our recent studies demonstrating that the benefit 
of MSC therapy is increased by the over-expression of specific factors, namely Stromal 
Cell Derived Factor -1 (SDF-1)35 and Monocyte Chemoattractant Protein-3 (MCP-3).52  
Studies in our laboratory have demonstrated that MSC home to myocardial tissue in 
response to MCP-3, and that re-establishment of MCP-3 weeks after Acute Myocardial 
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Infarction (AMI) re-establishes MSC homing to the heart leading to improved cardiac 
function. The expression of MCP-3 in the absence of MSC infusion had no effect.  
Interestingly, unlike virtually all preclinical cell transplantation studies published to date, 
the improvement in LV dimensions and function was achieved in the absence of 
neovascularization or an increase in vascular density.52  These observations suggest that 
the MCP-3 based recruitment of MSC late after AMI leads to the expression of as yet 
undefined paracrine factors that are able to reverse LV remodeling without inducing 
vessel development or growth.  
 
We thus hypothesize that this MSC-MCP3 mediated improvement in ventricular 
function is attributed to reverse ventricular remodeling. Also, this reverse ventricular 
remodeling is ascribed to paracrine factors secreted in the microenvironment.  
   
The main focus of this aim was to identify key pathways and candidate proteins that 
are modified as a result of the improvement in cardiac function when MCP-3 is expressed 
followed by MSC infusions, in chronic heart failure hearts. Whole genome analysis 
provides a comprehensive list of information on all genes in the genome that are affected 
as a result of the application of therapy. Therefore this would be a viable option to 
identify these proteins and the pathways associated in the changes that lead to functional 
improvement. 
 
The primary focus is to identify candidates associated with reversing ventricular 
remodeling, following therapy with mesenchymal stem cells. To understand and identify 
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these proteins we employed whole genome analysis studied pathways upregulated 
following treatments with MSC therapy. Important aspects of genome wide experiments 
are the large number of genes and their associated pathways assessed and the high 
sensitivity of this approach. We investigated secreted proteins, and thus were able to 
eliminate specific genes associated with the respective tissue types either host or 
engrafted. Moreover, we looked specifically for pathways associated with the cardiac 
lineage and the changes mediated in the cardiac tissue.  
 
8.2 Methods 
 
8.2.1 Experimental Plan 
 
Group 1 MCP-3 transfected cardiac fibroblasts MSC x 6 doses 
Group 2 (control) MCP-3 transfected cardiac fibroblasts Saline 
Group 3 (control) Cardiac fibroblasts  MSC x 6 doses 
Group 4 (control) Cardiac Fibroblasts Saline 
Group 5 (control) Saline MSC x 6 dose 
Group 6 (control) Saline Saline 
 
Table 8-1 : Animal groups involved in stem cell therapy 
 
135 
 
8.2.2 Isolation of MSCs  
 
Rat bone marrow was isolated by flushing rat femurs and tibias with 0.6 ml DMEM 
repeatedly till all of it is extracted. Clumps of bone marrow were gently minced using a 
20 gauge needle and a 10 ml syringe.  Cells were then be removed by Percoll density 
gradient. This bone marrow was washed with PBS three times to remove all debris and 
then plated in a dish with MSC media, comprising 10% FBS and 1% antibiotic in low 
glucose DMEM, and incubated at 37ºC for three days. The mesenchymal stem cells  
adhere to the plate leaving the endothelial cells in suspension. The media was changed in 
order to obtain a pure population of MSC cells. This culture is then sorted negatively 
after 4 passages for CD45 and CD34, by magnetic cell sorting techniques in order to 
obtain a double purified and pure population of MSCs.  
 
8.2.3 Isolation of Cardiac Fibroblasts 
 
The left ventricles of 3 to 5 rats were pooled together, minced and placed in 100 
U/ml of collagenase XI and trypsin at 37 ºC for 10 minutes in a shaking incubator. The 
cell suspension was filtered out using gauze filtration and minced tissue was collected. 
The cell suspension was centrifuged at 2000 rpm for 10 minutes to sediment the cells. 
The cells were seeded in Ham’s modified DME medium supplemented with 10 % FBS 
and 1% antibiotic containing Penicillin and Streptomycin. Non adherent cells were 
removed after 2 hours of incubation and the adherent cells were washed twice with 
phosphate buffered solution (PBS). The resulting adherent fibroblasts were cultured in 
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Ham’s modified DMEM medium supplemented with 10% FBS and 1% antibiotic 
containing Penicillin and Streptomycin on T75 flasks and incubated in 37ºC and 5% CO2.  
 
8.2.4 Transfection of Cardiac Fibroblasts with MCP-3 
 
MCP-3 from total RNA was cloned into expression vector pcDNA3.1 and a MYC 
TAG was attached in order to detect the gene. The cardiac fibroblast culture dish was 
treated with the MCP-3 encoding expression vector, or the control pcDNA vector 
overnight in the presence of FUGENE. MCP-3 expression was selected by neomycin by 
the addition of Geneticin to the media for two weeks. The surviving cells were expanded 
and used for the experiment.  
 
8.2.5 Experimental animals 
 
We used male Lewis rats (Jackson Laboratories) for the chronic heart failure study. 
All animals were 8 week old weighing 200-225 grams. There were 5 animals in each 
group involved in the study (Table 8-1). 
 
8.2.6 Intramyocardial Cardiac Fibroblast delivery 
 
To inject the cardiac fibroblasts, the chest will be reopened two weeks post MI, 
applying the same procedure as above, and using a 30 gauge needle, 100µl of DNA 
solution will be injected per injection site. There will be 4 injection sites in all, around the 
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border zone. The border zone will be identified by the blanched region around the LAD. 
The DNA will be injected into the wall and blanching will be observed when the DNA is 
injected. The chest will be closed as mentioned above for the LAD ligation.  
 
8.2.7 Infusion of Mesenchymal Stem Cells 
 
Mesenchymal stem cells will be infused via the tail vein using a 30 gauge needle. 
The needle will be inserted and blood will be drawn from the vein to ensure the site of 
injection. 2 million MSCs in 100 µl volume will be injected over a period of 1 minute to 
avoid any emboli formation.  
 
8.2.8 Isolation of total RNA 
 
RNA from tissue samples will be isolated using the Trizol reagents. Briefly, the 
tissues are homogenized in Trizol in dry ice and chloroform is added to this. The aqueous 
phase obtained is collected and mixed with isopropanol and centrifuged to collect the 
samples. RNAgents denaturing solution (from Qiagen) is then added to this to dissolve 
the pellet. Samples are again collected with isopropanol and are centrifuged to collect the 
samples at the bottom. This sample is not treated with 75% ethanol and again centrifuged 
to collect samples. The supernatant is again discarded without disturbing the pellet and 
the pellet is dissolved in DEPC water for future use. Further clean up of the RNA will be 
done with the use of the Qiagen kit as per the manufacturer’s instructions. 
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8.2.9 Preparation of cRNA 
 
First-strand cDNA was synthesized using Oligo dT and Superscript II RT (Invitrogen, 
Grand Island, NY). Alternatively, cDNA will be prepared using OVATION RNA 
Amplification System (NuGen Technologies, Inc., San Carlos, CA). cDNA amplification 
products will then be fragmented and chemically-labeled with biotin to generate 
biotinylated cDNA targets. Each Affymetrix gene chip for rat genome will be hybridized 
with fragmented and biotin-labeled target (2.5 μg) in 200 μl of hybridization cocktail. 
Target denaturation is performed at 99°C for 2 minutes, followed by hybridization for 18 
hours. Arrays then will be washed and stained using Genechip Fluidic Station 450, and 
hybridization signals will be amplified using antibody amplification with goat IgG 
(Sigma-Aldrich) and anti-streptavidin biotinylated antibody (Vector Laboratories, 
Burlingame, CA).  
 
8.2.10 Affymetrix Analysis 
 
Eight micrograms of total RNA from rats treated with MSC and MCP-3 and control 
rats with MCP-3 without MSCs was tested. Affymetrix GeneChip Rat Exon Arrays 1.0, 
which allow analysis of >23,000 transcripts, was performed in triplicates and analyzed 
with Affymetrix Microarray Suite (MAS 5.0). All possible comparisons Comparison 
between MSC-MCP-3 treated animals vs. Saline MCP-3 treated control animals was 
tested. Chips were scanned on a Affymetrix Gene Chip Scanner 3000, using GeneChip 
Operating Software (GCOS) version 3.0. Background correction and normalization was 
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done using Robust Multichip Average (RMA) with GeneSpring V 7.3.1 software (Silicon 
Genetics, Redwood City, CA). Volcano plots were used to identify differentially 
expressed genes using the parametric testing assuming variances are equal (filters based 
on the results of a Student's two-sample t-test for two groups or a one-way analysis of 
variance (ANOVA) for multiple groups) and no multiple testing correction. Comparisons 
were done between MSC MCP-3 treated group and the Saline MCP-3 treated control 
group. The differentially expressed gene list was loaded into IPA 5.0 software 
(www.ingenuity.com) to perform biological network and functional analyses.  
 
8.3 Results 
 
8.3.1 Stem cell therapy improves cardiac function in chronic heart failure 
 
8 week old rats were infarcted via LAD ligation. 4 weeks post ligation, all rats had a 
diminished fractional shortening of < 30%. The chests were re opened and cardiac 
fibroblasts were transplanted into the heart wall at 2 million cells per animal.  Cardiac 
fibroblasts were modified to secrete increased levels of MCP-3 or were used as is, as 
controls. One day post transplantation, 2 million mesenchymal stem cells were infused 
via the tail vein, 6 times in a period of 12 days. 3 days after the last infusion, rats were 
analyzed for cardiac function, via echocardiographic analysis.   
 
Pre injection all rats had a fractional shortening less than 30%. Rats that received 
mesenchymal stem cells showed increase in cardiac function, immediately post stem cell 
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therapy, as compared to the rats that did not receive stem cell therapy. Among the ones 
that received stem cell therapy, rodents with boosted MCP-3 activity showed the 
maximum benefit as compared to the all other groups. (Figure 8-1) 
 
 
Figure 8-1 : Change in cardiac function with MSC therapy in vivo  
Ischemic rat hearts were injected with cardiac fibroblasts overexpressing the homing 
factor for mesenchymal stem cells, MCP-3 and infused with mesenchymal stem cells. 
Animals that received both treatments showed an improvement in cardiac function, 3 
days post treatment, as compared to the ones that did not receive mesenchymal stem 
cells. (n=5) 
 
8.3.2 Identification of pathways and genes involved in cardiac repair  
 
Among all the groups, the RNA from the group with MSC and MCP-3 treatment and 
the animals from the MCP-3 with saline group were sent for whole genome analysis. The 
results from the whole genome analysis were sorted in order to identify a sub set of genes 
that were maximally affected by the therapy, thus leading to improved cardiac 
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functioning, via reverse ventricular remodeling. The gene expression results were 
supplied by whole genome analysis. Gene profiling were conducted with RNA isolated 
from the left ventricles of treated and control rats.  
 
Microarray analysis was performed on RNA isolated from each group to identify 
differentially expressed genes, using the Affymetrix Rat exon 2.0 array. Signals were 
loaded into Gene Chip Operating Software (GCOS) and normalized using the Robust 
Multichip Average (RMA) algorithm. The normalized set was further sorted to provide a 
more ideal normalization with the GC-RMA software. Instead of eliminating the 
mismatch genes, as provided by RMA analysis, the GC RMA, supplies a graded average 
for each gene, with a simulated number for the mismatch, as provided by the number of 
G and C rich regions in the probe. This subset of genes was then sorted based on 
Significance of Microarray studies, to remove false positives for p values with a False 
Detection Rate of 20%. The expressed genes were finally sorted based on p values (<0.05) 
and fold changes.  
 
To provide a more specific subset of differentially expressed genes, with a p value of 
0.05 and a Fold change of 2, these genes were subject to ANOVA to determine the 
number of genes that are expressed differentially. Following these sorting measures a 
small subset of secreted genes were identified, based on their locations in the cell either 
in the cytoplasm, the cell wall, or extra cellular matrix. (Table 8-2).  Among these genes, 
some were upregulated and some were down regulated. PSG-19 and LIF were 
upregulated and our focus was on these genes.  
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Gene ID Gene Name Function 
Upregulated Genes   
PSG-18 Pregnancy Specific Glycoprotein 18 Induces IL10 
LIF Leukemia Inhibitory factor Proliferation of cells 
Downregulated Genes   
CTF1 Cardiotrophin 1 cardioprotective 
SERPINH1 Serpin Peptidase Inhibitor Cell survival 
MIP/CCL3 Macrophage Inflammatory Protein Pro-inflammation 
VCAN Versican Macrophage adhesion 
REG3A Regenerating Islet-Derived 3 alpha Pancreatitis associated 
protein 
 
Table 8-2 : Genes of secreted proteins involved in cardiac repair with MSC therapy 
 
 
8.3.3 RT PCR Analysis for individual paracrine factors 
 
RT-PCR analysis was carried out with primers specific for the PSG-19 gens with the 
RNA isolated from the tissues of all animal groups. Primers were designed with the 
software provided in the NCBI website. For RT-PCR analysis, forward primer of 
GAGCCTTGTTGGAGCTGAAG and reverse primer of AGGGCTACACCCTGA 
ACAGA were used. However, there was no difference between the amount of this 
protein expressed by the various groups. 
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8.3.4 Pathway Analysis with Ingenuity Pathway Analysis Software 
 
Pathway analysis provides highly sophisticated information on the interactions 
between genes and the relationship between one another, with respect to various 
functions. The various analyses were performed as described above. Briefly, the results 
from the Affymetrix data analysis was subject to normalization software with GC-RMA, 
and sorted based on p values. This data set is referred to as the reference set. Instead of 
using all the genes in the rat genome as the reference set, this subset of affected and 
normalized genes was used as the reference. This data set was further subject to a 20% 
false detection rate in the SAM analysis, to identify and eliminate false p-values. The 
following subset that ensued was the data set for the pathway analysis. This data set was 
analyzed to determine the interactions between these differentially significant genes.  
 
Pathway analysis was able to provide us with information regarding specific genes 
(either up or down regulated) that was associated with cardiovascular functions, including 
development and disorder. These genes were then sorted into a subset that can provide 
leads into factors that may affect ventricular remodeling. (Table 8-3) 
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Symbol Gene Name Fold Change Location Type(s) 
Upregulated genes        
 MIF macrophage migration 
inhibitory factor 
(glycosylation-
inhibiting factor) 
2.84  Extracellular 
Space 
 cytokine 
 LIF leukemia inhibitory 
factor (cholinergic 
differentiation factor) 
2.27  Extracellular 
Space 
 cytokine 
 SFRP4 secreted frizzled-
related protein 4 
2.27  Plasma Membrane Trans-
membrane 
receptor 
 TNNI3 troponin I type 3 
(cardiac) 
2.24  Cytoplasm  transporter 
 MEF2B myocyte enhancer 
factor 2B 
2.24  Nucleus transcription 
regulator 
 APOH apolipoprotein H 
(beta-2-glycoprotein I) 
2.21  Extracellular 
Space 
 transporter 
 FSHB follicle stimulating 
hormone, beta 
polypeptide 
2.19  Extracellular 
Space 
 other 
 UTS2 urotensin 2 2.18  Extracellular 
Space 
 other 
CYSLTR2 cysteinyl leukotriene 
receptor 2 
2.14  Plasma Membrane  GPCR 
 DRD1 dopamine receptor D1 2.13  Plasma Membrane  GPCR 
 HCN2 hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 2 
2.12  Plasma Membrane  ion channel 
 
CLEC11A 
C-type lectin domain 
family 11, member A 
2.12  Extracellular 
Space 
 growth 
factor 
 GLRX3 glutaredoxin 3 2.12  Cytoplasm  enzyme 
 VEGFA vascular endothelial 
growth factor A 
2.10  Extracellular 
Space 
 growth 
factor 
 GRIN2A glutamate receptor, 
ionotropic, N-methyl 
D-aspartate 2A 
2.10  Plasma Membrane  ion channel 
 MAX MYC associated factor 
X 
2.09  Nucleus  transcription 
regulator 
 ES22 esterase 22 2.08  Cytoplasm  enzyme 
 EGF epidermal growth 
factor 
2.07  Extracellular 
Space 
 growth 
factor 
 GHR growth hormone 2.07  Plasma Membrane  
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receptor transmembra
ne receptor 
 MAPT microtubule-associated 
protein tau 
2.05  Cytoplasm  other 
 GRM5 glutamate receptor, 
metabotropic 5 
2.05  Plasma Membrane  GPCR 
 AGTR1B angiotensin II 
receptor, type 1b 
2.05  Plasma Membrane  GPCR 
 PIK3C2G phosphoinositide-3-
kinase, class 2, gamma 
polypeptide 
2.04  Cytoplasm  kinase 
 IFNG interferon, gamma 2.03  Extracellular 
Space 
 cytokine 
 KRT1 keratin 1 2.03  Cytoplasm  other 
 CSF3 colony stimulating 
factor 3 (granulocyte) 
2.02  Extracellular 
Space 
 cytokine 
 CAV3 caveolin 3 2.02  Plasma Membrane  enzyme 
 NOS2 nitric oxide synthase 2, 
inducible 
2.02  Cytoplasm  enzyme 
 GRIA2 glutamate receptor, 
ionotropic, AMPA 2 
2.02  Plasma Membrane  ion channel 
 AMPD1 adenosine 
monophosphate 
deaminase 1 
2.01  unknown  enzyme 
 PDGFA platelet-derived 
growth factor alpha 
polypeptide 
2.01  Extracellular 
Space 
 growth 
factor 
 ATP2B3 ATPase, Ca++ 
transporting, plasma 
membrane 3 
2.01  Plasma Membrane  transporter 
 AACS acetoacetyl-CoA 
synthetase 
2.00  Cytoplasm  enzyme 
 CEBPA CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
2.00  Nucleus  transcription 
regulator 
         
  
 Downregulated genes 
 TIMP1 TIMP metallopeptidase 
inhibitor 1 
-3.99  Extracellular 
Space 
 other 
 FN1 fibronectin 1 -3.74  Plasma 
Membrane 
 enzyme 
 VCAN versican -3.54  Extracellular 
Space 
 other 
 C3AR1 complement component 3a 
receptor 1 
-3.45  Plasma 
Membrane 
 GPCR 
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 CXCL13 chemokine (C-X-C motif) 
ligand 13 
-3.43  Extracellular 
Space 
 cytokine 
 SERPINA3 serpin peptidase inhibitor, 
clade A member 3 
-3.23  Extracellular 
Space 
 other 
 KCNJ2 potassium inwardly-
rectifying channel, 
subfamily J, member 2 
-3.19  Plasma 
Membrane 
 ion channel 
 SERPINE1 serpin peptidase inhibitor, 
clade E 
-3.18  Extracellular 
Space 
 other 
 CCR5 chemokine (C-C motif) 
receptor 5 
-3.17  Plasma 
Membrane 
 GPCR 
 VCAM1 vascular cell adhesion 
molecule 1 
-3.16  Plasma 
Membrane 
 other 
 HSPB1 heat shock 27kDa protein 1 -3.11  Cytoplasm  other 
 LOX lysyl oxidase -3.03  Extracellular 
Space 
 enzyme 
 CCR2 chemokine (C-C motif) 
receptor 2 
-2.99  Plasma 
Membrane 
 GPCR 
 CCL13 chemokine (C-C motif) 
ligand 13 
-2.98  Extracellular 
Space 
 cytokine 
 NOV nephroblastoma 
overexpressed gene 
-2.97  Extracellular 
Space 
 growth factor 
 HTR1B 5-hydroxytryptamine 
(serotonin) receptor 1B 
-2.91  Plasma 
Membrane 
 GPCR 
 ANXA2 annexin A2 -2.86  Plasma 
Membrane 
 other 
 THY1 Thy-1 cell surface antigen -2.85  Plasma 
Membrane 
 other 
 ANPEP alanyl (membrane) 
aminopeptidase 
-2.85  Plasma 
Membrane 
 peptidase 
 MET met proto-oncogene 
(hepatocyte growth factor 
receptor) 
-2.84  Plasma 
Membrane 
 kinase 
 ENPP3 ectonucleotide 
pyrophosphatase/phosphod
iesterase 3 
-2.82  Plasma 
Membrane 
 enzyme 
 MSLN mesothelin -2.80  Extracellular 
Space 
 other 
 CP ceruloplasmin (ferroxidase) -2.79  Extracellular 
Space 
 enzyme 
 SIRPA signal-regulatory protein 
alpha 
-2.77  Plasma 
Membrane 
 phosphatase 
 ITGAM integrin, alpha M 
(complement component 3 
receptor 3 subunit) 
-2.76  Plasma 
Membrane 
 other 
 NCAM1 neural cell adhesion -2.75  Plasma  other 
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molecule 1 Membrane 
 CYBB cytochrome b-245, beta 
polypeptide 
-2.75  Cytoplasm  enzyme 
 SELE selectin E -2.74  Plasma 
Membrane 
 other 
 MMP2 matrix metallopeptidase 2 -2.73  Extracellular 
Space 
 peptidase 
 FZD2 frizzled homolog 2 
(Drosophila) 
-2.71  Plasma 
Membrane 
 GPCR 
 FIGF c-fos induced growth factor 
(vascular endothelial 
growth factor D) 
-2.69  Extracellular 
Space 
 growth factor 
 PTPRC protein tyrosine 
phosphatase, receptor type, 
C 
-2.69  Plasma 
Membrane 
 phosphatase 
 CD14 CD14 molecule -2.69  Plasma 
Membrane 
 
transmembran
e receptor 
 RRAD Ras-related associated with 
diabetes 
-2.68  Cytoplasm  enzyme 
 LGALS3 lectin, galactoside-binding, 
soluble, 3 
-2.66  Extracellular 
Space 
 other 
 DMBT1 deleted in malignant brain 
tumors 1 
-2.65  Plasma 
Membrane 
 
transmembran
e receptor 
 RPS6 ribosomal protein S6 -2.65  Cytoplasm  other 
 UTS2R urotensin 2 receptor -2.65  Plasma 
Membrane 
 GPCR 
 S100A4 S100 calcium binding 
protein A4 
-2.63  Cytoplasm  other 
 UGCG UDP-glucose ceramide 
glucosyltransferase 
-2.63  Cytoplasm  enzyme 
 APLNR apelin receptor -2.62  Plasma 
Membrane 
 GPCR 
 CD53 CD53 molecule -2.62  Plasma 
Membrane 
 other 
 TGFB2 transforming growth factor, 
beta 2 
-2.62  Extracellular 
Space 
 growth factor 
 ACTN1 actinin, alpha 1 -2.61  Cytoplasm  other 
 TGM2 transglutaminase 2 -2.60  Cytoplasm  enzyme 
 PRRX1 paired related homeobox 1 -2.59  Nucleus  transcription 
regulator 
 TRH thyrotropin-releasing 
hormone 
-2.59  Extracellular 
Space 
 other 
 PMP22 peripheral myelin protein 
22 
-2.58  Plasma 
Membrane 
 other 
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 IGF1 insulin-like growth factor 1 -2.57  Extracellular 
Space 
 growth factor 
 TGFBR2 transforming growth factor, 
beta receptor II 
-2.57  Plasma 
Membrane 
 kinase 
 JAK2 Janus kinase 2 -2.56  Cytoplasm  kinase 
 CD44 CD44 molecule (Indian 
blood group) 
-2.55  Plasma 
Membrane 
 other 
 CITED2 Cbp/p300-interacting 
transactivator 
-2.55  Nucleus  transcription 
regulator 
 EMP1 epithelial membrane 
protein 1 
-2.55  Plasma 
Membrane 
 other 
 DAB2 disabled homolog 2, 
mitogen-responsive 
phosphoprotein 
-2.55  Plasma 
Membrane 
 other 
 CPT1A carnitine 
palmitoyltransferase 1A 
(liver) 
-2.55  Cytoplasm  enzyme 
 HSPA5 heat shock 70kDa protein 5 
(glucose-regulated protein, 
78kDa) 
-2.55  Cytoplasm  other 
 PTPN6 protein tyrosine 
phosphatase, non-receptor 
type 6 
-2.54  Cytoplasm  phosphatase 
 FGG fibrinogen gamma chain -2.54  Extracellular 
Space 
 other 
 ADD3 adducin 3 (gamma) -2.54  Cytoplasm  other 
 CTSB cathepsin B -2.54  Cytoplasm  peptidase 
 HIF1A hypoxia inducible factor 1, 
alpha subunit 
-2.53  Nucleus  transcription 
regulator 
 SNCG synuclein, gamma (breast 
cancer-specific protein 1) 
-2.53  Cytoplasm  other 
 HTR2A 5-hydroxytryptamine 
(serotonin) receptor 2A 
-2.52  Plasma 
Membrane 
 GPCR 
 AP2A2 adaptor-related protein 
complex 2, alpha 2 subunit 
-2.51  Cytoplasm  transporter 
 EGR1 early growth response 1 -2.51  Nucleus  transcription 
regulator 
 MAGED1 melanoma antigen family 
D, 1 
-2.51  Plasma 
Membrane 
 transcription 
regulator 
 APP amyloid beta (A4) 
precursor protein 
-2.50  Plasma 
Membrane 
 other 
 GRN granulin -2.50  Extracellular 
Space 
 growth factor 
 BMP2 bone morphogenetic 
protein 2 
-2.49  Extracellular 
Space 
 growth factor 
 EDNRA endothelin receptor type A -2.49  Plasma  
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Membrane transmembran
e receptor 
 TP53 tumor protein p53 -2.49  Nucleus  transcription 
regulator 
 AXL AXL receptor tyrosine 
kinase 
-2.49  Plasma 
Membrane 
 kinase 
 CASP3 caspase 3, apoptosis-
related cysteine peptidase 
-2.49  Cytoplasm  peptidase 
 TGFB1 transforming growth factor, 
beta 1 
-2.49  Extracellular 
Space 
 growth factor 
 ARHGDIB Rho GDP dissociation 
inhibitor (GDI) beta 
-2.48  Cytoplasm  other 
 SELP selectin P (granule 
membrane protein 140kDa, 
antigen CD62) 
-2.48  Plasma 
Membrane 
 other 
 ITGB1 integrin, beta 1 -2.48  Plasma 
Membrane 
 
transmembran
e receptor 
 HBEGF heparin-binding EGF-like 
growth factor 
-2.48  Extracellular 
Space 
 growth factor 
 OLR1 oxidized low density 
lipoprotein (lectin-like) 
receptor 1 
-2.48  Plasma 
Membrane 
 
transmembran
e receptor 
 JUP junction plakoglobin -2.47  Plasma 
Membrane 
 other 
 GJA1 gap junction protein, alpha 
1, 43kDa 
-2.47  Plasma 
Membrane 
 transporter 
 SERPINF1 serpin peptidase inhibitor, 
clade F 
-2.47  Extracellular 
Space 
 other 
 TNFRSF1A tumor necrosis factor 
receptor superfamily, 
member 1A 
-2.47  Plasma 
Membrane 
 
transmembran
e receptor 
 PDGFC platelet derived growth 
factor C 
-2.46  Extracellular 
Space 
 growth factor 
 TLR2 toll-like receptor 2 -2.46  Plasma 
Membrane 
 
transmembran
e receptor 
 GSK3B glycogen synthase kinase 3 
beta 
-2.45  Nucleus  kinase 
 PTGS1 prostaglandin-
endoperoxide synthase 1 
-2.45  Cytoplasm  enzyme 
 CYB5R3 cytochrome b5 reductase 3 -2.45  Cytoplasm  enzyme 
 SCAMP2 secretory carrier membrane 
protein 2 
-2.44  Cytoplasm  transporter 
 JAG1 jagged 1 (Alagille 
syndrome) 
-2.44  Extracellular 
Space 
 growth factor 
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 GPAM glycerol-3-phosphate 
acyltransferase, 
mitochondrial 
-2.44  Cytoplasm  enzyme 
 IL6ST interleukin 6 signal 
transducer 
-2.44  Plasma 
Membrane 
 
transmembran
e receptor 
 LYN v-yes-1 Yamaguchi 
sarcoma viral related 
oncogene homolog 
-2.43  Cytoplasm  kinase 
 STAT3 signal transducer and 
activator of transcription 3 
-2.43  Nucleus  transcription 
regulator 
 EXTL3 exostoses (multiple)-like 3 -2.43  Cytoplasm  enzyme 
 NPPA natriuretic peptide 
precursor A 
-2.43  Extracellular 
Space 
 other 
 LPAR1 lysophosphatidic acid 
receptor 1 
-2.42  Plasma 
Membrane 
 GPCR 
 NOTCH2 Notch homolog 2 
(Drosophila) 
-2.42  Plasma 
Membrane 
 transcription 
regulator 
 P4HB prolyl 4-hydroxylase, beta 
polypeptide 
-2.42  Cytoplasm  enzyme 
 ATP6AP1 ATPase, H+ transporting, 
lysosomal accessory 
protein 1 
-2.42  Cytoplasm  transporter 
 TPM2 tropomyosin 2 (beta) -2.41  Cytoplasm  other 
 ATP2B4 ATPase, Ca++ 
transporting, plasma 
membrane 4 
-2.41  Plasma 
Membrane 
 transporter 
 MYO5A myosin VA (heavy chain 
12, myoxin) 
-2.41  Cytoplasm  enzyme 
 DMD dystrophin -2.40  Plasma 
Membrane 
 other 
 CLU clusterin -2.40  Extracellular 
Space 
 other 
 FSTL1 follistatin-like 1 -2.40  Extracellular 
Space 
 other 
 OGG1 8-oxoguanine DNA 
glycosylase 
-2.40  Nucleus  enzyme 
 CTNNB1 catenin (cadherin-
associated protein), beta 1, 
88kDa 
-2.40  Nucleus  transcription 
regulator 
 GNB1 guanine nucleotide binding 
protein (G protein), beta 
polypeptide 1 
-2.40  Plasma 
Membrane 
 enzyme 
 PSEN1 presenilin 1 -2.40  Plasma 
Membrane 
 peptidase 
 NCSTN nicastrin -2.39  Plasma  peptidase 
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Membrane 
 VIM vimentin -2.39  Cytoplasm  other 
 TAGLN transgelin -2.38  Cytoplasm  other 
 CD81 CD81 molecule -2.38  Plasma 
Membrane 
 other 
 CSPG4 chondroitin sulfate 
proteoglycan 4 
-2.38  Plasma 
Membrane 
 other 
 NRAS neuroblastoma RAS viral 
(v-ras) oncogene homolog 
-2.38  Plasma 
Membrane 
 enzyme 
 ACTN4 actinin, alpha 4 -2.37  Cytoplasm  other 
 SHMT2 serine 
hydroxymethyltransferase 
2 (mitochondrial) 
-2.37  Cytoplasm  enzyme 
 ACVR1B activin A receptor, type IB -2.37  Plasma 
Membrane 
 kinase 
 ADORA1 adenosine A1 receptor -2.37  Plasma 
Membrane 
 GPCR 
 IL1R1 interleukin 1 receptor, I -2.37  Plasma 
Membrane 
transmembran
e receptor 
 EPHA7 EPH receptor A7 -2.37  Plasma 
Membrane 
 kinase 
 HCN4 hyperpolarization activated 
cyclic nucleotide-gated 
potassium channel 4 
-2.37  Plasma 
Membrane 
 ion channel 
 ODC1 ornithine decarboxylase 1 -2.37  Cytoplasm  enzyme 
 LCN2 lipocalin 2 -2.36  Extracellular 
Space 
 transporter 
 LIPE lipase, hormone-sensitive -2.36  Cytoplasm  enzyme 
 PTPRF protein tyrosine 
phosphatase, receptor, F 
-2.36  Plasma 
Membrane 
 phosphatase 
 RXRA retinoid X receptor, alpha -2.36  Nucleus receptor 
 CACNA1G calcium channel, voltage-
dependent, T type, alpha 
1G subunit 
-2.36  Plasma 
Membrane 
 ion channel 
 CASP2 caspase 2, apoptosis-
related cysteine peptidase 
-2.36  Cytoplasm  peptidase 
 ECE1 endothelin converting 
enzyme 1 
-2.36  Plasma 
Membrane 
 peptidase 
 CREBBP CREB binding protein -2.36  Nucleus  transcription 
regulator 
 LIPA lipase A, lysosomal acid, 
cholesterol esterase 
-2.36  Cytoplasm  enzyme 
 CD47 CD47 molecule -2.35  Plasma 
Membrane 
 other 
 GJB6 gap junction protein, beta 
6, 30kDa 
-2.35  Plasma 
Membrane 
 transporter 
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 MCM7 minichromosome 
maintenance complex 
component 7 
-2.35  Nucleus  enzyme 
 TIMP2 TIMP metallopeptidase 
inhibitor 2 
-2.35  Extracellular 
Space 
 other 
 DYNC1H1 dynein, cytoplasmic 1, 
heavy chain 1 
-2.34  Cytoplasm  peptidase 
 GAB2 GRB2-associated binding 
protein 2 
-2.34  Cytoplasm  other 
 PDPK1 3-phosphoinositide 
dependent protein kinase-1 
-2.34  Cytoplasm  kinase 
 TGIF1 TGFB-induced factor 
homeobox 1 
-2.34  Nucleus  transcription 
regulator 
 TRPC6 transient receptor potential 
cation channel, subfamily 
C, member 6 
-2.34  Plasma 
Membrane 
 ion channel 
 IGF1R insulin-like growth factor 1 
receptor 
-2.34  Plasma 
Membrane 
 Trans-
membrane 
receptor 
 GRIA3 glutamate receptor, 
ionotrophic, AMPA 3 
-2.33  Plasma 
Membrane 
 ion channel 
 VEGFC vascular endothelial growth 
factor C 
-2.33  Extracellular 
Space 
 growth factor 
 REST RE1-silencing transcription 
factor 
-2.33  Nucleus  transcription 
regulator 
 GALR2 galanin receptor 2 -2.33  Plasma 
Membrane 
 GPCR 
 ICAM1 intercellular adhesion 
molecule 1 
-2.33  Plasma 
Membrane 
transmembran
e receptor 
 IRS1 insulin receptor substrate 1 -2.33  Cytoplasm  other 
 LXN latexin -2.33  Cytoplasm  other 
 GPI glucose-6-phosphate 
isomerase 
-2.32  Extracellular 
Space 
 enzyme 
 AMPD3 adenosine monophosphate 
deaminase 3 
-2.32  unknown  enzyme 
 FST follistatin -2.32  Extracellular 
Space 
 other 
 NOTCH3 Notch homolog 3 
(Drosophila) 
-2.32  Plasma 
Membrane 
 transcription 
regulator 
 JAK1 Janus kinase 1 -2.31  Cytoplasm  kinase 
 ADM adrenomedullin -2.31  Extracellular 
Space 
 other 
 CDS2 CDP-diacylglycerol 
synthase 
-2.31  Cytoplasm  enzyme 
 DUSP5 dual specificity 
phosphatase 5 
-2.31  Nucleus  phosphatase 
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 SCARB2 scavenger receptor class B, 
member 2 
-2.31  Plasma 
Membrane 
 other 
 APAF1 apoptotic peptidase 
activating factor 1 
-2.31  Cytoplasm  other 
 CLTC clathrin, heavy chain (Hc) -2.31  Plasma 
Membrane 
 other 
 MAP3K1 mitogen-activated protein 
kinase kinase kinase 1 
-2.31  Cytoplasm  kinase 
 OGT O-linked N-
acetylglucosamine 
(GlcNAc) transferase 
-2.31  Cytoplasm  enzyme 
 DYNLT1 dynein, light chain, Tctex-
type 1 
-2.30  Cytoplasm  other 
 ITGA1 integrin, alpha 1 -2.30  Plasma 
Membrane 
 other 
 STXBP1 syntaxin binding protein 1 -2.30  Cytoplasm  transporter 
 CCND2 cyclin D2 -2.30  Nucleus  other 
 DIO2 deiodinase, iodothyronine, 
type II 
-2.30  Cytoplasm  enzyme 
 HNRNPD heterogeneous nuclear 
ribonucleoprotein D 
-2.30  Nucleus  transcription 
regulator 
 HYOU1 hypoxia up-regulated 1 -2.30  Cytoplasm  other 
 IGF2 insulin-like growth factor 2 
(somatomedin A) 
-2.30  Extracellular 
Space 
 growth factor 
 PLD2 phospholipase D2 -2.30  Cytoplasm  enzyme 
 DIO3 deiodinase, iodothyronine, 
type III 
-2.30  Plasma 
Membrane 
 enzyme 
 AGRN agrin -2.29  Plasma 
Membrane 
 other 
 ATP6V0C ATPase, H+ transporting, 
lysosomal 16kDa, V0 
subunit c 
-2.29  Cytoplasm  transporter 
 CXCR3 chemokine (C-X-C motif) 
receptor 3 
-2.29  Plasma 
Membrane 
 GPCR 
 MYD88 myeloid differentiation 
primary response gene (88) 
-2.29  Plasma 
Membrane 
 other 
 NRP1 neuropilin 1 -2.29  Plasma 
Membrane 
 
transmembran
e receptor 
 ADAM17 ADAM metallopeptidase 
domain 17 
-2.29  Plasma 
Membrane 
 peptidase 
 CAPN1 calpain 1, (mu/I) large 
subunit 
-2.29  Cytoplasm  peptidase 
 CXCR4 chemokine (C-X-C motif) 
receptor 4 
-2.28  Plasma 
Membrane 
 GPCR 
 FYN FYN oncogene related to -2.28  Plasma  kinase 
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SRC, FGR, YES Membrane 
 PDE3A phosphodiesterase 3A, 
cGMP-inhibited 
-2.28  Cytoplasm  enzyme 
 SMPD1 sphingomyelin 
phosphodiesterase 1, acid 
lysosomal 
-2.28  Cytoplasm  enzyme 
 STEAP3 STEAP family member 3 -2.28  Cytoplasm  transporter 
 ITPR1 inositol 1,4,5-triphosphate 
receptor, type 1 
-2.28  Cytoplasm  ion channel 
 SMAD1 SMAD family member 1 -2.28  Nucleus  transcription 
regulator 
 CDH2 cadherin 2, type 1, N-
cadherin (neuronal) 
-2.28  Plasma 
Membrane 
 other 
 CDK9 cyclin-dependent kinase 9 -2.28  Nucleus  kinase 
 EGFR epidermal growth factor 
receptor 
-2.28  Plasma 
Membrane 
 kinase 
 APC adenomatous polyposis coli -2.27  Nucleus  enzyme 
 CXCL2 chemokine (C-X-C motif) 
ligand 2 
-2.27  Extracellular 
Space 
 cytokine 
 MAP3K11 mitogen-activated protein 
kinase kinase kinase 11 
-2.27  Cytoplasm  kinase 
 PDE5A phosphodiesterase 5A, 
cGMP-specific 
-2.27  Cytoplasm  enzyme 
 PPP1R12A protein phosphatase 1, 
regulatory (inhibitor) 
subunit 12A 
-2.27  Cytoplasm  phosphatase 
 CCND1 cyclin D1 -2.27  Nucleus  other 
 CDH13 cadherin 13, H-cadherin 
(heart) 
-2.27  Plasma 
Membrane 
 other 
 ITSN1 intersectin 1 (SH3 domain 
protein) 
-2.27  Cytoplasm  other 
 MYO9B myosin IXB -2.27  Cytoplasm  enzyme 
 HTT huntingtin -2.26  Cytoplasm  transcription 
regulator 
 TSC2 tuberous sclerosis 2 -2.26  Cytoplasm  other 
 ERBB2 v-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 2, 
-2.26  Plasma 
Membrane 
 kinase 
 NSF N-ethylmaleimide-sensitive 
factor 
-2.26  Cytoplasm  transporter 
 VLDLR very low density 
lipoprotein receptor 
-2.26  Plasma 
Membrane 
 transporter 
 PSEN2 presenilin 2 (Alzheimer 
disease 4) 
-2.26  Cytoplasm  peptidase 
 CXCL12 chemokine (C-X-C motif) 
ligand 12 
-2.25  Extracellular 
Space 
 cytokine 
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 BID BH3 interacting domain 
death agonist 
-2.25  Cytoplasm  other 
 PRKCD protein kinase C, delta -2.25  Cytoplasm  kinase 
 IKBKB inhibitor of kappa light 
polypeptide gene enhancer 
in B-cells, kinase beta 
-2.25  Cytoplasm  kinase 
 ITPKB inositol 1,4,5-trisphosphate 
3-kinase B 
-2.25  Cytoplasm  kinase 
 
ARHGAP20 
Rho GTPase activating 
protein 20 
-2.25  unknown  other 
 CACNA1C calcium channel, voltage-
dependent, L type, alpha 
1C subunit 
-2.24  Plasma 
Membrane 
 ion channel 
 ERBB3 v-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 3 (avian) 
-2.24  Plasma 
Membrane 
 kinase 
 PLAU plasminogen activator, 
urokinase 
-2.24  Extracellular 
Space 
 peptidase 
 MMP9 matrix metallopeptidase 9 -2.24  Extracellular 
Space 
 peptidase 
 BIN1 bridging integrator 1 -2.23  Nucleus  other 
 GATA4 GATA binding protein 4 -2.23  Nucleus  transcription 
regulator 
 ETS1 v-ets erythroblastosis virus 
E26 oncogene homolog 1 
(avian) 
-2.23  Nucleus  transcription 
regulator 
 EP300 E1A binding protein p300 -2.23  Nucleus  transcription 
regulator 
 MADD MAP-kinase activating 
death domain 
-2.22  Cytoplasm  other 
 ADRA1A adrenergic, alpha-1A-, 
receptor 
-2.22  Plasma 
Membrane 
 GPCR 
 MTOR mechanistic target of 
rapamycin 
(serine/threonine kinase) 
-2.22  Nucleus  kinase 
 APOE apolipoprotein E -2.22  Extracellular 
Space 
 transporter 
 GNB2L1 guanine nucleotide binding 
protein (G protein), beta 
polypeptide 2-like 1 
-2.22  Cytoplasm  enzyme 
 SRC v-src sarcoma (Schmidt-
Ruppin A-2) viral 
oncogene homolog (avian) 
-2.22  Cytoplasm  kinase 
 SF1 splicing factor 1 -2.21  Nucleus transcription 
regulator 
 AXIN1 axin 1 -2.20  Cytoplasm  other 
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 DNM1 dynamin 1 -2.20  Cytoplasm  enzyme 
 CXCL1 chemokine (C-X-C motif) 
ligand 1 
-2.20  Extracellular 
Space 
 cytokine 
 ARHGEF7 Rho guanine nucleotide 
exchange factor (GEF) 7 
-2.20  Cytoplasm  other 
 ATG7 ATG7 autophagy related 7 
homolog (S. cerevisiae) 
-2.19  Cytoplasm  enzyme 
 CTF1 cardiotrophin 1 -2.19  Extracellular 
Space 
 cytokine 
 DCTN1 dynactin 1 (p150, glued 
homolog, Drosophila) 
-2.19  Cytoplasm  other 
 KHSRP KH-type splicing 
regulatory protein 
-2.19  Nucleus  enzyme 
 GRB2 growth factor receptor-
bound protein 2 
-2.18  Cytoplasm  other 
 APH1A  anterior pharynx defective 
1a homolog (C. elegans) 
-2.18  Cytoplasm  peptidase 
 CASP9 caspase 9, apoptosis-
related cysteine peptidase 
-2.18  Cytoplasm  peptidase 
 CABIN1 calcineurin binding protein 
1 
-2.18  Nucleus  other 
 MAPK1 mitogen-activated protein 
kinase 1 
-2.18  Cytoplasm  kinase 
 SMAD3 SMAD family member 3 -2.18  Nucleus  transcription 
regulator 
 GIT1 G protein-coupled receptor 
kinase interacting ArfGAP 
1 
-2.17  Nucleus  other 
 CDK5 cyclin-dependent kinase 5 -2.16  Nucleus  kinase 
 SNAP29 synaptosomal-associated 
protein, 29kDa 
-2.16  Cytoplasm  transporter 
 DLG4 discs, large homolog 4 
(Drosophila) 
-2.15  Plasma 
Membrane 
 kinase 
 PDE3B phosphodiesterase 3B, 
cGMP-inhibited 
-2.15  Cytoplasm  enzyme 
 PPP1CC protein phosphatase 1, 
catalytic subunit, gamma 
isozyme 
-2.15  Cytoplasm  phosphatase 
 NOS3 nitric oxide synthase 3 
(endothelial cell) 
-2.14  Cytoplasm  enzyme 
 PTEN phosphatase and tensin 
homolog 
-2.14  Cytoplasm  phosphatase 
 IL4 interleukin 4 -2.14  Extracellular 
Space 
 cytokine 
 PTK2 PTK2 protein tyrosine 
kinase 2 
-2.14  Cytoplasm  kinase 
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 CLIP2 CAP-GLY domain 
containing linker protein 2 
-2.13  Cytoplasm  transcription 
regulator 
 MAPK3 mitogen-activated protein 
kinase 3 
-2.13  Cytoplasm  kinase 
 CASP4 caspase 4, apoptosis-
related cysteine peptidase 
-2.13  Cytoplasm  peptidase 
 PRL prolactin -2.11  Extracellular 
Space 
 cytokine 
 ZNF423 zinc finger protein 423 -2.10  Nucleus  transcription 
regulator 
 NFKB2 nuclear factor of kappa 
light polypeptide gene 
enhancer in B-cells 2 
-2.10  Nucleus  transcription 
regulator 
 CREB1 cAMP responsive element 
binding protein 1 
-2.10  Nucleus  transcription 
regulator 
 CD2AP CD2-associated protein -2.09  Cytoplasm  other 
 NPPB natriuretic peptide 
precursor B 
-2.09  Extracellular 
Space 
 other 
 PXN paxillin -2.09  Cytoplasm  other 
 CRYAB crystallin, alpha B -2.08  Nucleus  other 
 VEGFB 
(includes 
EG:89811) 
vascular endothelial growth 
factor B 
-2.08  Extracellular 
Space 
 other 
 TNF tumor necrosis factor -2.08  Extracellular 
Space 
 cytokine 
 AGT angiotensinogen (serpin 
peptidase inhibitor, clade 
A, member 8) 
-2.07  Extracellular 
Space 
 other 
 DCTN2 dynactin 2 (p50) -2.07  Cytoplasm  other 
 WNT4 wingless-type MMTV 
integration site family, 
member 4 
-2.06  Extracellular 
Space 
 other 
 SHH sonic hedgehog homolog 
(Drosophila) 
-2.05  Extracellular 
Space 
 peptidase 
 ADRB2 adrenergic, beta-2-, 
receptor, surface 
-2.04  Plasma 
Membrane 
 GPCR 
 BCL2 B-cell CLL/lymphoma 2 -2.03  Cytoplasm  other 
 GRIN2B glutamate receptor, 
ionotropic, N-methyl D-
aspartate 2B 
-2.03  Plasma 
Membrane 
 ion channel 
 PPARG peroxisome proliferator-
activated receptor gamma 
-2.03  Nucleus  ligand-
dependent 
nuclear 
receptor 
 NOTCH4 Notch homolog 4 
(Drosophila) 
-2.02  Plasma 
Membrane 
 transcription 
regulator 
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 GRIN1 glutamate receptor, 
ionotropic, N-methyl D-
aspartate 1 
-2.01  Plasma 
Membrane 
 ion channel 
 GRM1 glutamate receptor, 
metabotropic 1 
-2.01  Plasma 
Membrane 
 GPCR 
 FSHR follicle stimulating 
hormone receptor 
-2.01  Plasma 
Membrane 
 GPCR 
 PKIG protein kinase (cAMP-
dependent, catalytic) 
inhibitor gamma 
-2.01  unknown  other 
 CDK5R1 cyclin-dependent kinase 5, 
regulatory subunit 1 (p35) 
-2.01  Nucleus  kinase 
 REN renin -2.01  Extracellular 
Space 
 peptidase 
 
Table 8-3 : Genes associated with cardiac function 
 
 
8.4 Discussion 
 
The repair of ventricular tissues, following ischemia can lead to an improvement in 
the quality of life in patients suffering from chronic heart failure. Various studies have 
focused on the need for angiogenesis in ischemic tissue, in order to stimulate hibernating 
myocardium and provide for cardiac functional benefit.12,34,48 However, the application of 
mesenchymal stem cells delivered peri infarct, as a response to the MSC homing factor, 
monocyte chemoattractant protein-3 (MCP-3) led to a significant improvement in cardiac 
benefit, without any improvement in angiogenesis, or the differentiation of MSCs to 
cardiac myocytes in the infarct tissue.52 Therefore, in order to understand the molecular 
mechanisms involved, and to identify lead paracrine factors responsible for reverse 
ventricular remodeling, we analyzed these tissues for all up and down regulated genes, 
following MSC therapy, using microarray studies.  We approached the microarray 
159 
 
analysis data with two different aspects, one primarily to look for secreted proteins in the 
tissue based on fold changes and p-values, and another to look for specific proteins 
associated with cardiovascular functions, based on p values and interactions between the 
differentially expressed genes.  
 
Secreted proteins in the treated group were based on the location of these proteins, in 
the extra cellular space. We identified 6 secreted proteins that were differentially 
expressed with a fold change of greater than 2. Among these proteins, two were 
upregulated, and we looked at these 2 genes, Leukemia inhibitory factor, is a gene that 
promotes proliferation of cells, but there hasn’t been any studies to see its effect on 
cardiac benefit. However, PSG-18 (pregnancy specific glycoprotein 18) has been shown 
to induce a cardioprotective protein IL10.207 IL10 has been implicated in heart failure to 
promote cardiac functional benefit, by preventing the infiltration of macrophages.208,209 
However, on studying the expression of PSG-19 based on RT PCR analysis between all 
the groups, we did not obtain any conclusive evidence of this being a differentially 
expressed gene between all the groups.  
 
Differentially expressed genes, associated with cardiovascular functions, were then 
analyzed based on pathway analysis networks. Network studies allow us to understand 
the interactions between the various genes and the role they play within the various 
pathways that they are involved in.165, 166 This data is provided by literature from previous 
studies performed and uploaded onto the software. However, the lack of a complete 
library does not provide accurate and updated information, but can still provide various 
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leads that can be pursued in order to understand the molecular pathways associated with 
reverse ventricular remodeling.147 A list of the complete genes, as obtained from the 
pathway analysis software has been provided. Some of the upregulated genes have been 
shown to provide cardiac benefit and some have been shown to increase the risk involved 
with the disease, and circulating levels of these proteins are used as diagnostic markers 
for the disease. Some proteins, such as macrophage migration inhibition factor (MIF), 
and interferon gamma (IFNg) have been shown to increase the risk for heart failure.210, 211 
Other proteins such as SFRP-4 (secreted frizzled receptor protein 4) promotes cardiac 
protection by reducing fibrosis size in ischemic models,54, 212 MEF2b (myocyte enhancer 
protein 2b) is essential for heart development,213 CLEC11A, also known as SCGF (Stem 
cell growth factor) is secreted and is required by an autocrine process responsible for the 
proliferation of hematopoietic stem cells,214 VEGf (Vascular endothelial growth factor) is 
responsible for angiogenesis in infarct tissues,215 GLRX3 (glutaredoxin 3) reduces the 
risks involved with cardiac failure in diabetic mice, 216 and CAV3 (caveolin 3) 
overexpression has been studied as a means to provide cardiac protection.217 Taking cue 
from the various studies performed earlier, and correlating them to this cardiovascular 
gene list provided by this study, we are able to identify novel molecular mechanisms 
involved in reverse ventricular remodeling.  
 
This study paves the way for future studies, where these specific genes can be 
focused on for ventricular repair, and can be validated by protein and RT PCR analysis.  
 
 
161 
 
CHAPTER IX 
 
SUMMARY AND CONCLUSIONS 
 
9 SUMMARY AND CONCLUSIONS 
 
Overall, we have developed and designed a gene drug that can provide significant 
improvements in cardiac function, capable of translating to a clinical setting. We have 
engineered a delivery package, using nanoparticlulate carriers with homing ligands, 
capable of targeting the polymeric carrier to ischemic tissues. We have analyzed 
pathways responsible for reverse ventricular leads and have paved the way for future 
research responsible for improving the quality of life in patients, by inducing the reversal 
of ventricular remodeling. The conclusions and outcomes, based on in vivo and in vitro 
studies, as elucidated by previous chapters above, are outlined here.  
 
We investigated the use of optical imaging as a tool for detecting gene expression 
studies. We used a Luciferase gene, one that emits chemiluminescence in the presence of 
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an i.p. injection of luciferin, as our gene of interest for the bioluminescence studies in 
chronic heart failure rodent models. The chemiluminescence emitted was quantified and 
analyzed in order to understand the genetic profile of this plasmid.  
 
We noticed the changes in expression profiles, with the use of enhancer elements in 
the gene design, thus correlating to the boosts in gene expression. Utilizing a cooled 
camera to detect bioluminescence can help understand the genetic profile in gene therapy 
and eliminate the need for complicated bioassays.  
 
We designed a gene vector with enhancer elements, supported from the expression 
data collected by the bioluminescence studies and used this vector to now express the 
hSDF-1 gene, responsible for providing cardiac benefit in ischemic myocardium 
 
We observed the improvements in cardiac function, in vivo and its correlation to the 
expression profiles, and were able to design a gene vector, capable of delivering the SDF-
1 gene to ischemic myocardiums and provide sustained benefit, lasting up to 2 months 
following therapy.  
 
We investigated the mechanism by which SDF-1 gene transfer provides cardiac 
benefit and attributed that to improved angiogenesis in the infarcted region of the cardiac 
tissue. We also observed a reduction in fibrosis area, but this did not correspond to the 
amount of benefit.  
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Employing phage panning techniques, we identified a targeting ligand out of 
millions of peptides that is specific to the infarcted region of the heart. This ligand was 
determined to be a 7 mer sequence of RQPRMKR. 
 
We synthesized this peptide and tagged it with a fluorescent tag, to be able to view it 
with optical microscopy. This peptide is specific to the heart and not other organs. 
 
We engineered nanoparticles made with polymeric PLGA and investigated the 
distribution patterns, uptake and release, in vitro, in cardiac fibroblasts and in vivo in 
chronic heart failure rodents. We identified the uptake to happen in the first one hour 
after the addition of particles, and continued release for up to 24 hours post addition, in 
culture dishes.  
 
The role of the size of particles was determined, when we observed that size and 
uptake was inversely co related. The addition of larger particles (un sonicated ones) 
mediated lower uptake than sonicated, smaller sized particles.  
 
The presence of targeting peptides did not affect the amount of uptake in cells 
growing on culture plates specifying its role in targeting of the particles, and not in cell 
penetration.  
 
In vivo studies with nanoparticles, in rodents with chronic heart failure, determined 
the role of targeting peptides. More particles, with targeting peptides, released the dye in 
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the infarcted region as compared to particles without the targeting peptide. The non 
targeting particles were found flushed away from circulation, into the liver.  
 
To determine novel pathways responsible for ventricular remodeling, we 
investigated the role of mesenchymal stem cells with whole genome analysis. Whole 
genome analysis was able to provide accurate and detailed information, regarding all the 
pathways and nodal genes, up regulated due to stem cell therapy.  
 
The recruitment of mesenchymal stem cells by monocyte chemoattractant protein-3, 
late after acute myocardial infarction, was able to provide cardiac benefit in function, due 
to paracrine effects.  
 
We identified a list of differentially expressed genes responsible for ventricular 
remodeling. Some of these genes have been studied to provide cardiac benefit.  
 
Overall, we have developed a non viral gene therapy based delivery of h-Stromal 
derived cell factor -1 plasmid to benefit regeneration of cardiac myocardium due to 
improved angiogenesis. We have developed a carrier system, capable of transporting this 
gene, via the circulation, to the area of injury, in the heart, and deliver the drug gene. We 
have paved the way for new research in cardiac regeneration by identifying novel 
pathways responsible for reverse ventricular regeneration.  
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Significance and Clinical Impact 
 
This study has identified a key gene drug responsible for providing benefit to the 
myocardium. On the other hand, we have designed and optimized this drug to sustain 
long enough and translate clinically viable quantities of protein in order to provide 
significant benefit long after the loss of gene expression. We have been able to able to 
verify our findings, and develop a method for improvement in cardiac function without 
the use of any cell types, or viral particles involved. This principle and gene and vector 
design can now be extended to larger animals and clinical populations towards AMI 
leading to CHF patients. 
 
As mentioned above, over 10% of the US population over the age of 65 years has the 
diagnosis of congestive heart failure (CHF).  The majority of the patients have CHF due 
to a history MI. These findings could be particularly useful in treating these patients. 
 
Apart from the drug design we have identified a nanoparticulate carrier system, 
capable of encapsulating this drug. If we are able to verify these findings and extend this 
system towards targeted and effective drug delivery to ischemic cardiac tissue, this will 
eliminate the need for painful surgeries and will provide an easier yet effective strategy to 
treat the older populations, for whom, surgery may be a cause for risk.  
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Future Directions 
 
This study has provided an extensive insight into the design and delivery of gene 
drugs to the myocardium. However, we anticipate that the future studies will be in many 
aspects. One will bring about extensive research in utilizing gene therapy without the use 
of viral or cellular delivery methods not only for cardiovascular but in all areas of gene 
therapy.  
 
Another aspect will be to utilize this novel engineered nanoparticle delivery 
mechanism for any delivery of drug or gene to an ischemic myocardium. This will pave 
the way for future studies of taking these findings of this experiment into studies 
involving larger animals and into the clinical populations.  
 
A third aspect will be to study defined cardiac pathways and genes identified by the 
microarray study and launch into a series of experiments involving animal studies and 
protein analysis to identify nodal proteins responsible for  reverse ventricular remodeling. 
These proteins can then be packaged into the nanocarriers identified above, in a vector 
design as constructed above, in order to come up with more effective strategies for the 
repair of cardiac tissue following ischemic damage.  
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